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Abstract
Epstein-Barr virus (EBV) establishes persistent infection in over 90% of adults
worldwide. It is associated with a number of human diseases including infectious
mononucleosis (IM), nasopharyngeal carcinoma (NPC), Hodgkin's disease (FID)
and post-transplant lymphoproliferative disease (PTLD). This thesis reports two
separate studies on immunotherapy ofEBV positive PTLD and on pathogenesis of
EBV related diseases in relation to cytokine gene expression. PTLD is a B cell
malignancy seen in 1-10% of solid organ transplant recipients. Severe combined
immunodeficient (SCID) mice serve as a murine model for PTLD because
subcutaneous (s/c) inoculation of in vitro transformed lymphoblastoid cell lines
(LCLs) result in human EBV-positive PTLD like tumours in these animals. The
aim of the first study was to use the SCID model to investigate the effect of
varying doses of human unmanipulated peripheral blood mononuclear cells
(PBMC), polyclonal and EBV peptide-specific cytotoxic T cell lines (CTL) on
outgrowth and therapy of autologous LCL tumours. Effector cells were mixed with
fixed tumorigenic dose of autologous LCL cells at varying ratios and injected s/c
into SCID mice. Unmanipulated PBMC failed to control the outgrowth of LCL
tumours. Polyclonal CTLs prevented tumour outgrowth down to the CTL:LCL
ratio of 0.25:1 suggesting that outgrowth of EBV-positive tumours is effectively
controlled by autologous EBV-specific CTLs. Polyclonal CTLs also improved
survival of SCID mice with already established autologous LCL tumours. Positive
effect ofCTL on survival and tumour mass reduction was greater in animals with
small tumour mass at start of therapy as compared to those with larger tumours.
Delivery of multiple CTL infusions via the intravenous (I/V) route was more
effective in reducing tumour mass than injection of a single fixed CTL dose via the
I/V or intra-tumour route. In contrast, only the EBV peptide-specific CTLs with a
higher frequency of detectable precursors in the peripheral blood prevented tumour
outgrowth below CTL:LCL ratio of 1:1. Peptide-specific CTLs targetting an
immunodominant LMP1 epitope also successfully controlled outgrowth of LCL
tumours below CTL:LCL ratio of 1:1, suggesting the possible extension of CTL
therapy to EBV positive malignancies with restricted EBV gene expression
patterns.
The second study investigated the cytokine gene expression pattern of EBV
associated diseases. Dysregulation of the cytokine network has been proposed as a
cofactor in pathogenesis ofEBV related conditions. Higher level of cytokine gene
expression has been found in lymphoid tissue of patients with IM as compared to
normal individuals and in cases ofEBV positive PTLD, HD and NPC as compared
to EBV negative cases. In our study we investigated the cytokine profile of a tonsil
from an acute IM case, human PBMC induced SCID tumours, PTLD, NPC and
HD by non-isotopic in situ hybridisation. We also identified the cell type
responsible for cytokine production and its relationship to EBV infection. A mixed
T helper (Th)-l and 2 type cytokine expression pattern was observed in all EBV
positive tissue. However, in IM, PTLD and NPC a higher percentage of cells
expressed IL-6 and IL-10. In all diseases except NPC cytokine production was
predominantly seen in EBV positive cells. In NPC a higher percentage of
infiltrating T cells expressed cytokines than the epithelial tumour cells. Overall our
results show that autocrine cytokine production by EBV positive cells may
contribute to the pathogenesis of EBV related diseases. However, it is plausible
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Members of the Herpesviridae exist worldwide and infect a wide range of hosts
(Roizman et al, 1990). At least eight different species have been identified which
infect humans. These are herpes simplex viruses (HSV) 1 and 2, Varicella-zoster
virus (VZV), human cytomegalovirus (CMV), Epstein-Barr virus (EBV) and
human herpes viruses 6, 7 and 8 (HHV6, HHV7, HHV8).




Herpes simplex virus type 1 (HSV1)
Herpes simplex virus type 2 (HSV2)
Genus Varicelloviruses





Human herpesvirus 6 (HHV6)
Human herpesvirus 7 (HHV7)
Subfamily Gammaherpesvirinae
Genus Lymphocryptoviruses
Epstein-Barr virus (EBV, HHV-4)
Human herpesvirus 8 (Kaposi's sarcoma associated herpesvirus,
KSHV, HHV-8)
1.1.2 Physical and Biological Properties
All herpesviruses are morphologically identical. The virion consists of an
icosahedral nucleocapsid, about 100 nm in diameter (Wildy et al, 1963). A lipid
bilayer envelope derived from the inner nuclear membrane of the host cell,
l
surrounds the nucleocapsid (Morgan et al, 1959). Virus-encoded glycoproteins are
incorporated into the host derived envelope. Between the capsid and the envelope
is an area called the tegument, an amorphous protein layer (Morgan et al, 1968).
The icosahedral capsid contains a double-stranded DNA genome in die form of a
toroid (Furlong et al, 1972). The genome consists of 4 equimolar isomers with
terminal and internal inverted repeats (Furlong et al, 1972). Virus enters the cell
by endocytosis, the capsid is uncoated and viral DNA is released in the host cell
nucleus. Viral DNA replicates in host cell nucleus and virus particles acquire an
envelope by budding from the nuclear membrane (Roizman and Furlong, 1974).
Virions are transported to the outside of the cell by transport through
intracytoplasmic cisternae or cytoplasmic vesicles.
Primary infection with herpesviruses is usually subclinical. Following primary
infection, the virus establishes a latent infection in the host and can reactivate at
any time. However, in immunocompetent individuals clinical disease after
reactivation is usually localized and of short duration. Severity of symptomatic
disease can increase in stressed, elderly and immunocompromised persons and
may be generalized, severe, and even life threatening. Gamma-herpesviruses in
particular are associated with a variety ofmalignancies in this scenario.
2
1.2 Epstein-Barr Virus
Epstein-Barr virus (EBV) or human herpes virus 4 (HHV4), is a double stranded
DNA virus, which was originally visualized under an electron microscope by Sir
A. Epstein in an African Burkitfs lymphoma cell line (Epstein et al., 1964). EBV
is a member of genus lymphocryptovirus, subfamily gammmaherpesvirinae of the
family Herpesviridae.
1.2.1 History
In 1958 Denis Burkitt first described a malignant tumour of the jaw in the malaria
belt of east Africa (Burkitt, 1958). Due to the restricted geographical distribution
of the tumour to certain areas ofAfrica, and its close association with the malaria
endemic area, Burkitt suggested an infectious etiology for this tumour, transmitted
by the mosquito vector. In 1964, Epstein and Barr isolated a continuous cell line
from a Burkitt lymphoma tumour (Epstein & Barr, 1964) and later described the
presence of a herpesvirus in these cells (Epstein et al, 1964). The discovered virus
was named Epstein-Barr virus and was later recognized as the etiological agent of
infectious mononucleosis (Henle & Henle, 1968; Niederman et al, 1968). EBV
was also shown to immortalize lymphocytes in vitro (Pope et al, 1968) and cause
tumours in non-human primates (Shope & Miller, 1975).
1.2.2 EBV Morphology
EBV has a DNA core inside a icosahedral nucleocapsid made up of 162
capsomere. The nucleocapsid is surrounded by the viral envelope, which has a
trilaminar structure and is derived from the host cell membrane. An amorphous
material termed the tegument separates the the nucleocapsid from the envelope.
The most abundant EBV envelope glycoproteins are gp350 and gp220, which are
encoded by the same viral gene by alternative splicing of the mRNA (Dolyniuk et
al, 1976). Additional viral envelope glycoproteins expressed at much lower levels
include gp85, gp25, gp42/38, gp43, and gp78/55 (Li et al., 1995).
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1.2.3 EBV Genome
EBV has a linear, double stranded DNA genome which is 172 kilobase pairs (kbp)
in size (Dambaugh et al, 1980; Baer et al, 1984). The genome ends consist of
tandemly reiterated terminal repeats (TR) of approximately 540 base pairs (bp)
(Hayward et al, 1977; Given et al, 1979; Kintner et al, 1979). Within the genome
several internal repeats (IR) of about 3.1 kbp join short and long unique regions
(Laux et al., 1985; Keiff and Leibowitz 1990; Miller 1990). The number of
repeats in the DNA IR sequences varies between different EBV isolates, however
this number remains constant within individual isolates (Dambaugh et al, 1980;
Heller et al, 1981; Katz et al, 1988). Two types of EBV, termed EBV 1 and 2,
have been identified (Bornkamm et al, 1980; Dambaugh et al, 1984) of which
EBV 1 is the predominant type worldwide (Zimber et al, 1986). The two types
have 70-85% homologous DNA sequences (Sample et al, 1990) with the major
differences in the regions encoding nuclear antigens 2, 3, 4, and 6 and EBERS
(Dambaugh et al, 1984; Rowe et al, 1989; Arrand et al, 1989). The entire EBV
genome persists in the host cell as covalently closed circular episomal DNA
(Lindahl et al, 1976), or very rarely as linear-integrated DNA (Fennewald et al.,
1984).
1.2.4 EBV Cell Tropism
Over 90% of the adult human population worldwide shows serological evidence
of EBV infection (Henle & Henle, 1976). EBV has a narrow tissue tropism
limited to B and T lymphocytes and epithelial cells of primate origin (Glaser et al,
1978). Recently Savard et al have also reported infection of human monocytes
with EBV (Savard et al, 2000). They demonstrated presence of EBV
nucleocapsids in cytoplasm by electron microscopy (EM) and EBV DNA in
phagocytosis-defective monocytes (Savard et al, 2000). In vivo the virus enters via
the nasopharyngeal epithelium and infects recirculating B lymphocytes. Earlier
studies have suggested that EBV primarily infects the oropharyngeal epithelial
cells and subsequently establishes a latent infection in host B cells (Sixby et al,
1984). However, It is still not clear how EBV infects epithelial cells. A recent
study has reported that although cell free EBV is incapable of infecting epithelial
cells, cell to cell contact between EBV infected B cells and epithelial cells in co-
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culture can result in EBV infection of epithelial cell^via a receptor independant
pathway (Chang et al, 1999). Another recent study by Faulkner et al on a group of
individuals with a rare heritable disorder, X-linked agammaglobulinemia, who
lack mature B lymphocytes has shown that none of these individuals carried EBV
and lacked EBV-specific memory cytotoxic T lymphocytes, suggesting that B
lymphocytes, and not oropharyngeal epithelial cells, may be the target for primary
EBV infection (Faulkner et al, 1999). ). In vitro infection of B cells results in
immortalization and transformation of these cells into continuously proliferating
lymphoblastoid cell lines (LCL) (Pope et al, 1968). In vitro infection of squamous
epithelial cells results in lytic viral infection with consequent virus production and
cell death (Sixby et al, 1983).
1.2.5 Attachment and Entry
EBV enters B lymphocytes by attachment of viral envelope glycoprotein
gp350/220 to CD21 also known as complement receptor 2 (CR2), on the B cell
surface (Fingeroth, 1984; Nemerow et al, 1987). This is followed by gp85-gp25-
induced fusion of the viral envelope with the cell membrane, and release of the
nucleocapsid into host cell cytoplasm (Miller and Hutt-Fletcher 1992). Entry also
requires the binding of another surface glycoprotein gp42 with FILA-DR (Spriggs
et al, 1996) and B cells not expressing HLA-DR are resistant to infection by EBV
(Li et al, 1997). Apart from binding to HLA-DR, gp42 can also facilitate viral
en1 rry into host cells by using HLA-DP and HLA-DQ as co-receptors (Haan et al,
2000).
1.2.6 Immortalization of B cells into Lymphoblastoid Cell Lines
Internalization of the virus particle by a resting B cell results in the activation of
endogenous heat shock proteins (hsp)-70 and hsp-90 and P56Lck (Cheung et al,
1991; 1993). 24 hours post-infection EBV expresses nine proteins termed the
latent cycle antigens. These include EBV nuclear antigens (EBNA) 1 to 6 and
latent membrane proteins (LMP) 1 and 2a and 2b. Two non-translated RNAs;
EBV-encoded early RNA (EBER) 1 & 2 are also expressed in early infection
(Dilner et al, 1988; Roger et al, 1992). After 48 hours, the EBNA proteins reach
the maximum level at which they persist throughout latent infection (Moss et al,
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1981; 1986), the infected cells are enlarged and and express LMP1 induced B cell
activation marker CD23 (Wang et al, 1990). The cells enter mitosis at 72 hours
post infection (Sinclair et al, 1994) and continue to divide indefinitely, giving rise
to a lymphoblastoid cell line (LCL), which expresses all B cell activation markers;
CD23, CD30, CD39, CD70 and ki24. The type of gene expression seen in LCLs is
termed a full latent viral gene expression.
1.2.7 Latent Infection
In vivo EBV infection of B cells is life long and the virus persists in the host cells
in a latent form as a self-replicating extra chromosomal episome, which replicates
once per cell division during S phase with transfer of one daughter molecule to
each daughter cell (Yates and Guan, 1991; Mackey et al., 1995). Latent infection
is punctuated with periodic reactivation of viral replication and shedding of whole
virions. Full latent viral gene expression is not observed in all latent EBV
infections (Rowe et al, 1987). On the basis of expression of latent cycle antigens,
EBV latency has been divided into three forms known as latency types I, II, and
III (Rowe et al., 1992; Brooks et al., 1993). In type I latency EBERS 1 and 2 and
EBNA1 mRNA are expressed by the virus and EBNA1 is the only latent protein
synthesized. This type of latency is observed in Burkitt's lymphoma (Rowe et al,
1986). Latency II is seen in EBV-related nasopharyngeal carcinoma, T cell
tumours, and Hodgkin's disease (Brooks et al., 1993; Deacon et al, 1993;
Minarovits et al., 1994; Yoshiyama et al., 1995 ) and is characterized by the
expression of EBERS, EBNA1, LMP1 and LMP 2a and 2b. In latency III all the
latent genes (EBERS 1 & 2, EBNA 1, 2, 3, 4, 5, and 6, LMP1 and LMP 2a and
2b), are expressed. Latency III is observed in EBV immortalized lymphoblastoid
e
cell lines and EBV related lymphoprolifrative disease (Brumbaugh et al, 1985).
1.2.8 EBV Encoded Latent Cycle Proteins
1.2.8.1 EBNA1
EBNA1 is a 65 to 85 kD phosphoprotein with an N-terminal and a C-terminal
domain. The two domains are joined by a glycine/alanine rich internal repeat
sequence of variable length. The length of the internal repeat determines the size
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of EBNA1 (Kirchmaier and Sugden 1995; Mackey et al., 1995). EBNA1 C-
terminal domain has DNA binding properties (Ambinder et al, 1990). EBNA1
mediates viral DNA replication and is essential for maintainence of the episomal
copy number during cell division (Rawlins et el, 1985; Yates et al., 1985). The
mechanism of activation of DNA replication by EBNA1 is not understood
completely (Kirchmaier and Sugden 1995; Mackey et al., 1995). EBNA1 is
present in all three types of EBV latency and is expressed in all EBV related
tumours (Jones et al., 1989; Snudden et al., 1994).
1.2.8.2 EBNA2
EBNA2 is an 86 kDa phosphoprotein, which regulates viral and cellular gene
transcription by transactivation of EBV and host cell-encoded genes. EBNA2 is
essential for B cell immortalisation (Cohen et al, 1989) since deletion mutants fail
to immortalise B cells (Rabson et al, 1982; Hammerschmidt et al, 1989). EBNA2
transactivates EBNA1, 3, 4, 6, LMP1 and LMP 2a and 2b expression (Abbot et
al., 1990; Wang et al., 1990b; Robertson et al., 1995; Cohen et al, 1989) and up-
regulates expression of cellular onocogenes c-fgr and be1-2 and B cell activation
markers CD21, and CD23 (Cohen et al., 1991; Wang et al., 1990a; Wang et al.,
1991). EBNA2 does not bind DNA directly and its transcriptional transactivation
function is mediated by the recombinant signal-binding protein (RBP-Jk)
(Johannsen et al, 1996; Groux et al, 1997). EBNA2 binding to RBP-Jk is essential
for B cell immortalisation because deletion of EBNA2 codons close to the site
which interacts with RBP-Jk results in inhibition of its ability to immortalise B
cells (Elarada et al, 1998).
1.2.8.3 EBNA3, 4 and 6
EBNA3, 4 and 6 (also termed EBNA 3a, 3b and 3c respectively) are grouped
together because they have a common origin. Like EBNA2, EBNA3, 4 and 6
interact with RBP-Jk and induce or modify transcription of genes under its control
(Robertson et al, 1996; Cludts and Farrel, 1998). EBNA3, 4 and 6 compete with
EBNA2 for binding with RBP-Jk and therefore have a potential to modulate
EBNA2-induced transactivation of LMP 1 and LMP2a and 2b. (Krauer et al, 1996;
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Longnecker and Miller 1996; Bourillot et al, 1998). EBNA4 is not essential for B
cell immortalisation in vitro (Tomkinson and Kieff, 1992) but it upregulates bell
expression and reduces the sensitivity of transformed cells to apoptosis (Silins et
al, 1995). EBNA6 up regulates the expression of CD21 (Wang et al, 1990). It has
also been reported that EBNA6 transfection of the Raji cell line, which has
deletions in EBNA6 open reading frame, results in upregulation of LMP1 and
CD23 (Allday et al, 1993).
1.2.8.4 EBNA5
EBNA5 or EBNA-LP (leader protein) is encoded from the open reading frame
which forms the leader sequence of each EBNA mRNA (Wang et al., 1987). It is
localized in small granules within the host cell nucleus (Wang et al, 1987) where
it is thought to control processing of EBV RNAs (Kieff & Liebowitz, 1990). It is
suggested that EBNA5 plays a role in B lymphocyte immortalisation by
stimulating and regulating EBNA2 mediated transcriptional activation
(Longnecker and Miller 1996; Harada and Kieff, 1997). Recombinant viruses with
deletions in EBNA5 show reduced, but still detectable, immortalising ability.
EBNA5 cooperates with EBNA2 in causing transition ofEBV infected cells from
GO to G1 phase during replication (Sinclair et al, 1994) and upregulates
expression of LMP1 (Nitsche et al, 1997).
1.2.8.5 LMP1
LMP1 is a 58-63 kDa protein with both cytoplasmic and transmembrane domains
(Leibowitz et al., 1986). LMP1 is a viral oncogene essential for B cell
immortalisation (Kaye et al, 1993). LMP1 transforms rodent fibroblasts in vitro
(Wang et al, 1985) and has been shown to induce expression of activation markers
and adhesion molecules when transfected in EBV negative Burkitfs lymphoma
cells or primary B lymphocytes (Wang et al, 1988; Birkenbach et al., 1993).
LMP1 also upregulates the expression of bcl-2, a cellular oncogene (Henderson et
al., 1991), human IL-10 (Nakagomi et al, 1994) and transcription factor NF-kB
(Hammarskjold & Simurda, 1992, Huen et al, 1995) through which it exerts its
effects on cytokine gene expression in host cells (discussed in detail in section
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1.6). Recently it has been suggested that LMP1 contributes to the generation of
Reed-Sternberg (R/S) cells in Hodgkin's disease by down-regulating the
expression of CD99. In LCLs this leads to generation of cells with morphology
and functions identical to those of R/S cells (Kim et al, 2000).
1.2.8.6 LMP 2a and 2b
LMP2a and 2b are 53 and 40 kDa proteins encoded by two mRNAs that have
eight common exons (Longnecker et al., 1991). LMP2a is thought to prevent
lytic viral replication in latently infected B cells (Miller et al, 1994). LMP2b is
thought to downregulate this activity of LMP2a. LMP2a and 2b are under the
control of separate promoters and differential expression may result in either lytic
activation or maintenance of latent infection (Longnecker and Miller 1996).
Although previously it has been reported that LMP2a and 2b are essential for
efficient transformation of B cells (Brielmeier et al, 1996), recently Speck et al,
have reported that recombinant EB virus lacking LMP2a and 2b immortalises B
cells as efficiently as the wild type virus and thus shown that LMP2a and 2b are
not involved in B cell transformation by EBV (Speck et al, 1999).
1.2.8.7 EBER1 and EBER2
EBV encodes two non-translated Epstein-Barr virus-associated early RNAs
known as EBER1 and 2. Both EBERs are transcribed by RNA polymerase III and
are the most abundantly expressed RNAs in all three forms of EBV latency
(approximately 107 copies per cell). It is suggested that EBERs are involved in the
transcription and processing of viral RNA and are associated with initiation of
transcription of all other viral mRNAs (Glickman et al., 1988). Previously it has
been reported that EBERs are not required for in vitro B cell immortalisation and
virus replication (Swaminathan et al, 1991). However, it has recently been shown
that EBERs have oncogenic functions in BL cells and are responsible for the
malignant phenotype and resistance to apoptosis in the BL cell line Akata
(Komano et al, 1999). EBER gene transfection into EBV-negative Akata lines
restored their capacity to grow in soft agar, tumorigenicity in SCID mice,
resistance to apoptotic inducers, and upregulated expression of bcl-2 oncoprotein.
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1.2.9 Lytic Cycle
EBV infection of B-lymphocytes is predominantly latent. Infection of epithelial
cells can be latent, as in NPC, but predominantly leads to complete viral
replication resulting in cytolysis (Sista et al., 1995). In the lytic cycle (virus-
productive), the synthesis and expression ofEBNA 1-6, LMP and LMP 2a and 2b
is followed by expression ofEBV lytic cycle genes in a sequential manner. Lytic
cycle genes are classified as immediate early, early and late genes. Each set
activates the expression of the next set. There are two immediate early genes:
BZLF1 and BRLF1. Early genes include the early antigens (EA), which are of
two types: EA-diffuse and EA-restricted (EA-D & EA-R). The EA-R is only
found in the nucleus and EA-D is found both in the nucleus and the cytoplasm
(reviewed in Crawford et al., 1987). Expression of early genes is followed by viral
DNA synthesis and finally the late genes are expressed which are structural
proteins.
1.3 Primary EBV Infection
Primary infection is usually asymptomatic in children although it might be
accompanied by mild pharyngeal disease (Henle et al, 1979). However, if primary
infection is delayed till early adulthood (15-25 years) it is often symptomatic and
manifests as infectious mononucleosis or glandular fever (Henle & Henle, 1979).
1.3.1 Infectious Mononucleosis (IM)
EBV was first identified as the cause of IM in 1968 (Henle et al, 1968; Niederman
et al, 1968).
1.3.1.2 Pathogenesis
IM is a disease mainly of the adolescents and EBV transmission occurs via
salivary exchange during kissing. The B cells in the lymphoid tissue of the
pharynx get infected and from this site the EBV infected B cells are disseminated
throughout the body via the blood stream. Primary EBV infection results in a
strong but self-limited, immune response in the host, associated with appearance
of a variety of immunoglobulins (including the heterophile antibody, auto¬
antibodies and antibodies to EBV antigens) and expansion of EBV-specific CTLs
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in the host. The exaggerated immune response (mainly CD8 T cells) is thought to
contribute to the clinical symptoms of IM (Foss et al, 1994).
1.3.1.3 Clinical Manifestations
The incubation period of IM is estimated to be 30-50 days. Classic symptoms
include sore throat, fever and fatigue. Common clinical signs observed include
lymphadenopathy, splenomegaly, hepatomegaly, eyelid edema, exanthems, and
enanthems. Signs and symptoms can be abrupt or may be preceded by a prolonged
prodromal period of fever with mild pharyngitits. Lymph node involvement is
bilateral and most commonly involves the posterior and anterior cervical chains.
Less commonly the axillary and inguinal nodes may be involved (Schooley,
1955). IM is usually self limiting and resolves in 1-2 weeks, but in 1:2000 cases it
can become chronic (Virelizier et al, 1978). Protracted or recurrent symptoms of
infectious mononucleosis are called chronic active mononucleosis and this
condition is characterised by fatigue, fever, pharyngitis, hepatitis and depression
(Andersson, 1991). The syndrome may continue for months and years following
typical IM with persistent serological evidence of primary EBV infection (Okano
et al., 1988).
Acute IM patients show moderate peripheral leukocytosis (>20,000/mm3). More
than 50% (or greater than 4,500/mm3) of these leukocytes are lymphocytes
(mainly CD8 positive T cells) of which at least 10% (or greater than 1,000/mm3)
are atypical lymphocytes previously referred to as Downy cells. The
lymphocytosis is due to EBV infection of B-cells followed by anti-EBV T and
NK cell proliferation. Mild thrombocytopenia occurs in around 50% cases with
platelet counts ranging from 100,000 to 140,000/ mm3. 90% cases may develop a
mild hepatitis in the second or third week with up to two-fold increase in hepatic
enzymes: lactic dehydrogenases, alkaline phosphatase and the transaminases.
1.3.1.4 Complications
Complications are rare after acute IM but can be serious. These include upper
airway obstruction (Wolfe et al, 1980), rash associated with ampicillin
administration (Patel, 1968, Pullen et al, 1967), splenic rupture and neurologic
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complications such as Guillain-Barre syndrome (Reller, 1973), cranial nerve
palsies, aseptic meningitis and meningoencephalitis (Grose et al, 1975,
Domachowske et al, 1996, Eshel et al, 1987).
1.3.1.5 Diagnosis
IM is routinely diagnosed by serological detection of the heterophile antibody
(McDougal, 1978). Heterophile antibody is of IgM class and is present in 60-70%
of patients in the first week of clinical illness and can persist for up to 12 months.
IgG and IgM antibodies directed against EBV-specific antigens can be detected
by immunofluorescence assays, enzyme immunoassays, and immunoblot
techniques. Presence of IgM anti-VCA and absence of antibodies to EBNA is
diagnostic of acute, primary infection.
1.4 Immune Response to EBV
The first line of defence against the virus is interferon, secreted by virally infected
B cells. It may control EBV-induced B cell proliferation by antiviral replication
activity and enhancement of natural killer (NK) cell activity. (Lotz et al., 1986).
1.4.1 Humoral Immune Response to EBV
The first antibodies to appear after EBV infection are the anti-VCA IgM and IgG.
These antibodies appear before the onset of clinical disease and the IgG response
persists for life (reviewed in Crawford et al., 1987). Anti-EA-D IgG antibodies
develop transiently and disappear during convalescence. However, in some cases
they may persist at low titres (Linde, 1992). EA-R antibodies are rarely present in
acute infection (de The, 1982). Anti-EBNAl IgG are not present in acute infection
and are only detected weeks to months post infection and then persist indefinitely
(Henle et al., 1987).
1.4.2 Cellular Immune Response to EBV
The anti-EBV cellular immune response involves both NK cells and EBV
antigen-specific T cells which have the potential to kill EBV infected cells (Callan
et al, 1998). NK cell killing of EBV infected cells is both direct and antibody
dependent, however, a higher effector to target ratio is required for target lysis as
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compared to CTLs (Masucci et al, 1981). EBV-specific CD8 positive CTLs
recognize HLA class I associated EBV antigen epitopes presented on B cells or
other antigen presenting cells (APC). These persist in the immunocompetent host
as CTL precursors (CTLp) with frequencies ranging between 1/400-1/42,000 of
the total T cell population (Kusunoki et al, 1993). HLA class II restricted anti-
EBV CD4-positive T cells also appear during primary EBV infection but are
present at much lower levels as compared to the CD8 positive CTLs (Misko et al
1984). The CTL response to different EBV latent antigens is not equal and in
majority of cases CTLs are primarily directed against immunodominant epitopes
within primary sequences of EBNA 3, 4 and 6 (Khanna et al, 1992, Murray et al,
1992, Rickinson, 1998). A lesser degree of response is seen to EBNA 2, 5, LMP1
and LMP 2a and 2b (Gavioli et al 1992, Khanna et al, 1992, Murray et al, 1992,
Khanna et al, 1998). Dominance of response against particular antigen epitopes
depends upon level of expression of the epitope on the host cell surface. Lee et al
studied the level of expression of HLA-A-11 restricted EBNA4 epitopes and
found that the dominant HLA-A-11 epitope was presented on the cell surface at a
frequency higher than that of other HLA-A-11 restricted EBNA4 epitopes (Lee et
al, 1995). Immune dominance of an epitope is also influenced by the efficacy with
which it binds to HLA molecules (Khanna et al, 1997). Non-binding to HLA
molecules is thought to be the reason why CTL response to EBNA1 is rare and
has only been detected in occasional cases (Blake et al, 1997). EBNA1 contains a
200 residue long glycine-alanine repeat region, which prevents its degradation by
the host cell and prevents complexing of EBNA1 antigenic epitopes with HLA
molecules for presentation at the host cell surface (Levitskaya et al, 1997; Sharipo
et al, 1998). Various HLA class I restricted immunodominant epitopes have been
identified in EBV antigens (Murray et al, 1992). A list of immunogenic EBV
antigen epitopes, their position in the primary antigen sequence and HLA
restriction is shown in table 1.1. A strong CTL response to EBV lytic antigens is
also seen during primary infection. This response is stronger than that to latent
cycle antigens during the primary infection but the numbers of lytic antigen-
specific CTLs fall after acute infection (Steven et al, 1997, Callan et al, 1998, Tan
et al, 1999, Khanna et al, 1999). However, CTLs directed against immediate early
genes: ZEBRA and BHRF-1 are maintained at significant frequencies after acute
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infection has subsided (White et al, 1996). This may serve to limit the number of
B cells undergoing lytic viral infection and thus control virus production.
Table 1.1
Defined T cell immunogenic epitopes of EBV-encoded proteins and presenting HLA-
alleles
F.BV Antigen HLA Allele Residue Epitope
Sequence





t B2704 236-244 RRRWRRLTV
B60 200-208 IEDPPFNSL





EBNA-4 All 399-408 AVFDRKSVAK
All 416-424 IVTDFSVIK









(Adapted from O'Reilly et al, 1998)
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1.5 EBV Related Malignancies
1.5.1 Post-transplant Lymphoproliferative Disease (PTLD)
Post-transplant B cell lymphoproliferative disorders (PTLD) include a variety of
lymphoid hyperplasias and neoplasms that are observed in organ transplant
recipients. These opportunistic neoplasms occur as a consequence of the
immunosuppression, which is required to prevent graft rejection (Brumbaugh et
al, 1985, Swinnen, et al 1995). EBV is thought to be an important cofactor in the
development of PTLD and is present within the malignant B cells in 90% cases
(Chadburn et al, 1997). EBV related PTLD occurs in approximately 1-2% bone
marrow, 1% renal, 2% liver, 5-9%, heart/lung, 2-10% heart and 19% of intestinal
transplant recipients (Chen et al, 1993; Reyes et al, 1996). PTLD tumour cells are
phenotypically similar to LCL cells in that they express all EBV latent antigens
and B cell activation marker CD23 (Young et al, 1989; Thomas et al, 1990).
PTLD most commonly arises within the first post-transplant year (Penn, 1994).
The tumour may arise in lymphoid tissues such as tonsils or lymph nodes, but
often occurs in extranodal sites. PTLD can arise from either donor or recipient
cells but most commonly arises from recipient cells in solid organ transplant
patients and donor cells in bone marrow recipients (Chadburn et al, 1995;
Weissmann et al, 1995; Zutter et al, 1988). Involvement of the transplanted organ
in the mal ignant process is reported in 30-40% of cases (Cohen, 1991).
1.5.1.1 Histology and Classification of PTLD
Histologically PTLD can range from hyperplastic lesions or atypical lymphoid
lesions, to aggressive B cell lymphomas, which are usually of the non-Hodgkins
variety (Harris et al 1997). PTLD was first classified into four separate
histological categories in 1981 by Frizzera et al (Frizzera et al, 1981):
polymorphic diffuse B cell hyperplasia, polymorphic B cell lymphoma, reactive
lymphoid hyperplasia and immunoblastic sarcoma. In 1988, Nalesnik separated
monomorphic tumours from the polymorphic form of the disease (Nalesnik et al,
1988) and in 1995, Knowles et al combined tumour histology with molecular
genetic analysis and classified PTLD into: reactive hyperplasia of plasma cells,
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monoclonal polymorphic hyperplasia and polymorphic lymphoma and true
monoclonal lymphomas with possible alterations in proto-oncogenes and/or tumor
suppressor genes (TSG) (Knowles et al, 1995). In 1997 Harris et al added
plasmacytomas, T cell rich B-cell lymphomas, and T cell lymphomas to the PTLD
classification (Harris et al, 1997).
1.5.1.2 Pathogenesis ofPTLD
The association of PTLD tumours with EBV was first shown by detection of
EBNA antigen in tumour sections (Crawford et al, 1980) and later by the
demonstration of EBV DNA within PTLD tissue (Weiss & Movahed, 1989).
Immunosuppressive drugs used in transplantation have been shown to suppress
EBV-specific CTL response in vitro (Crawford et al, 1981; Tsoukas et al, 1982;
Burman & Crawford, 1991) and very low EBV-specific CTL activity has been
reported in transplant recipients during immunosuppression (Haque et al, 1997).
In 1-10% cases this results in an uncontrolled proliferation of EBV transformed
B-cells, causing PTLD (Penn, 1989). Graft recipients who are EBV negative prior
to transplantation but seroconvert after the procedure are at particular risk because
they do not have a memory CTL response to EBV.
EBV latent gene expression in most PTLD tumours is latency type III (Thomas et
al, 1990; Young, 1989). However, latency types II and I have been observed in
some cases (Thomas et al, 1990; Gratama et al, 1991; Delecluse et al, 1995).
Although most transplant recipients are EBV seropositive, the occurrence of
PTLD in only a small proportion of these cases is suggestive of additional factors
required for PTLD development. The tumour frequently occurs in the GI tract and
the transplanted organ, which are both sites of chronic antigenic stimulation and
are rich in cytokines (Chen et al, 1993; Cohen, 1991). Tumours are infiltrated with
CD4+ T cells, which might provide growth factors for tumour development
(Perera et al, 1998). Serum levels of Th type 2 cytokines: IL-4, 6 and 10 have
been reported to be elevated in PTLD patients as compared to normal individuals
(Tosato et al, 1993; Mathur et al, 1994) and IL-4 and 10 mRNA has been detected
in PTLD tissue by reverse transcriptase-polymerase chain reaction (RT-PCR)
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(Nalesnik et al, 1999). These cytokines are B cell growth factors and might
contribute to the pathogenesis of the disease.
1.5.1.3 Treatment of PTLD
1.5.1.3.1 Conventional Treatment
Reduction or discontinuation of immunosuppression is the standard first line
treatment for PTLD (Starzl et al, 1984, Kawa et al, 2000). This allows the host
immune system to recover and mount an anti-EBV response. In a study by
Malatack et al less severe disease such as lymphadenopathy was controlled by
50% reduction in immunosuppression but lymphomas and disseminated disease
required complete withdrawal of immunosuppressive drugs (Malatack et al,
1991). However, withdrawal of immunosuppressive drugs can result in allograft
rejection (Swinnen, 1995). This can be avoided by giving the minumum dose of
immunosuppressive therapy required for prevention of graft rejection (Swinnen,
1995). Anti-virals such acyclovir and gangcyclovir have been used successfully to
control PTLD in certain studies (Darenkov et al, 1997). However both these drugs
have no effect on latent virus infection and their role in treatment of PTLD is
dubious. Alpha-interferon has also been used effectively to induce regression in
PTLD tumours in transplant recipients (Davis et al, 1998; Faro et al, 1996). Multi-
agent chemotherapy induced remission of PTLD in 75% cases in a study by
Swinnen et al on cardiac transplant recipients (Swinnen et al, 1997). In another
study Balfour et al reported remission of PTLD in solid organ transplant patients
with a combination of cyclophosphamide and prednisone. (Balfour et al, 1999).
Recently, Schoch et al reported successful treatment of a lung transplant recipient
undergoing acute graft rejection and suffering from EBV-positive PTLD, with a
combination of extracorporeal photochemotherapy and moderate reduction of
immunosuppressive therapy (Schoch et al, 1999).
1.5.1.3.2 Adoptive Cellular Immunotherapy
Cellular immunotherapy was introduced in 1992, when human cytomegalovirus
(HCMV)-specific CD8+ T cells were grown in vitro and used to reconstitute
immunity to human cytomegalovirus (Riddell et al, 1992). Since then major
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advances have been made in the field of adoptive cellular therapy for many human
diseases particularly cancers including malignant melanoma, ovarian carcinoma
(Han et al, 1999, Hayashi et al, 1999), colorectal cancer (Miyazono et al, 1999),
bladder cancer (Peralta et al, 1999), HPV related cervical carcinoma (Schoell et
al, 1999), EBV-related Hodgkin's disease (Roskrow et al, 1998) and PTLD (Boyle
et al, 1993; Papadopoulos et al, 1994; Rooney et al, 1995; Khanna et al, 1999).
Several studies have demonstrated that PBMC or in vitro expanded EBV specific
T cells from transplant donors can control growth ofPTLD tumours (Heslop et al,
1994; Heslop et al, 1996). In 1994 Papadopoulos et al reported complete
regression of EBV related PTLD in five bone marrow transplant recipients with
repeated small dose infusion of donor PBMC. However, graft-versus-host disease
(GvHD) was a complication observed in all cases in this study due to the
alloreactive T cells in unfractionated donor PBMC (Papadopoulos et al, 1994). In
1997 Nalesnik et al acheived regression of PTLD in four transplant patients who
were unresponsive to reduction in immunosuppression by using PBMC cultured
in vitro with IL2 for 10-12 days (Nalesnik et al, 1997). Phenotypic analysis
showed that the expanded cells had large populations of both T and NK cells,
which were specific for both autologous and allogeneic EBV transformed cells
and demonstrated a strong cytotoxicty to K562 cells, a leuka^nic cell line
sensitive to NK cell killing (Nalesnik et al, 1997). To reduce the problem of
GvHD in PTLD patients, the use of in vitro grown virus-specific T cells, which
have been stimulated with autologous cells presenting viral target antigens was
first reported by Rooney et al in 1995. They used in vitro generated donor EBV-
specific T cells for prevention of PTLD in pediatric bone marrow transplant
(BMT) recipients. T cell lines were grown and expanded in vitro with autologous
(donor) irradiated LCL cells as stimulators. T cells were expanded for 21-28 days
to select the EBV-specific T cell clones and potentially reduce the population of
alloreactive T cells. To trace the fate of the infused T cells in vivo, the cells were
labeled with a retroviral vector carrying a neomycin resistance gene (neoR). Three
BMT patients with PTLD of donor cell origin were treated with the labeled T
cells. All the three patients showed regression of disease (Rooney et al, 1995). In
another study the same group prophylactically infused 25 BMT recipients with
neoR-marked donor CTLs. None of the patients developed PTLD in contrast to the
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historical non-CTL treated transplant group in which 19% (5 out of 27) developed
PTLD. No GvHD was observed in patients infused with the EBV-specific CTLs
and the cells could be detected in the peripheral blood of recipients for a periods
of 18 months (Heslop et al, 1996).
All these studies were carried out in BMT recipients where the tumour is of donor
cell origin and the donor is healthy and available for providing CTLs. However,
PTLD tumours in solid organ transplant recipients originate from recipient cells
(Cen et al, 1991; Weismann et al, 1995) and the donor is often cadaveric or not
readily accessible. Therefore, logical approaches to cellular immunotherapy of
PTLD in this scenario would be to either store recipient PBMC prior to
transplantation and immunosuppression or to use in vitro expanded EBV-specific
allogeneic HLA-matched CTLs (reviewed in Haque et al, 1999). The feasability
and safety of in vitro generated autologous EBV-specific CTLs for control of
PTLD has been studied by Haque et al in three healthy solid organ transplant
recipients (Haque et al, 1998). Infusions of escalating doses of CTLs were
delivered at fixed intervals to each patient post transplant. EBV-specific CTL
precursor (CTLp) numbers rose higher than those measured in pre-transplant
samples and remained high till 3 months after the last infusion. CTLp were
functional and EBV-specific when tested in standard chromium release assays.
Compared to pretransplant levels, EBV DNA levels rose post transplant but
dropped to levels lower than pretransplant levels after CTL infusions and
remained low for 3 months post infusion. The patients remained healthy and no
GvHD was observed (Haque et al, 1998). In another study autologous EBV-
specific CTLs generated from an EBV seronegative solid organ transplant
recipient, who seroconverted post transplant and developed PTLD, have been
successfully used to cause regression of the tumour (Khanna et al, 1999).
Due to the non-likelihood of obtaining pre-transplant PBMC samples from all
transplant patienbinterest is now turning more towards PTLD therapy with in vitro
grown HLA-matched but allogeneic CTLs (reviewed in Haque et al, 1999) which
could serve as an inexpensive and a less labour intensive alternative to growing
autologous CTLs from all transplant patients. The same group is now in the
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process of developing an EBV-specific CTL bank from EBV-seropositive healthy
donors of different HLA types. This would provide immediate cellular therapy for
PTLD cases refractory to conventional treatment (Haque et al, 1999).
In contrast to PTLD, which expresses the full range of latent viral proteins, other
EBV-related malignancies (BL, NPC, HD) do not express all the EBV genes
(Kerr et al, 1992; Ambinder & Mann, 1994; Rickinson et al, 1998). CTL
responses to EBNA1 have not been observed because of lack of presentation of
EBNA1 immunogenic epitopes on host cell surface (Kerr et al, 1992, Wrightham
et al, 1995). However, studies have shown that the malignant epithelial cells in
NPC and Reed-Sternberg cells in EBV positive HD express LMP1 and 2 along
with EBNA1 (Khanna et al, 1998; Sing et al, 1997). Cells expressing
immunodominant epitopes from within the primary LMP1 and 2 sequences could
serve as potential targets for CTLs specific for these epitopes. Although CTL
response to LMPs constitiutes a minor proportion of overall EBV-specific CTL
response, recently CTL target epitopes have been identified in LMP1 (Khanna et
al, 1998) and LMP2a and 2b (Lee et al, 1997, Khanna et al, 1999). In vitro
expanded CTLs targeted to these epitopes have been shown to effectively lyse
cells expressing these epitopes (Khanna et al, 1999). Therefore, selective in vitro
expansion of epitope-specific CTLs could form the basis of a CTL therapy for
EBV related malignancies which have a restricted pattern of EBV gene
expression.
1.5.2 EBV related Nasopharyngeal Carcinoma (NPC)
NPC is a rare squamous cell carcinoma of the nasopharynx (Old et al, 1966) with
a world wide annual incidence 1 per 100,000 persons (Hirayama, 1978).
However, compared to the rest of the world it has a higher incidence in China,
Africa, Alaska and Greenland (Muir et al, 1972) with the highest incidence in
Southern Chinese of 23.3 and 8.9 per 100,000 for males and females respectively
(Simons et al, 1982; Muir et al, 1972; Fandi et al 1994).
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1.5.2.1 Histological Appearance and Classification
Electron microscopy has shown that all NPC tumours are of squamous epithelial
cell origin (Ensley et al, 1986, Fandi et al, 1994). However, tumours differ in their
histological appearance and are classified into two main histologic types. 70%
tumours are undifferentiated non-keratinising type, 30% show squamous
differentiation (Niedobitek et al, 1991).
1.5.2.2 Aetiology & Pathogenesis
NPC has a multifactorial aetiology. It shows a strong association with EBV (Neel
et al, 1984). EBV genome and expression ofEBV latent antigens have been found
in both non-differentiated and in well differentiated NPC tumours (Anderson-
Anvert et al, 1979; Raab-Traub et al, 1987). EBV in NPC tumours shows type II
latency with expression of EBERS, EBNA1, LMP1 and LMP2a and 2b (Fahraeus
et al, 1988; Brooks et al, 1992). Environmental factors such as tumour-promoting
factors in regional food are also thought to predispose to NPC. Herbal remedies
made from plant extracts of the families Euphorbiaceae and Thymeliaceae
containing phorbol esters, and childhood consumption of salted fish containing
carcinogenic volatile nitrosamines, mainly N-nitrosodimethylamine and N-
nitrosodiethylamine, have been suggested as a risk factors (Hirayama, 1978; Yu,
1990). It is suggested that both these environmental factors interact with EBV by
increasing its replication and facilitating the oncogenic effect of LMP1. More
recently Ho et al have reported NPC occurence in three workers in Taiwan who
faced prolonged exposure to sulphuric acid vapour (Ho et al, 1999). NPC also has
a higher incidence in individuals with the HLA types A2, Aw33, Bw46, B58,
DR9 Cwll, C3 (Chan, 1990) and DR3 (Mellins et al, 1990). HLA A2, Cwll,
Bw46 with a missing DR9 locus are associated with old age onset (over 30 years
of age) of NPC and indicate a better prognosis than the early age onset variety
(below age of 30 years), which is associated with HLA Aw33, C3, Bw58 and
DR3 (Chan et al, 1983; 1990; Zhu et al, 1990).
1.5.2.3 Signs and Symptoms
Most commonly NPC presents as unilateral or bilateral, painless, enlarged
cervical lymph nodes (approximately 75% of patients) (Sham et al, 1990). Upper
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cervical nodes are the first to be affected and nodal involvement progresses in a
cephalad-caudal direction (Sham et al, 1990). Other common symptoms are nasal
obstruction, epistaxis, diminished hearing (Su & Juan, 1985), tinnitus and
recurrent otitis media (Chowdhury et al, 1988). Neurological involvement
indicates advanced local disease and commonly causes headache and cranial
nerve dysfunction (usually V-VI or IX-XII), which can present as altered facial
sensations, diplopia, trigeminal neuralgia and Horner's syndrome (Skinner et al,
1991).
1.5.2.4 Diagnosis and Treatment
NPC is diagnosed by visual examination (mirror or endoscopic) and biopsy of the
nasopharyngeal mass, computed tomographic (CT) scan or magnetic resonance
imaging (MR1) (Vogl et al, 1990). Serological detection of anti-VCA IgA
supports the diagnosis of EBV related NPC (Tarn et al, 1990). Smaller tumours
can be cured by radiation therapy, with survival rates of 80% to 90% (Bailet et al,
1992). Large or disseminated tumours or tumours not responding to radiotherapy,
are treated with concurrent chemotherapy with cisplatin and 5 flourouracil (Ong et
al, 1999; Chua et al, 2000). Prognosis depends upon the size of the tumor, stage,
and involvement of neck nodes (Sanguineti et al, 1997). Advanced disease,
associated with cervical lymph node, cranial nerve, and bone involvement are
often difficult to control and distant metastases occur despite local control (Fandi
et al, 1994; Fandi et al, 2000; Teo et al, 1999).
1.5.3 Hodgkin's Disease (HD)
Hodgkin's disease is a lymphoid malignancy first described by Thomas Hodgkin
(Hodgkin T, 1832). Histologically HD is distinct from other lymphomas because
of the presence of multinucleated giant Reed-Sternberg (R/S) cells (Reed, 1902).
R/S cells are characteristic of HD and contain two or more nuclei of large size
with large inclusion-like nucleoli. Nucleoli are surrounded by a clear zone with
homogeneous eosinophilic or amphophilic staining characteristics. Due to rarity
of R/S cells in HD comprehensive analysis of their origin has not been possible.
However, recently Cossman et al reported similarities between gene expression of
R/S cells and germinal center B cells and have suggested that R/S cells are
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derived from a B cell lineage (Cossman et al, 1999). The R/S cells can vary in
their morphological appearance, depending on the histological subtype.
1.5.3.1 Cellular Classification
Pathologists currently use the Rye modification of the Lukes' classification for the
histologic classification for adult Hodgkin's disease (Lukes et al, 1966)
Classic HP




In the nodular sclerosis type HD thick fibrous bands divide the lymph node into
cellular nodules containing the neoplastic proliferation. The external fibrous
capsule is also thickened. Lacunar cells are a variety of R/S cells and a feature
unique to nodular sclerosis HD.
1.5.3.1.2 Mixed Cellularity
Mixed cellularity HD has a background of inflammatory cells comprised mainly
of lymphocytes, eosinophils, neutrophils, histiocytes and plasma cells. Compared
to other HD types this has more numerous R/S cells, and has a slightly worse
prognosis.
1.5.3.1.3 Lymphocyte Depletion
In the lymphocyte depletion HD necrosis is prominent in the germinal centers,
surrounded by R/S cells. Some cases of lymphocyte depletion contain infiltrating
atypical cells, sometimes referred to as sarcomatoid cells.
1.5.3.1.4 Lymphocyte Predominant
Lymphocyte-predominant HD is distinct from classic disease. R/S cells are very
rare and frequently absent and the immunophenotype is CD15-, CD20+, CD30-,
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CD45+, while the profile for classic HD is CD15+, CD20-, CD30+, CD45- (von
Wasielewski et al, 1997; Bodis et al, 1997). Although the classical and
lymphocyte predominant varieties of HD differ in their immunophenotype, no
significant difference is observed between their clinical response or outcome to
standard therapies (Diehl et al, 1999).
1.5.3.2 Aetiology of HD
60% of HD cases are associated with EBV. However, the exact relationship
between EBV and pathogenesis ofHD is still unclear. The first evidence of EBV
involvement in the pathogenesis ofHD came in the early seventies when different
scientific groups detected high titre anti-EBV antibodies in sera of patients
suffering with HD (Goldman et al, 1970; Johansson et al, 1970). EBV genome
and latent EBV genes have been detected in both R/S and mononuclear HD cells
(Karameris et al, 1992) and EBV genome was found in both mixed cellularity and
nodular sclerosing varieties ofHD (Boiocchi et al, 1992). The risk of developing
HD 5 years post acute IM infection is increased 5 to 6 folds as compared to
controls (Mueller et al, 1989).
1.5.3.3 Clinical Manifestations and Disease Staging
The most common presentation of HD is painless lymphadenopathy, usually
involving the cervical nodes but occasionally the axillary or inguinal/femoral
nodes. Constitutional symptoms such as irregular low grade fever, drenching night
sweats, and over 10% weight loss can preceed clinical HD. Thoracic disease may
present with cough, chest pain, dyspnea, and, rarely hemoptysis. Bone
involvement can present as bone pain and/or back pain and signs and symptoms
of spinal cord compression. Anemia and splenomegaly with hypersplenism may
also be seen.
The staging classification currently in use for HD was adopted in 1971 at the Ann
Arbor Conference (Carbone et al, 1971) and later modified at the Cotswolds
meeting (Lister et al, 1989). HD is divided into four stages based on a
combination of clinical and pathologic features of the disease. Stages are further
subclassified into A and B categories: Category A includes patients with no
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clinical symptoms and category B includes cases with defined general symptoms:
unexplained loss of more than 10% of body weight in the 6 months before
diagnosis, unexplained fever with temperatures above 38 degrees Celsius,
drenching night sweats (Carbone et al, 1971)
Stage I
Stage I involves a single lymph node region or localized involvement of a
single extralymphatic organ or site.
Stage II
Stage II involves 2 or more lymph node regions or a single associated
extralymphatic organ or site and its regional lymph node(s) with or without
involvement of other lymph node regions on the same side of the diaphragm.
Stage III
Stage III involves lymph node regions on both sides of the diaphragm with or
without involvement of an associated extralymphatic organ. Splenic involvement
is included in stage III disease.
Stage IV
Stage IV involves disseminated (multifocal) disease on one or both sides of
diaphragm accompanied by distant (nonregional) nodal involvement.
1.5.3.4 Treatment and Prognosis
Without treatment HD has a 5 year survival rate of 5% however, chemotherapy
and radiotherapy achieve cures in up to 70% of cases. In early disease radiation
therapy is delivered locally to clinically involved sites and to regions of initial
nodal involvement (Sears et al, 1997). Paediatric or advanced-staged adult
patients also receive chemotherapy in conjunction with radiotherapy. EBV-
specific cytotoxic T cell therapy has also been used to treat relapsed EBV positive
HD. However, the success rate has not been as good as that for PTLD. Rooney et
al, generated autologous EBV specific CTLs from 11 HD patients and treated 3
with gene-marked EBV-specific CTLs. All three patients showed transient
recovery from clinical symptoms but relapsed during or after termination of CTL
treatment (Rooney et al, 1998).
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1.5.4 Burkitt's Lymphoma (BL)
Burkitt's lymphoma is one of the fastest growing human cancers. It is a
monoclonal B cell neoplasm characterized by small non-cleaved cells that express
surface IgM (Pelicci et al, 1986). BL cells contain one of three cytogenetic
abnormalities involving a translocation between chromosomes 8 and 14,
chromosomes 8 and 22 or chromosomes 2 and 8. The abnormality is a balanced,
reciprocal translocation of genetic material from the long arm of chromosome 8 to
the long arm of chromosome 2, 14 or 22 and results in dysregulation of c-myc
oncogene on chromosome 8 by bringing it under the control of an
immunoglobulin gene promorter on chromosomes 14, 22 or 2 (Bernheim et al,
1981). BL has two variants: African and non-African (also referred to as endemic
and sporadic). Both types are histologically and cytogenetically similar but have
different epidemiologic patterns and clinical presentations.
1.5.4.1 Pathogenesis
EBV is associated with the African type with EBV genome detected in 97% cases
(zur Hausen & Shulte-Holthausen, 1970; Anderson et al, 1976). BL cells display
type 1 EBV latency; EBERS 1 and 2 and EBNA1 are the only genes expressed
(Rowe et al, 1986). Another co-factor associated with African BL pathogenesis is
Plasmodium falciparum malaria (Burkitt, 1969). It is suggested that
hyperendemic-malaria induced immunosuppression contributes to EBV-driven B
cell proliferation in BL patients. High turnover of B cells in the bone marrow is
thought to result in one of the three chromosomal translocations specific to BL
(Lenoir & Bornkamm, 1987).
1.5.4.2 Clinical Features and Treatment
African BL is more common in male than female children with the mean age of
onset of 7 years (Quinn, 1983). It can occur at any site in the body but 70%
present as a rapidly growing jaw or orbital mass. Less commonly BL can present
as an abdominal mass involving the kidneys and ovaries, however, nodal and bone
marrow involvement is not usual (Burkitt, 1958, Burkitt & O'Conner, 1961). The
tumour is rapidly growing, firm and painless and if not treated is invariably fatal
(Burkitt, 1983). The alkylating agent cyclophosphamide is the drug of choice for
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the treatment of BL (Ziegler et al, 1970) which induces complete sustained
remission in 50% cases, especially if tumours are small.
1.5.5 X-linked lymphoproliferative Syndrome (X-LPS) or Duncan's disease
This is a rare familial disorder, which occurs in people carrying a defective gene
on chromosome X, which selectively disables the host's immune control of EBV
infection resulting in uncontrolled proliferation of EBV-infected lymphocytes
(Purtilo et al, 1974, Skare et al, 1987). This causes fatal IM with liver disease in
70% of those affected (Jager et al, 1998). Some patients survive the initial
infection but later develop fulminant lymphoproliferative disease (plasmacytoma,
B cell and histiocytic lymphoma), hypogammaglobulinemia and other
immunologic abnormalities (Purtilo et al, 1982, Mroczek et al 1987). The genetic
abnormality associated with X-LPS has been localized to the Xq25 (Maia &
Garawacki, 1999). A recent study by Sayos et al suggested that dysregulation of
T/B-cell interactions induced by signaling lymphocyte activation molecule
(SLAM), due to the absence of its inhibitor SLAM-associated protein (SAP),
leads to an inability to control EBV driven B-cell proliferation (Sayos et al, 1998).
SLAM is a glycoprotein belonging to the immunoglobulin gene superfamily
(Cocks et al, 1995). It is expressed by both B and T cells and is a potent stimulator
of cell activation and proliferation (Punnonen et al, 1997). The gene for SAP has
been mapped to the same area as the X-LPS gene and mutations in SAP have been
identified in patients with X-LPS (Sayos et al, 1998). Unless treated X-LPS
inevitably results in death by age of 40 (Grierson & Purtilo, 1987).
1.5.6 Oral hairy leukoplakia (OHL)
OHL is an EBV associated epithelial lesion associated with immunodeficiency
and most commonly occurs in AIDS patients (Wurapa et al, 1999) but is also
observed in transplant recipients (Greenspan et al, 1985). It is found
predominantly on the lateral margins of the tongue, but can also occur on the
lining of the cheek and under the tongue (Greenspan et al, 1984) The lesions are
white in appearance with an irregular surface and fine vertical corrugations.
(Greenspan et al, 1984, Kabani et al 1989). The size and appearance of the lesion
varies and it can be unilateral or bilateral. Most commonly OHL is asymptomatic
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and does not require treatment. Lesions regress with prolonged acyclovir
treatment and temporary resolution has been achieved with desciclovir, an analog
of acyclovir (Greenspan et al, 1990).
The lesion contains replicating EB viral DNA and may be co-infected with
multiple EBV strains (Webster-Cyriaqu & Raab-Traub, 1998). Webster-Cyriaqu
& Raab-Traub characterized EBV gene transcription within OHL biopsy
specimens and found expression ofEBERS 1 & 2, EBNA1-6, LMP1, LMP 2a and
2b and BamHI A rightward reading frame mRNA in the lesion (Webster-Cyriaqu
& Raab-Traub, 1998).
1.6 Cytokines Production by EBV Infected Cells
Cytokines are soluble proteins and peptides which act as humoral regulators at the
inter and intra-cellular level to modulate functional activities of individual cells
and tissues both under normal and pathological conditions (Balkwill & Burke,
1989). Effects of cytokines can be autocrine, paracrine, or both (Kennedy and
Jones, 1991). Unlike classical hormones, cytokines are not produced by cells
present in specialized glandular tissue, and they act on a wider spectrum of target
cells (Imura et al, 1991). Cytokine network is a term used to refer to the
interactions between cytokines to control synthesis and biological activities of
themselves or/and other cytokines (Balkwill and Burke, 1989). The cytokine
network usually operates in a cascade where one cytokine triggers the expression
of one or more cytokines, which in turn, induce production or inhibition of other
cytokines or growth factors. Factors produced earlier or later in the cascade may
affect other cytokines and create feedback regulatory circuits. Cytokines can have
both beneficial and damaging effects depending upon the pathology which
stimulates or inhibits their secretion.
Studies have shown that addition of monocytes to in vitro cultured EBV infected
B cells can potentiate their growth and transformation ( Tosato et al, 1988). Cell
free supernatants from cultured monocytes and EBV immortalized B cells have
also been shown to promote growth of EBV transformed cells in vitro (Tosato et
al, 1989). These findings suggest that EBV transformed cells produce soluble B
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cell growth factors (cytokines), which are released in the supernatant and can
promote their own growth. In contrast, it has also been reported that T cells inhibit
the growth of EBV infected cells both by cytotoxicity and production of growth
supressing cytokines (Rickinson et al, 1996). This data suggests that the growth of
EBV infected B cells is controlled through both autocrine and paracrine
production of cytokines. Autocrine cytokine production by EBV infected B cells
is influenced by LMP1 via its ability to activate NF-kB/REL transcription factors
(Huen et al, 1995; Devergne et al, 1996). These transcription factors exist in an
inactivated form in the cytosol, complexed with a group of inhibitory IkB proteins
(Siebenlist et al, 1994). When activated they regulate the expression of IL-1, 2, 6,
8, tumour necrosis factor (TNF) a and TNFp (Siebenlist et al, 1994).
1.6.1 IL-1
Both translated IL-1 protein and transcribed IL-1 mRNA have been detected in
LCLs in vitro in several studies (Scala et al, 1984; Matsushima et al, 1985;
Vandenabeele et al, 1990). IL-1 secreted by LCLs is functional and increases
cellular proliferation rate (Blazar et al, 1990). IL-1 up-regulation is mediated
mainly by LMP1 through activation ofNF-kB (Krauer et al, 1998).
1.6.2 IL-2
IL-2, also called the T cell growth factor (TCGF), induces non-antigen related
proliferation ofT cells. Due to its positive effects on T cell proliferation IL-2 has
been used in adoptive immunotherapy of various human cancers (discussed in
section 1.5.1.3.2). Previous studies have shown that IL-2 is also secreted by LCLs
(Mouzaki et al, 1995) and normal B cells can be induced to secrete IL-2 if
stimulated with CD40 ligand (Kindler et al, 1995). IL-2 also promotes
proliferation of activated B-cells and both normal and malignant B cells express
an IL-2 receptor, which suggests that IL-2 can act on B cells in an autocrine
fashion (de Totero et al, 1995). IL-2 stimulates IFNy production in peripheral
lymphocytes and also induces the secretion of IL-1 , TNF-alpha and TNF-beta .
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1.6.3 IL-4
Banchereau et al reported IL-4 as a B cell growth factor irrespective of EBV
infection (Banchereau et al, 1991). In their study IL-4 promoted long term in vitro
growth ofEBV negative B cells. A recent study has reported that IL-4 enhances B
cell proliferation by reducing the average time cells take to enter the first division
cycle and by promoting normal B cell survival (Hasbold et al, 1999). In contrast,
it has been reported that EBV immortalized B cells produce IL-4 at a very low
level (Ohnishi et al, 1997). Other studies have shown that IL-4 either has no effect
on growth of LCLs and may actually inhibit their proliferation (Bende et al, 1992;
Defiance et al, 1992). It has been suggested that inhibition ofB cell growth by IL-
4 is due to its ability to inhibit IL-6 synthesis, which is a B cell growth factor
(Efermann et al, 1991).
1.6.4 IL-6
IL-6 is recognised as a B cell growth and differentiation factor (Yokoi et al,
1990). The main source of IL-6 in vivo is activated monocytes, fibroblasts and
endothelial cells (Helle et al, 1991). Feeder layers of activated monocytes and
fibroblasts have been shown to promote activation and proliferation of B cells in
vitro and IL-6 could be isolated from the culture supernatants (Tosato et al, 1988).
IL-6 is produced by LCLs (Tosato et al, 1990) and it has been reported that these
cells express a functional IL-6 receptor. This suggests that EBV infected B cells
might maintain their own growth by autocrine production of IL-6. Other studies
have shown that LCLs transfected with IL-6 gene are more tumourigenic than
non-IL-6 transfected LCLs in athymic mice (Scala et al, 1990; Tanner et al, 1991).
Increased tumourigenicity of IL-6 is thought to be because of its effects on B cell
growth and differentiation (Yokoi et al, 1990), its ability to inhibit NK cell
activity (Tanner et al, 1991) and its angiogenetic properties (Folkman, 1992).
1.6.5 IL-10
IL-10 is thought to be an immunosupressive cytokine. Transgenic mice expressing
human IL-10 fail to mount a significant T or B cell immune response when
immunologically challenged (Groux et al, 1999). IL-10 is produced in vitro by
both normal and EBV-transformed B cells (Armitage et al, 1993; Burdin et al,
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1993; Sairenji et al, 1998). IL-10 inhibits the synthesis of IFNy by Th-1 cells
(D'Andrea et al, 1993) and this inhibition is mediated indirectly by suppression of
IL-12 production (Gagro & Gordon, 1999). IL-10 is also known as B cell
differentiation factor (BCDF) and in vitro stimulates B-cell differentiation,
increases the MHC class II expression on these cells and induces antibody
production in activated B cells (Emelie et al, 1997). A previous study has reported
that IL-10 abrogates the cytotoxic capacity of T cells through suppression of T-
cell activation and through enhancement of growth of EBV-infected B-cells
(Bejarano & Masucci, 1998). Addition of exogenous IL-10 and EB viral
preparation to cultured B cells potentiates virus induced B cell transformation and
proliferation (Burdin et al, 1993). Other studies have observed a reduction in
cellular proliferation on addition of neutralizing anti-IL-10 antibodies added to B
cell cultures and LCLs (Stuart et al, 1995; Beatty et al, 1997). IL-10 has similar
effects on B cells as IL-6 and a recent study investigating their interaction has
reported that although both IL-10 and IL-6 promote B cell differentiation and Ig
production, they do so by independant mechanisms (Bonig et al, 1998). They
showed that stimulation of B-cells with IL-10 suppressed autocrine IL-6
production. However, IL-6 levels remained sufficiently high to stimulate its
receptor, and IL-6 binding to the B-cell surface was not affected (Bonig et al,
1998).
1.6.6 IFN-y
IFN-y is predominantly a negative regulator of B cell differentiation and
proliferation (O'Neil et al, 1999). In vitro, it upregulates the interaction between T
cells and APCs by inducing expression of costimulatory molecules such as CD80
and CD86 on lymphoma and leukaemia cell lines (Tsukada et al, 1997; Zheng et
al, 1998). IFN-y has also been reported to arrest tumour growth in conjunction
with CD8+ T cells in tumour mouse models (Farrar et al, 1999) and in a study by
Sgadari et al, it caused regression of subcutaneous human BL tumours in nude
mice (Sgadari et al, 1997).
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1.6.7 Viral IL-10 (vIL-10)
EB viral BCRF-1 protein is expressed during the lytic phase ofEBV life cycle in
B-lymphocytes (Stewart et al, 1994) but not in latency and therefore is thought not
to play a role in pathogenesis ofEBV related malignancies (Hayes et al, 1999). It
is structurally related and functionally similar to human IL-10 and is termed viral
IL-10 (vIL-10) (Hsu et al, 1990; Vieira et al, 1991). vIL-10 can be detected in the
serum in 50-60% cases of acute IM and chronic active EBV infection, (Taga et al,
1995; Kanegane et al, 1997) and it is suggested that vIL-10 suppresses antiviral
immune responses by specifically inhibiting T cell proliferation in response to
antigenic stimuli (Waal Malefyt et al, 1991). T cell inhibition by vIL-10 is
mediated by suppression of EFNy production (Vieira et al, 1991) and down-
regulation of cytokine production by monocytes (de Waal Malefyt et al, 1991).
Like human IL-10, vIL-10 promotes B cell proliferation and prevents apoptosis in
these cells (Rousset et al, 1992; Burdin et al, 1993; Levy et al, 1994). Miyazaki et
al have reported that blocking of vIL-10 gene with antisense oligonucleotides
resulted in inhibition of transformation of B cells (Miyazaki et al, 1993). These
reports suggests that like human IL-10, vIL-10 promotes the growth and
proliferation ofEBV infected B cells.
1.7 Cytokine Production by EBV Related Malignancies
1.7.1 PTLD
The cytokine profile of PTLD tumours has been studied by serological, reverse
transcriptase polymerase chain reaction (RT-PCR) and flowcytometry techniques.
In PTLD patients serum levels of IL-4, 6 and 10 have been reported to be raised
as compared to normal controls (Tosato et al, 1993; Mathur et al, 1994; Gamier,
1999) and IL-4 and IL-10 mRNA has been detected in primary PTLD tissue by
RT-PCR (Nalesnik et al, 1999). Johannessen et al, detected IL-2, 4, 6, 10 and
INFy mRNA by RT-PCR in EBV positive PBMC induced I/P tumours in SCID
mice, which serve as an in vivo animal model for PTLD (Johannesson et al, 2000).
PTLD tumours have been shown to be heavily infiltrated with CD4-positive T
cells (Perera et al, 1998) and it is possible that apart from autocrine cytokine
production by tumour cells, infiltrating T cells may be another source of cytokine
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production in PTLD. Birkeland et al, compared pre- and post-transplant serum
levels of IL-10 from PTLD patients and have reported a progressive increase in
serum IL-10 levels with disease progression (Birkeland et al, 1999).
1.7.2 Hodgkin's Disease (HD)
Blay et al measured serum levels of IL-1 alpha, IL-2, IL-4, IL-6 and tumour
necrosis factor (TNF) in 24 untreated patients with Hodgkin's disease by ELISA
and detected increased levels of IL-1, IL-2 and IL-6 in most cases compared to
healthy controls (Blay et al, 1994). In another study the expression of IL-10 in HD
tissue was investigated in 30 cases by immunostaining. Hodgkin and R/S cells in
16 of the 30 cases were EBV positive and tested positive for IL-10 expression
(Ohshima et al, 1995). Studies by other groups have also confirmed the expression
of IL-10 in HD (Herbst et al, 1996) and high serum levels of IL-10 have been
correlated with poor prognosis (Sarris et al, 1999). Increased IL-6 gene expression
and serum IL-6 levels have also been reported in HD (Gruss et al, 1992; Kurzrock
et al, 1993). Herbst et al, investigated IL-6 expression in EBV positive and
negative cases of HD. 84% of the EBV positive cases expressed IL-6 while only
51% of the EBV negative cases expressed IL-6 (Herbst et al, 1997). Like IL-10,
serum IL-6 levels are also thought to be correlated with clinical outcome of the
disease, with IL-6 levels rising before treatment is started and returning to
undetectable once remission has been acheived (Seymour et al, 1997).
1.7.3 Nasopharyngeal Carcinoma (NPC)
A recent study has reported immunohistochemical detection of increased IFN-y
levels in EBV related NPC (Tang et al, 1999). In this study the IFN-y signal was
predominantly observed in the infiltrating T lymphocytes. Fujieda et al, detected
IL-10 expression in EBV-related NPC by immunohistochemistry and they
negatively correlated its expression with 5 year survival of the patients (Fujieda et
al, 1999). The study included 21 patients out of which 12 tested positive for IL-
10. 87.5% of the IL-10 negative group survived for 5 years in contrast to only
15.6% of IL-10 positive patients. Statistical analysis showed that IL-10 expression
was significant as an independent prognostic indicator of overall survival (Fujieda
et al, 1999). Huang et al, recently investigated the expression profile of 12
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cytokines in NPC tumours by flowcytometry. RT-PCR was used to detect IL-1, 2,
4, 5, 6, 10, INFy, TNFa, TGFp, and IL-1 receptors. The tumours tested positive
for all cytokines with elevated expression of IL-1 compared to control tissue.
They identified the cell types responsible for IL-1 production to be both the
malignant epithelial cells and the infiltrating CD4+ T cells (Huang et al, 1999).
1.8 The Severe Combined Imuunodeficient (SCID) Mouse Model
SCID mice are C.B.-17 strain mice, which lack functional T and B cells (Bosma
et al, 1983). They harbor the scid/scid mutation, which affects the V(D)J
recombinase enzyme system involved in immunoglobulin (Ig) and T cell receptor
(TCR) gene rearrangements (Schuler et al, 1986). The scid/scid mutation prevents
productive rearrangement of immune receptor genes and results in arrest of
developing lymphoid cells at the immature "triple negative" phase, which do not
express T and B cell surface markers (Murphy et al, 1994). Although transcripts
of TCR y and [3 have been detected in SCID thymocytes, transcripts of complete
TCR gene rearrangements have not been demonstrated (Schuler et al, 1986).
Similarly complete transcripts of Ig gene rearrangements have not been detected
in immature SCID B cells (Schuler et al, 1988). With maturation, SCID mice
develop rudimentary antibody and T cell responses and are referred to as "leaky"
(Bosma, 1991). By 12 months of age SCID mice develop low levels of antibody
and oligoclonal B cells and T cells (Bosma, 1992). Some of the T cells are
functional because they can cause rejection of allogeneic skin grafts but do not
proliferate in response to lymphocyte mitogens (Bosma et al, 1992).
1.8.1 Xenograft of Human PBMC in the SCID Mouse; Model for EBV-
Related Lymphoid Malignancies
Due to absence of functional T and B cells, SCID mice accept xenografted human
cells. Transplanted human PBMC in the SCID mouse survive for at least 13
months and also maintain their immune function (Mosier et al, 1988, 1989). This
property makes these animals an ideal model to study human viral infections such
as HIV (van Kuyk et al, 1994) and cancers such as metastatic melanoma
(Sabzevari et al, 1993) and post-transplant lymphoma (Boyle et al, 1993). When
SCID mice are injected I/P with PBMC from EBV seropositive donors some
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develop tumours within 8-16 weeks (Mosier et al, 1988, 1991; Ramqvist et al,
1991). The tumours are of human B cell origin and histologically resemble
immunoblastic lymphomas (Mosier et al, 1988, 1990). The tumours cells have the
same surface phenotype as LCL cells and express CD 19, 20, 23, 39, and HLA
Class II molecules (Mosier et al, 1990). The cells express EBNA 1, 2, 3, 4, 5 and
6 and LMP1 & 2 (Rowe et al, 1990), which is consistent with type III EBV latent
gene expression pattern and is similar to EBV gene expression in the majority of
PTLD tumours (section 1.5.1.2). Thus these tumours are a model for studying
PTLD pathogenesis and investigating the e-fficacy of new treatment modalities in
vivo. Although some studies have reported that human CD8+ T cells show
diminished function when injected into SCID mice (de Kroon et al, 1997),
tumours induced in these animals by I/P or EV injection of human LCL or PBMC
from EBV seropositive donors have been successfully treated with adoptive
transfer of in vitro generated autologous EBV-specific T cells (Boyle et al, 1993;
Buchsbaum et al, 1996). Boyle et al, generated EBV-specific CTL by in vitro
stimulation ofPBMC with autologous irradiated LCLs. SCID mice were injected
with LCL cells and EBV-specific CTLs were either adoptively transferred
immediately or seven days after LCL injections. Control groups included SCID
mice engrafted with LCL cells alone. Animals in the control group rapidly
developed B cell lymphomas (mean, 20 days). However, tumours were either
prevented or significantly delayed in mice injected with LCL and CD8+ EBV-
specific CTLs. In contrast, HLA mismatched EBV-specific CTL failed to
suppress or delay tumour occurence. (Boyle et al, 1993). In another study Lacerda
et al, demonstrated that after CTL infusion, the PBMC-induced SCID tumours
showed infiltration of T cells into the tumour and cause rapid tumour regression
(Lacerda et al, 1996). They initially tested the effects of adoptive transfer of
autologous PBMC, purified T cells, interleukin IL-2-activated PBMC or anti-
CD3-activated T cells on PBMC induced tumours in SCID mice. None of the
above cell types improved survival of treated mice. In contrast, in vitro expanded
EBV-specific CTL, from EBV-seropositive donors exhibited strong EBV-specific
and HLA-restricted activity both in vitro and in vivo and caused complete
regression of autologous PBMC induced tumours. Moreover, these CTLs did not
have any effect on HLA-mismatched LCL induced tumours. Mice bearing two
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subcutaneous EBV+ tumours, one autologous and the other HLA mismatched to
the EBV-specific CTL donor, showed regression of only the autologous tumour
after intravenous infusion of EBV-specific CTLs. Autologous CTLs were
detectable in the tumours 24 hours after intravenous adoptive transfer and
immunophenotypic analyses showed the infiltrating cells to be predominantly
CD3 and CD8 positive and CD4 negative (Lacerda et al, 1996).
1.9 Aim of the Study
The present study was divided into two parts. The aim of the first part was to
investigate the in vivo effect of different immune effector cells on outgrowth of
autologous EBV positive human tumours in the SCID mouse. The second part of
the study focused on the cytokine gene expression pattern of EBV-associated
diseases, the cell type producing the cytokines and relationship between EBV
infection and cytokine expression by non-isotopic in situ hybridisation technique.
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2. Materials and Methods
2.1 Chemical & Reagents






Ethanol molecular biology grade 43743 4U BDH




Giemsa stain 35086 4X BDH
Glycerol 284545E BDH
Hydrochloric acid 101254H BDH
iso-Pentane 103614T BDH
Magnesium chloride M2670 Sigma
Magnesium sulphate M2643 Sigma
Silane M6514 Sigma
Mix bed resin M8032 Sigma
Paraformaldehyde 294474L BDH
PBS BRILa SLS
Phosphate citrate buffer P4809 Sigma
Polyvinylpyrrolidine P5288 Sigma
Potassium chloride P/4280/53 Fisher
Potassium dihydrogen orthophosphate 60353 Fluka
Potassium-di hydrogen orthophosphate P/5245/60 Fisher
RNase R-5503 Sigma
RNase away 73129 Kramel Biotec
Sodium azide 30111 2G BDH
Sodium carbonate 10240 4H BDH
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Chemical/Reagent Cat. No. Company
Sodium chloride S7653 Sigma
Sodium citrate S/3280/65 Fisher
Sodium hydrogen carbonate 10247 4V BDH
Sodium hydroxide pellets S/4880/60 Fisher
Sodium-di hydrogen orthophosphate 30158 4L BDH
Sulphuric acid 2.5M 191675A BDH
Triton X100 X-100 Sigma




Balance Phillip Harris Sartorius
Carousel Scotlab/Anachem Gilson
Cell harvester Skatron Skatron
Centrifuge Fisher Sanyo
Centrifuge: microfuge SLS MSE
137 Cesium Source Nordion Canadian Atomic
Energy
Cytospin Shandon Hybaid
Forceps: dissecting Inter Focus BDH
Freezer -20°C John Lewis Liebher
Freezer -70°C Cryotechnics Assab
Fridge Wolf Labs Labcold
Gamma counter/printer EG&G Wallac Wallac
Haemocytometer BDH BDH
Immunostaining tray RA Lamb RA Lamb
Incubator CO2 Leec Leec
Liquid nitrogen container Boro Labs LAir Liquid
Lquid nitrogen dewar Merck Dilvac
Lquid nitrogen dewar 25L Cryotenics Statebourn
Magnetic stirrer Jencons Voss
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Product Supplier Make
Microbiological saftey cabinet MAT MAT
Micropipettes Life Science Gilson
Microscope: binocular Leitz Leitz
Microscope: inverted R A Lamb Olympus
Multichannel Pipette Life Science Int Finnpipette
pH meter Fisher Hanna
Pipette aid SLS Bibby
Radiation: mini Viewing Barrier Nuclear Services Nuclear Services
Radiation: monitor & case Mini Instruments Mini Instruments
Reflector and stand Int Market Supply BDH
Rocking table Denley Lukham




2.3 Suppliers Contact Information
Aldrich Chemical Co Ltd, Gillingham, Dorset
Amersham / Pharmacia Biotec Uk Ltd, Little Chalfont, Buck
Anachem Ltd/ Scotlab, Luton, Bedfordshire
BDH/Merck Ltd, Box 15, Fresh Water Rd, Dagenham, Essex
Becton Dickinson, Between Towns Rd, Cowley, Oxford
Bibby Sterilin, Tilling Drive, Stone, Staffordshire
J. Bibby Science Products, Tilling Drive, Stone, Staffs
Boc Ltd Special Gases, Deer Park Rd, London
Boehringer Mannheim Uk Ltd, Bell Lane, Lewes, East Sussex
Boro Labs, Paices Hill, Aldermaston, Berks
Bright Technologies Ltd, Kilamarsh, Sheffield
Cambridge Bioscience, Newmarket Rd, Cambridge
Camlab Ltd, Nuffield Rd, Cambridge
Chemicon International Inc., Cricklewood Lane, London
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Chiron Uk Ltd, Salamander Quay West, Park Lane, Harefield, Middlesex
Corning Costar Uk, High Wycombe, Bucks
Cryotechnics, Albion Road, Edinburgh
Dako Ltd, Denmark House, Angal Drove, Ely, Cambridge
Denley Instruments Ltd, Denley House, Hawkin Rd, Colchester
EG&G Wallac, Crownhill Business Centre, Crownhill, Milton Keynes
European Instruments, Headington, Oxford
Farenheit Lab Supplies, Rotherham, Yorks
Fisher Scientific UK, Loughborough, Leicestershire
Gibco/Life Technologies Ltd, Inchinnan Buisness Park, Paisley
C A Hendley (Essex) Ltd, Loughton, Essex
Heraeus Equipment, 9 Wates Way, Brentwood, Essex
Hybaid Ltd, Ashford, Middlesex
ICN Biomedical, Basingstoke, Hampshire
ICN Pharmaceuticals, Thame, Oxon
Interfocus, Haverhill, Suffolk
Invitrogen, De Schelp 12, 9351 Nv Leek, Holland
Jencons Scienific Ltd, Leighton Buzzard, Bedfordshire
Kimberley Clark Ltd, Larkfield, Maidstone, Kent
Life Science International (Uk) Ltd, Basingstoke, Hampshire
Microinstruments (Oxford) Ltd, Witney, Oxford
Millipore Ltd, Watford, Hertfordshire
Mini-Instruments Ltd, Burnham on Crouch, Essex
Nuclear Services Ltd, Bude, Cornwal
Olympus Optical Uk Ltd, Honduras St, London
Oxoid Ltd, Basingstoke, Hants,
Philip Harris Scientific, Park Royal, London
Promega, Delta House, Chilworth Research Centre, Southampton
Raymond Lamb, London
R&D Systems Europe Ltd, Abingdon, Oxofordshire,
Sanyo Gallenkamp Pic, Monarch Way, Loughborough, Leicestershire
Scientific Lab Supplies Ltd, Wilford, Nottinghamshire
Scottish Antibody Production Unit, Law Hospital, Carluke, Lanarkshire
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Serotec Ltd, Kidlington, Oxfordshire
Sigma Chemical Co. Ltd, Poole, Dorset
Tissue Culture Services Ltd, Claydon, Buckingham
Vector Labs, Bretton, Peterborough
Whatman Lab Sales Ltd, Maidstone, Kent
WolfLaboratories Ltd, High Wycombe, Buckinghamshire
2.4 Solutions and Reagents
2.4.1 Cell Culture
NOTE: All reagents stored at +4°C unless stated otherwise.
Culture Medium





Fetal Calf Serum 10-20% v/v
Made up in lxRPMI
Wash Medium
Hanks Balanced Salt Solution (HBSS)
Freezing Medium








Made in PBS and stored at -20°C
500ug/ml
2.4.2 In Situ Hybridization
NOTE: All reagents made up in DEPC treated ddH20, autoclaved (except those
containing alcohol) prior to use and stored at R/T unless stated otherwise.
DEPC Treated ddH20
DEPC 0.5% v/v
Stirred and kept overnight and autoclaved.
Ethanol




























Formamide plus AG 501-X8 Resin 10% w/v
Stirred over night in fume hood and filtered.




lOx Phosphate EDTA (PE)




EDTA pH 8 0.05M
Stored at 4°C








(Made in PBS) 0.4% w/v
Made fresh with each run.
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Proteinase K









Sodium citrate 0.6% w/v
Giemsa Stain 5% v/v
Animal Sera 2-20% v/v
(Diluted in Modified TBS) Stored at -20°C
Silane (Made in Acetone) 2% v/v
2.5 Probe Cocktails for in situ detection of cytokine mRNA
Antisense oligonucleotide probe cocktails were obtained from R&D systems, UK.
Each probe cocktail contained equimolar mixtures of sequences from within 3-4
exons from each cytokine mRNA sequence. The average length/number of base
pairs per exon was 30 and each was digoxigenin (DIG) at both 3' and 5' ends.
A
Probes were dissolved in 250pls of DEPC treated water to give a stock
concentration of 20ng/pl and stored at -70°C in 5ul aliquots. For use 45pis of
hybridization buffer was added to each 5pi aliquot to get a final concentration of
2ng/pl. 20ng of probe was added to each section during in situ hybridization
procedure. The probes and their properties are listed in table 2.1
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Table 2.1
Oligonucleotide Probe Cocktails used for In Situ Detection of Cytokine
mRNA
Probe Exons (equiniolar mixture)
IL-2 1,2,3,4




3-actin 3, 4, 5, 5/6
2.6 Primary, Secondary and Tertiary Antibodies and Normal Animal Sera
Details of primary, secondary and tertiary antibodies used in this study are listed
in tables 2.2 and 2.3. Primary antibodies were titrated individually to establish the
optimum concentration required for positive results. Secondary and tertiary
antibodies were used at concentrations ranging between 1:100 to 1:1000 (as
suggested by manufacturer). Normal animal sera were filtered and stored at -20°C.
Table 2.2
Primary Antibodies used in the Study
Antibody Reactivity Host Clone Isotvpe Dilution
Used
CD20 Human Mouse L-26 IgG2a,kappa 1:50
CD15 Human Mouse MY-1 IgM, kappa 1:50
CD30 (Ki-1) Human Mouse Ber-H2 IgGl 1:50
CD20 Human Mouse BCA-B/20 IgG2a 1:20
CD57 Human Mouse NK-1 IgM 1:20
Macrophage Human Mouse LN-5 IgM 1:20
CD3 Human Rabbit Polyclonal IgG 1:20
CD3 Human Mouse Polyclonal IgG 1:10
CD8 Human Mouse Polyclonal IgG 1:10
DIG DIG Sheep Polyclonal IgG 1:25
FITC FITC Rabbit Polyclonal IgG 1:100
DIG: Digoxigenin, FITC: Fluorec&in isothiocyanate,
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Table 2.3
Secondary & Tertiary Antibodies used in the Study
Specificity Host Lsotvpe Reporter Molecule
Mouse Rabbit IgG Biotin
Mouse Rabbit IgG FITC
Sheep Rabbit IgG Biotin
Rabbit Goat IgG Biotin
Sheep Rabbit IgG Biotin
Goat/Sheep Donkey IgG FITC
Digoxigenin Sheep IgG AP
Mouse Sheep IgG FITC
Mouse Sheep IgG HRP
Mouse Sheep IgG Biotin
Mouse Sheep IgG FITC
Rabbit Donkey IgG Biotin
Goat/Sheep Donkey IgG Biotin
FITC: Fluorecein isothiocyanate, AP: Alkaline phosphatase, HRP: Horseradish
peroxidase
2.7 Cell Culture Techniques
2.7.1 Culture Conditions
Cells suspended in culture medium (CM) were either plated out in 24 and 96 well
plates or in 25cm2 or 75cm2 cell culture flasks at 37° C in 5% CO2 and fed as
required.
2.7.2 Feeding ofCell Lines
Cell lines kept in 24 or 96 well plates were fed weekly or as required by replacing
half of the medium from each well with fresh CM. Cultures kept in flasks were
fed by addition of fresh CM as required.
2.7.3 Thawing and Washing of Cell Lines
Frozen cell lines were thawed in a water bath at 37°C. Hank's balanced salt
solution (HBSS) (wash medium) was added slowly to prevent cell disruption.
Cells were centrifuged for seven minutes at 400g. The supernatant was discarded
and the cell pellet was resuspended in CM.
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2.7.4 Cell Count and Viability
Cells were counted in a Neubaur haemocytometer by making a 1:1 dilution of cell
suspension in trypan blue (0.5% w/v). Viability of cells was checked by not
counting cells staining with Trypan blue (non-viable cells).
2.7.5 Viable Freezing of cell lines
Cells were counted, washed once and frozen in (FM) at a cell concentration of 2-5
x 107 per 1ml ofmedium. Cells were transferred to a 1.5ml cryotube and stored at
-70°C for 24 hours before transfer to liquid nitrogen.
2.7.6 Separation of Peripheral Blood mononuclear Cells (PBMCs) from
Heparin treated Whole Blood
Heparinized whole blood was layered over an equal volume of Ficol-Hypaque™
in a 50ml universal tube and centrifuged at 540g for 15 minutes. Red cells
sed anented to the bottom of the tube and PBMCs formed a layer at the interface
between the Ficol-HypaquerM and plasma. 500uls of plasma were collected in a
cryotube and kept at 4°C for EBV serology. The PBMCs were harvested, washed
twice, and either cultured or frozen for future use.
2.7.7 Phytohaemagglutinin (PHA) Stimulation of PBMC
T cell growth was stimulated in vitro by addition of lOug/ml ofPHA to PBMC at
a concentration of 2 x 106/ml in CM. Cells were kept at 37°C in 5% CO2 for 48
hours, then washed and used as required.
2.7.8 In vitro generation of LCLs
107 washed PBMCs were suspended in 1ml of concentrated EBV preparation
(kindly provided by Professor D H Crawford, Medical Microbiology, University
ofEdinburgh) and incubated at 37°C in 5% CO2 for one hour. Cells were washed
twice to remove unbound virus, suspended in lOmls of culture medium containing
cyclosporin A (CyA) and plated out in 5 wells of a 24 well plate at a final cell
count of 2 x 106 cells in a volume of 2mls/well. Cells were incubated at 37°C in
5% CO2 and fed weekly. After 4-6 weeks cell viability was checked by trypan
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blue exclusion. Cells were harvested, transferred to a 25cm2 cell culture flask and
expanded and/or frozen as required.
2.7.9 y-Irradiation of Cells
Cell proliferation was inhibited by introduction ofDNA damage by exposure to y-
irradiation from a 137Cesium source. Exposure time (ET) required to deliver 4000
rads was calculated by the following formula:
ET = Y x 60minutes x 1.10
4.07 x 104 rad/hour x DF
Y was the desired irradiation dose (4000 rads for LCLs and 2000 rads for
PBMCs) and DF was decay factor for the cesium source.
2.7.10 In vitro Cytotoxic T Cell Culture
PBMCs were plated in a 24 well plate at a concentration of 2 x 106 cells/well (in
lml of CM). 5 x 104 irradiated autologous LCL cells suspended in 1ml of CM
were added to each well (PBMC:LCL ratio of 40:1) to stimulate EBV-specific
CTL growth. Cells were incubated for ten days at 37°C in 5% CO2 and observed
under an inverted microscope for CTL clumps. On day 10 cells were harvested,
pooled, counted and re-stimulated with irradiated autologous LCL at a ratio of 4:1
(106 CTL plus 5 x 104 LCL cells in 2mls of CM/well) in a 24 well plate. On day
14, 40 units of recombinant human IL-2, in lOOuls of CM were added to each
well. CTL cultures were maintained and expanded by addition of IL-2 on every
second day and weekly re-stimulation with irradiated autologous LCLs at
CTL:LCL ratio of 4:1. Cells were frozen once sufficient number? had been
generated.
2.7.11 In vitro Generation of Peptide Specific CTLs
Individual aliquots ofPBMC were pulsed for two hours at 37°C with exogenous
peptides at a concentration of 20ug/106 cells. Peptide-pulsed PBMC were washed
once, irradiated at 2000 rads and were mixed with fresh autologous PBMC at a
ratio of 1:1. Cells were cultured for ten days in 24 well culture plates at a
concentration of 2x106 cells in 2mls of CM/well. On day 10 the cells were re-
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stimulated with peptide labelled, irradiated autologous PBMC at a ratio of 1:1 and
kept in culture in a 24 well plate for a further four days. On day 14 cells were
either frozen or used as required.
2.7.12 Limiting Dilution Analysis
Precursor frequency for EBV-specific CTLs in PBMC was measured using the
limiting dilution analysis. 20,000 responder cells (CTLs) in 200uls of CM were
added to wells in the first row of a 96 well round-bottomed plate. lOOuls of CM
was added to the next five rows. Serial dilutions of responder cells were made by
taking lOOuls from the first row and adding it to the second row. The process was
repeated for all rows. Six to twelve replicate wells were set up for each cell
concentration. 2.5xl04 peptide coated and irradiated stimulator cells (autologous
PBMC) in lOOuls ofCM were added to each well. The cells were cultured for 14
days at 37°C in 5% CO2 to allow differentiation and expansion of CTL
precursors. On day 14 the contents of each well were harvested and tested against
peptide-pulsed autologous PBMC in a standard 3lCr release assay. Wells were
scored as positive if the precent release of 3lCr exceeded the mean release from
the non-stimulated spontaneous release control wells. The number of cultures that
failed to lyse the peptide-labelled PBMC was recorded for each set of replicates.
Poisson distribution was used to determine the concentration of cells in a well that
on average, contained a single, specific precursor cell.
2.7.13 Cytotoxicity Assay on Polyclonal and Peptide-Specific CTL Lines
Cytotoxicity of polyclonal and peptide-specific CTLs was tested in a standard
four hour 31Cr release assay. Targets for polyclonal CTLs included autologous
LCL cells, allogeneic LCL cells and K562 (NK target) cells. Targets for peptide-
specific CTLs included autologous peptide labelled and unlabelled PBMC,
autologous LCL and allogeneic LCL. Cytotoxicity of each CTL line was tested at
3 cell concentrations (2xl03, 105 and 5xl04) at CTL:LCL ratios of 20:1, 10:1 and
5:1. Each cell concentration was plated in triplicate in a 96 well round bottomed
plate in a final volume of lOOul of CM/well. CTLs were plated out in separate
plates for each target cell line. Triplicate maximum release wells containing
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lOOuls of 1.0% Triton-X 100, and spontaneous release wells containing lOOuls of
CM were included as controls.
106 cells from each target were incubated with 3.7 MBq of slCr for one hour at
37°C. Cells were washed twice and re-suspended in lOmls of CM to give a final
cell concentration of 103 cells/ml. lOOuls (104 cells) of the target cell were added
to spontaneous and maximum release wells and to all wells containing CTL. Cells
were incubated at 37°C for 4 hours or overnight (16 hours). Following the
incubation period, plates were centrifuged at 500g for 7 minutes and lOOuls of
supernatant from each well was transferred to scintillation vials and read in a
gamma counter. Counts per minute were recorded for each well. All triplicates
were averaged and percent-specific lysis was calculated using the following
formula.
% Specific Lysis = Test Value - Spontaneous Release x 100
Maximum Release - Spontaneous Release
2.8 In vivo Effect of Autologous CTL on Outgrowth of LCL Induced
Subcutaneous Tumours In SCID Mice
2.8.1 SCID Mice
3-6 weeks old SCID mice were obtained from the transgenic unit of Medical
Microbiology, University of Edinburgh. Animals were kept under aseptic
conditions in isolators.
2.8.2 Definition of Minimum Number of LCL Cells Required to Give Rise to
Subcutaneous Tumours Regularly in SCID Mice
To establish the minimum number of LCL cells required for consistent tumour
outgrowth in SCID mice 106, 2xl06 and 4xl06 cells from each LCL were injected
subcutaneously into 3 separate SCID mice. Each cell dose was injected into two
mice on either side of the body, lateral to the lumbar spine. Animals were
observed for 16-20 weeks for gross tumour outgrowth.
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2.8.3 In vivo Prevention of LCL-induced Subcutaneous Tumours in SCID
Mice by in vitro Generated Effector Cells.
PBMCs, polyclonal CTLs and peptide-specific CTLs from EBV positive donors
were mixed with tumourigenic dose of autologous LCL cells in effector:LCL
ratios of 2:1, 1:1, 0.5:1, 0.25:1 and 0.12:1 (4 x 106, 2 x 106, 106, 5 x 105 and 105
PBMC were mixed with 2 x 106 autologous LCL cells). Each mixture was
injected subcutaneously in two SCID mice at 2 sites/mouse or as a single midline
injection. LCL and effector only controls were included for all experiments. LCL
only control received 2 x 106 cells and effector only controls received cell numbers
OXsl
equal to^highest dose injected with effector and LCL mixed injections. Animals
were observed for gross tumour outgrowth for a 100 days.
2.8.4 In vivo Treatment of LCL induced Subcutaneous Tumours in SCID
Mice by in v/Yro-generated Effector Cells.
Single midline subcutaneous LCL tumours were induced in SCID mice . Single
and multiple fixed dose CTL injections (3 x 106 cells) were delivered after
appearance of gross tumours. Two routes of CTL delivery intravenous (I/V) and
intratumour (I/T) were used. The duration of the experiment was 100 days.
Control groups included SCID mice injected with LCL only.
2.9 In situ Hybridization and Immunochemistry
2.9.1 General Methods
2.9.1.1 Silane Coating of Slides
A 2% v/v solution of silane was made in acetone. Slides were immersed in this
solution for 20 seconds, followed by a quick rinse in acetone followed by distilled
water. Slides were wrapped in foil to protect from dust and dried at 37°C.
2.9.1.2 Cytospin Preparation
106 cells were washed twice in PBS and resuspended in 1 ml. lOOuls were placed
in each well of cytocentrifuge and spun at 150,000 rpm for 3 minutes onto silane
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coated glass slides. Slides were air dried and fixed for ten minutes at 4°C in
methanol and/or 4% formalin. Slides were stored at -20°C.
2.9.1.3 Counterstaining of Slides
Counterstaining was not routinely used with in situ hybridization or
immunochemistry techniques because of the possibility of masking a positive
signal by the stain. However, in some cases Evan's blue, Neutral Red, Vector Red
and Haematoxylin were used.
2.9.1.4 Permanent Mounting of Stained Sections
To avoid the risk of loss of precipitated substrates indicating positive signal by
dissolving in non-aqueous mounting media, sections were permanently mounted
in Faramount mounting medium (Dako).
2.9.1.5 Haematoxylin and Eosin Staining of Sections
Sections were incubated in Mayer's Haematoxylin (Sigma) for 5 minutes at room
temperature then washed and incubated with Eosin for 15 minutes. Slides were
washed in tap water and mounted.
2.9.2 In situ Hybridization for Human Cytokine mRNA.
2.9.2.1 Dewaxing & Rehydration
Paraffin was removed from wax embedded sections by two five-minute
immersions in Xylene at room temperature. Sections were rehydrated at room
temperature in 99% and 95% ethanol twice for one minute. This was followed by
a 5 minute wash in DEPC treated water. Signal to noise ratio was enhanced by
incubating slides in 2 x SSC at 60°C for ten minutes.
2.9.2.2 Titration of Proteinase K (PK) Digestion Time and Concentration
For unmasking mRNA signal, sections were treated with PK at 37°C in a humid
chamber. To find a PK concentration which gave optimum tissue digestion for
mRNA detection, varying PK concentrations (20ug/ml, lOug/ml, 8ug/ml and
5ug/ml) were tested for a fixed time period of 30 minutes. All concentrations
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resulted in over digestion of section, visible as tissue detachment from slides, over
digested vacuolated areas and intensely staining nucleoli. In the next step duration
of digestion was titrated for all the concentrations ofPK tested earlier. Digestion
times tested for each concentration were 20, 15 and 10 minutes. Optimum tissue
digestion with maximal preservation of tissue morphology and mRNA signal was
achieved with a PK concentration of lOug/ml for 10 minutes. This concentration
was used for paraffin embedded sections in the study. Optimum PK concentration
and digestion time for PBMC cytospins was titrated separately. PK concentrations
of 5ug/ml, 4ug/ml, 2ug/ml, lug/ml and no PK digestion were titrated for 10 and 5
minutes. Optimum signal was achieved with 2ug/ml ofPK for 10 minutes.
2.9.2.3 RNase Treatment of Sections
RNase was dissolved in RNase buffer to achieve a concentration of 25 mg/ml and
was stored at -20°C. Working solution was prepared by diluting RNase stock
solution in RNase buffer to get a final concentration of 25 ug/ml. Slides for RNase
digestion were placed into the RNase solution in a coplin jar, and incubated at
37°C for 30 minutes. Separate glassware and disposable plastic pipettes were used
for the RNase incubation to avoid contamination of non-RNase treated sections.
2.9.2.4 Fixation
PK and RNase digestion was halted by immersing slides in pre-cooled 0.4% w/v
solution of paraformaldehyde in 1 x PBS for 20 minutes at 4°C. Sections were
removed and washed once in 1 x PBS for three minutes.
2.9.2.5 Pre-Hybridization and Hybridization
Sections were incubated in 60uls of hybridization buffer for 30 minutes at 37°C.
This was followed by incubation of each section with 20ng of probe for 18-24
hours at 37°C in a humid chamber. Higher probe concentrations (30-40ng/section)
were used in a few runs during standardisation of the technique but did not
improve signal detection and were not used routinely.
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2.9.2.6 Stringency washes and blocking
To block non-specific signal sections were washed twice for 5 minutes in 4x and
2x SSC at 37°C and incubated for 15 minutes at R/T in TBS supplemented with
1% BSA, 0.1% Triton X 100 and 0.2mM MgCF. Sections were further incubated
in 2-20% sheep, rabbit and donkey serum at room temperature, for ten minutes
each to further block non-specific binding of primary, secondary and tertiary
antibodies.
2.9.2.7 Signal detection and amplification
Three protocols were followed to detect cytokine mRNA signal. In protocol 1
sections were incubated for two hours at R/T in a 1:100 dilution of an anti-
digoxigenin antibody coupled with alkaline phosphatase (AP). This was followed
by an O/N incubation in 5-bromo-4-choloro-3-indolyl phosphate/nitroblue
tetrazolium (BCIP/NBT) substrate. This protocol failed to detect mRNA signal in
all tissue tested.
In protocol 2 an indirect approach was taken by using an unlabelled sheep anti-
DIG antibody. Sections were incubated O/N at 4°C in a 1:25-50 dilution of the
anti-DIG antibody, followed by a 30 minute incubation at R/T in 1:100 dilution of
an anti-sheep antibody labeled with biotin. Signal was detected by incubation of
slides in a 1:5000 dilution of streptavidin (Dako) at R/T for 30 minutes followed
by a 30 minute incubation at R/T in a 1:1000 dilution of biotin labeled alkaline
phophatase (Dako). Substrate used was BCIP/NBT. mRNA signal detected by this
method was not strong enough for adequate interpretation.
To further enhance the signal, in protocol 3 extra steps were introduced by
including a FITC labeled antibody followed by an anti-FITC antibody. Sections
were incubated O/N at 4°C in a 1:50 dilution of a non-labeled sheep anti-DIG
antibody, followed by incubation for 30 minutes at R/T in a 1:100 dilution of a
FITC labeled donkey anti-sheep antibody. Slides were further incubated overnight
at 4°C in a 1:50 dilution of a rabbit anti-FITC antibody, followed by incubation
for 30 minutes at R/T in a 1:200 dilution of a goat anti-rabbit biotin labeled
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antibody. Detection was by the same method as in protocol 2. This protocol gave
interpretable results. Table 2.4 shows the steps in the three protocols.
Table 2.4
Three Signal Detection And Amplification Protocols Followed After Incubation
Of Sections With Digoxigenin Labeled Oligonucleotide Probes.
1st Protocol 2nd Protocol 3rd Protocol
1. 2 li R/T 1:500 sheep anti- 1. O/N 4°C 1:50 sheep anti- 1. O/N 4°C 1:50 sheep anti-
DIG-AP " DIG. DIG
2. Wash 2. Wash 2. Wash
|| 3. 30 min R/T 1:100 rabbit 3. 30 min R/T 1:100 donkey
anti-sheep Biotin labeled anti-sheep FITC labeled
4. Wash 4. Wash
5. 30 mill R/T 1:5000 5. O/N 4°C 1:50 rabbit
Streptavidin anti-FITC
6. Wash 6. Wash
7. 30 min R/T 1:1000 7. 30 mill R/T 1:100 goat
AP-Biotin. anti-rabbit Biotin labeled
8. Wash 8. Wash
9. 30 min R/T 1:5000
II Streptavidin
10. Wash




O/N R/T lOOul of ready to use BCIP/NBT (Sigma)
Sections washed as before and mounted in Faramount mounting medium (Dako)
(R/Troom temperature, O/N overnight, Dig digoxigenin, TBS tris buffered saline,
AP alkaline phosphatase, BCIP/NBT 5-bromo-4-chloro-3-indolyl phosphate/
nitroblue tetrazolium, Wash 2x5 min in 1 X TBS at R/T).
Extra steps added to each protocol are shown in red.
2.9.2.8 Titration of antibody, incubation period and incubation temperature
The anti-DIG and anti-FITC antibodies used in the study (table 2.2) were tested at
varying concentration under different incubation conditions for optimal signal
detection. Optimum results were obtained at antibody concentrations higher than
1:50 with overnight incubation at 4°C. Shorter incubation time did not give a
strong signal and increasing temperature to R/T or 37°C resulted in non-specific
signal. Secondary and tertiary antibodies (listed in table 2.3) were used at 1:100 to
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1:1000 dilutions at R/T for 30 minutes. Increasing temperature resulted in non¬
specific signal. Increasing time from 30 minutes to one hour slightly improved
signal, but further increase in time caused non-specific binding.
2.9.2.9 Incubation with 5-bromo-4-chloro-3-indolyIphosphate/nitrobIue
tetrazolium (BCIP/NBT)
BCIP/NBT was the AP substrate of choice for in situ hybridization. This substrate
produced a purple/blue precipitate. It gave a good localization of signal and had a
high sensitivity. It was also very stable and resistant to alcohol. Therefore sections
could be dehydrated and permanently mounted without loss of signal.
2.9.3 In situ Hybridization for EBER Detection
EBER mRNA was detected by using a commercial kit (Hybaid). Manufacturer's
instructions were followed with modifications. Sections were dewaxed,
rehydrated and PK digested as described above. PK digestion was halted by a
quick rinse in PBS, followed by dehydration of sections in 95% and 99% ethanols
respectively (2 x 1 minute in each). Sections were air dried and incubated with
one drop of pre-diluted FITC labeled probe at 60°C for ten mmutes and then at
37°C for two hours. Slides were washed three times in 1 x TBS and incubated
with a drop of a secondary AP conjugated anti-FITC antibody for two hours at
room temperature. Signal was detected by substrate (BCIP/NBT) precipitation.
Sections were mounted in Faramount mounting medium.
2.9.4 Immunochemistry for Detection of Cell Surface Markers
Microwaving of Sections
Microwaving of sections was used for immunophenotyping of tumour sections.
Wax embedded sections were dewaxed and rehydrated as described for NISEI.
Slides were microwaved three times for five minutes at 850 watts in citrate buffer
to expose cell surface antigens. To prevent sections from drying out during the
procedure evaporated solution was replaced with DEPC treated water between
each five minute treatment. Cytospin preparations were not microwaved.
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Immunochemistry
After microwaving slides were allowed to cool in the citrate buffer to R/T and
washed twice in PBS. Endogenous peroxidase was blocked by incubating sections
in 0.3% hydrogen peroxide for ten minutes if HRP was used as the detection
system. Sections were incubated with primary antibody O/N at either R/T or 4°C
at the concentration recommended by the manufacturer. Slides were washed and
incubated in a biotin labeled secondary antibody at a concentration recommended
by the manufacturer. Signal was detected using ABC-AP or ABC-HRP kits
(Dako) following manufacturer's instructions. Substrate used for HRP was DAB
and for AP was BC1P/NBT. Sections were permanently mounted in Farmount
mounting medium (Dako).
Microscopy
Signal was seen using standard bright field transillumination. Final magnifications
of 100 x, 200 x and 400 x were used to detect hybridisation signal (visible as
purple-blue deposits over cells expressing the target mRNA) and to calculate the




3.1 Pre-Clinical Tumour Model For Human EBV Positive Post
Transplant Lymphoproliferative Disease
This study was designed to test autologous unfractionated PBMC, polyclonal
EBV-specific and peptide specific cytotoxic T lymphocytes (CTL) from EBV
seropositive donors in prevention and treatment of EBV positive subcutaneous
human B cell tumours in a pre-clinical model, using SCID mice.
3.1.1 In vitro Generation and Testing of LCL from Ten Healthy EBV
Seropositive Blood Donors
To standardize an EBV positive human B cell tumour model in the SCID mouse,
a panel of ten human LCLs (No. 1-10) were grown in vitro by infection of PBMC
from EBV seropositive donors with concentrated EBV preparation. EBV status of
5 LCLs was confirmed by staining cytospin preparations for expression of the
EBNA complex in an anti-EBNA immunoflourescence assay (kindly carried out
by Miss Kate Britton, Medical Microbiology, University of Edinburgh). All five
LCLs were positive for expression of EBNA complex. Cytospin preparations
from five LCLs were stained for CD20, a B cell marker. Over 99% cells were
positive for expression of CD20, confirming the B cell lineage of the LCLs.
3.1.2 Standardization of a Subcutaneous EBV Positive B Cell Tumour
Model in SCID Mice
A subcutaneous EBV positive tumour model was designed to study the effect of
autologous PBMC, polyclonal EBV-specific CTLs and peptide-specific CTLs on
LCL tumour outgrowth in the SCID model.
3.1.3 Establishment of Minimum Number of LCL Cells Required to
Consistently Give Rise to Subcutaneous Tumours in SCID Mice
The minimum LCL cell number required for consistent tumour outgrowth in
SCID mice was established by subcutaneous injections of 106, 2 x 106 and 4 x 106
cells from each LCL into 3 separate SCID mice at 2 sites per mouse. Overall all
cell numbers injected resulted in subcutaneous tumours. Doses of 2 x 106 cells and
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above resulted ia tumour occurrence in 100% cases and average time to
appearance of gross tumour was 5.5 weeks for 2x106 and 5 weeks for 4 xlO6 cells.
The incidence of tumour generation with 106 cells was 55% and average time to
tumour outgrowth was 10 weeks. It was concluded that a 2 x 106 was the
minimum cell number required for regular tumour generation and this cell number
was used as the standard dose for subcutaneous tumour induction in SCID mice.
Results of the experiment are shown in table 3.1. Details of time to tumour
development for individual donors is listed in table 3.2
TABLE 3.1
Percentage of tumours seen with different LCL cell numbers injected
subcutaneously in SCID mice.
Number of LCL Percent Tumours Average time to tumour in
Cells Injected Outgrowth weeks
106 55% 10
2x 106 100% 5.5
4x 106 100% 5
TABLE 3.2
Time in Weeks To Tumour Development for Individual Donor LCLs
DONOR LCL CELL NUMBER INJECTED
106 2 XlO6 4 XlO6
SITE 1 / 2 SITE 1 / 2 SITE 1 / 2
1 10/09 04/07 3.5/05
2 NT/NT 05/05 04/06
3 07/NT 07/06 07/07
4 09/NT 04/05 04/06
5 11 /NT 4.5/06 4.5/05
6 15 /NT 4.5/06 04/06
7 8.5/10 04/05 3.5/4.5
8 12/13 05/6.5 4.5/05
9 NT /NT 07/08 05/06
10 09/ NT 4.5/07 04/04
NT: No Tumour
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3.2 Immunotherapy Of EBV Positive Subcutaneous Tumours in the SCID
Mouse Model
3.2.1 Effect of Unfractionated PBMCs on Outgrowth of LCL Induced
Subcutaneous Tumours In SCID Mice
Initially the effect of unfractionated autologous PBMCs from EBV seropositive
donors was assessed on the outgrowth of EBV positive tumours in SCID mice.
This was done to establish if T cells from within the PBMC population would
inhibit tumour outgrowth in the SCID mice. PBMC from three donors were mixed
with autologous LCL cells in PBMC:LCL ratios of 2:1, 1:1, 0.5:1, 0.25:1 and
0.12:1. Each mixture was injected subcutaneously at a single midline site in two
SCID mice each. Mice engrafted with LCL (2xl06 cells) and PBMC (4 x 106) only
were included as controls for all three donors. Tumours developed in all the LCL
only controls within 5-7 weeks whereas PBMC on their own did not cause
tumours in any case. PBMC from all three donors failed to alter tumour outgrowth
at PBMC:LCL ratios of 0.5:1 and below. PBMC from donor 3 prevented one
tumour at the PBMC:LCL ratio of 1:1. However, the same donor's PBMCs failed
to affect the LCL tumour outgrowth at the higher PBMC:LCL ratio of 2:1. PBMC
from donor 4 prevented half of the tumours at PBMC:LCL ratio of 1:1 and 2:1.
PBMC from donor 7 did notctffect tumour outgrowth at any PBMC:LCL ratio.
Since the number of animals in each group was small, statistical significance of
the results could not be measured. Results are shown in table 3.3
Table: 3.3
Effect of by Autologous Unfractionated PBMC on Outgrowth of LCL induced
tumours in SCID mice
PBMC:LCL RATIOS INJECTED
Donor 2:1 1:1 0.5:1 0.25:1 0.12:1
1 2 1 2 1 2 1 2 1 2
3 + + - + + + + + + +
4 - + - + + + + + + +
7 + + NT + NT + + + + +
+ = Gross subcutaneous tumour, - = No Tumour, NT = Not Tested
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3.2.2 Effect ofAutologous Polyclonal EBV-Specific CTLs on Outgrowth of
LCL Induced Subcutaneous Tumours In SCID Mice
The next set of experiments was designed to test if in vitro expanded EBV-
specific CTLs wouldo-ffect the outgrowth of autologous LCL tumours in vivo.
3.2.2.1 In vitro Generation and Testing of EBV Specific Polyclonal CTLs
EBV-specifIc polyclonal CTLs were generated from PBMC of ten donors and
expanded in vitro for a minimum of 4-6 weeks. The immunophenotype of all ten
CTL lines was determined by flow cytometry (kindly done by Mr. Alan Ross,
£jr
Vetinary Pathology, University of Edinburgh). Overall percentage of CD3
positive cells ranged between 72-97%. Percentage ofCD8 positive T cells ranged
between 28-67%. CD4 positive cells ranged between 8-43%. CTLs were also
tested for their cytotoxic activity against autologous and allogeneic LCLs in a
standard four hour51Cr release assay.
3.2.2.2 Results of Standard 4 Hour 51Cr release assay to Test Cytotoxic
Activity of CTLs
Specific lysis of autologous LCL and allogeneic LCL cells by each CTL was
tested in a standard four hour 3lCr release assay. NK cell activity (non-HLA
restricted killing) was assessed by including the K562 cell line as a target. All ten
CTLs showed higher killing of autologous LCLs as compared to the HLA
mismatched LCL and K562 cells. Results are displayed in figure 3.1. Overall lysis
of LCLs by autologous CTL lines varied from 35% to 70%. Lysis of allogeneic
LCLs and K562 cells ranged from -8% to 20% and -20% to 28% respectively.
Data from all ten donors was pooled and statistical analysis was carried out using
Chi-square test. Results showed a significant difference between percent specific
lysis of autologous and LOLA mismatched LCLs (p<0.001).
4
3.2.2.3 In vivo Effect Autologous CTL on Outgrowth of Subcutaneous
A
Autologous LCL Tumours in SCID Mice
To observe if in vitro generated EBV-specific CTLs would alter outgrowth of
autologous LCL tumours in SCID mice CTL cells were mixed with autologous
LCL cells in ratios 2:1, 1:1, 0.5:1, 0.25:1, 0.12:1, 0.06:1 and 0.03:1 and each
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mixture was injected subcutaneously in 2 SCID mice at 2 sites/mouse. Separate
animals injected with LCL cells (2x106) and CTL cells (4xl06) alone were
included as controls for all ten donors.
Figure 3.1
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The animals were observed regularly for tumour outgrowth for a period of 100
days and time to tumour development was also noted. All animals in the LCL
only control group developed tumours within 6 weeks. None of the mice in CTL
only control group developed tumours. Tumour incidence was zero for animals
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injected with CTL:LCL ratios: > 0.5:1. 30% animals developed tumours at
»
CTL:LCL ratio of 0.25:1 and tumour incidence1 was 100% in animals injected
with CTL:LCL ratios below 0.25:1. Results are shown in table 3.5. Table 3.6
shows the time to tumour development in weeks for different groups of animals.
The average time to tumour in the LCL only control group was 5.5 weeks, while
the average time to tumour outgrowth was 7.1 weeks for animals which received
lower CTL and LCL ratios and developed tumours. This delay in tumour
outgrowth was also observed in the group which received the lowest CTL number
(CTL:LCL ratio of 0.03:1). Results from each CTL:LCL ratio from all the donors
were pooled together and statistical analysis was performed using Chi-Square test
with application of Yate's correction. Analysis showed that, compared to LCL
only control group autologous CTL significantly prevented tumour outgrowth
down to CTL: LCL ratio 0.25:1 (P< 0.01).
TABLE 3.5
Outgrowth Of EBV Positive Subcutaneous Tumours In SCID Mice Receiving
Varying Concentrations of EBV Specific Cytotoxic T-Cells.
CTL LCL CTL:LCL RATIOS INJECTED
4X106 2X106 2:1 1:1 0.5:1 0.25:1 0.12:1 0.06:1 0.03:1
DONOR SCID mouse 1 / mouse 2
1/2 1/2 1 / 2 1/2 1/2 1/2 1/2
1 - + - - - + /- + + +
2 - + - - - - + + +
3 - + - - - - + + +
4 - + - - - - + + +
5 - + - - - -/ + NT
6 - + - - - + /- NT NT NT
7 - + - - - - + t- +
8 - + - - - + /- NT NT





10 - + - - - ™/V *NT NT NT
+ = Positive For Gross Tumour, - = No Gross Tumour, NT = Not Tested
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Table 3.6
Time To Tumour Development (In Weeks) following injection of LCL, CTL
and CTLrLCL mixture in SCID mice.





2:1 1:1 0.5:1 0.25:1 0.12:1 0.06:1 0.03:1
DONOR SCID Mouse 1 / Mouse 2
1/2 1/2 1/2 1/2 1/2 1/2 1/2
1 - 4 - - - 11- 9 6 7
2 - 5 - - - 7 7 6
3 - 5 - - - 8 9 8
4 - 6 - - - - 6 6 7
5 - 5 - - - -16
6 - 7 - - - 8/- NT NT NT
7 - 6 - - - - 7 7.5 6
8 - 4 - - - 7/- NT NT NT
9 - 7 - - - - / 8 NT NT NT
10 - 6 - - - -il NT NT NT
- = No Tumour, NT = Not tested
3.2.3 Effect ofAutologous EBV Lytic and Latent Antigen-Specific CTL on
Outgrowth of Subcutaneous Autologous LCL Tumours
Since polyclonal CTLs from all ten donors altered the growth of autologous LCL
tumours at very low CTL:LCL ratios, in the next step we observed the effect of
EBV peptide-specific CTLs on outgrowth of autologous LCL tumours.
3.2.3.1 In vitro Generation of Peptide Specific CTLs
Peptide-specific CTLs were generated in vitro from donor PBMC using a panel of
ten, 8-10mer long peptides. Autologous peptide pulsed PBMC were used as
stimulators.
Individual aliquots of PBMC were pulsed with exogenous peptides representing
immunodominant epitopes from EBV lytic cycle antigens gp350 and BMLF1 and
latent cycle antigens: EBNA 3, 4, 6 and LMP1. EBV antigens represented by the
peptides used, peptide sequences, their position in the primary antigen sequence
and HLA restriction are listed in table 3.7. The donors and their HLA type are
shown in table 3.8.
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Table 3.7
Peptides Representing Known Immunodominant Epitopes from within
Primary Sequences of EBV Lytic and Latent Cycle Antigens




BMLF1 280-288 GLCTLVAML A2
gp350 863-871 VLQWASLAV A2
LATENT CYCLE ANTIGENS
EBNA3 491-499 VFSDGRVAC A29
EBNA3 596-604 SVRDRLARL A2
EBNA3 458-466 YPLHEQHGM B35
EBNA4 657-666 VIETPYKPTW B44
EBNA6 335-343 KEHVIQNAF B44
EBNA6 281-290 EFNLLDFVRF B44
LMP1 125-133 YLLEMLWRL A2
Adapted from Rickinson & Moss, 1996
Table 3.8
HLA Types of Donors Selected for Generation of HLA restricted EBV
Peptide-Specific CTL lines.
DONOR HLA TYPE
HLA A HLA B
2 2 19 12 44
5 2 29 11 44
6 2 11 15 35
7 1 2 8 44
3.2.4 Analysis of CTL Response to Peptides Representing
Immunodominant Epitopes from EBV Lytic and Latent Cycle
Antigens in Donor 5.
A panel of six peptide-specific CTLs were generated from PBMC of donor 5. The
peptides used and their properties are listed in table 3.9.
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Table 3.9
Peptides used to Expand EBV epitope specific CTL lines from donor 5.
Sequences and HLA restriction of each peptide are listed.
No EBV Protein Residue Epitope HLA
Sequence Restriction
LYTIC CYCLE ANTIGENS
1 BMLF1 280-288 GLCTLVAML A2
2 gp350 863-871 VLQWASLAV A2
LATENT CYCLE ANTIGENS
3 EBNA3 491-499 VFSDGRVAC A29
4 EBNA4 657-666 VIETPYKPTW B44
5 EBNA6 335-343 KEHVIQNAF B44
6 EBNA6 281-290 EFNLLDFVRF B44
3.2.4.1 Determination of Frequency of EBV Epitope Specific CTL in
Peripheral Blood ofDonor 5
In order to establish if there was a relationship between precursor frequency of a
particular peptide-specific CTL with its ability to prevent LCL induced tumours
vivo, the frequency of each ep itope-specific CTL was determined in donor 5
PBMC. CTLp were non-detectable for BMLF1, gp350, EBNA3 and EBNA4
epitopes in donor 5 PBMC. However, CTLp for the two epitopes from within
EBNA6 were detected. Precursor frequency for KEHVIQNAF was 40 per 106
cells and that for EENLLDFVRF was 11 per 106 PBMC. Results are shown in
table 3.10 and figure 3.2.
Table 3.10
EBV Epitope-Specific CTL Precursor Frequency in Peripheral Blood of
Donor 5
EBV Protein Epitope Sequence III.A Restriction CTLp Frequency
per 10'' PBMC
LYTIC CYCLE ANTIGENS
BMLF1 GLCTLVAML A2 Undetectable
GP350 VLQWASLAV A2 undetectable
LATENT CYCL]E ANTIGENS
EBNA3 VFSDGRVAC A29 Undetectable
EBNA4 VIETPYKPTW B44 Undetectable
EBNA6 KEHVIQNAF B44 40
EBNA6 EENLLDFVRF B44 11
66
Figure 3.2
Poisson Distribution Slope of Relationship Between Number of Responding
and Percentage of Non-Responding Wells in LDA for Peptide-Specific CTLp
in Donor 5 PBMC.
a, Frequency ofKEIIVIQNAF Specific CTLp
0 10 20 30 40 50
b, Frequency ofEENLLDFVRF Specific CTLp
0 50 100 150 200
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3.2.4.2 51Cr release assay on Peptide-Specific CTLs from Donor 5
The specificity of each peptide-specific CTL was tested in a standard four hour
51Cr release assay. Targets included autologous PBMC coated with stimulator
peptides, autologous LCL cells, unlabeled PBMC and allogeneic LCL cells. In
vitro specific lysis of autologous peptide pulsed PBMCs by all CTLs varied
between 37-53%. The highest percent lysis (53%) was shown by CTL directed
against the epitope from the EBV lytic cycle antigen BMLF1, and the lowest
(37%) with CTL line directed against the KEHVIQNAF epitope ofEBNA6. Lysis
of autologous LCL varied between 14-22%. Highest percent lysis (22%) was
observed with CTL specific for BMLF1 and lowest (14%) with CTL specific for
the EBNA3 epitope. Lysis of allogeneic LCL cells and unlabelled autologous
PBMC remained below 5%. Results of the cytotoxicity assay are shown in figure
3.3.
3.2.4.3 In vivo Testing ofPeptide-Specific CTLs From Donor 5 In Prevention
ofAutologous LCL Tumours in SCID Mice
Each peptide-specific CTL was mixed with 2xl06 autologous LCL cells at
CTL:LCL ratios of 1:1,0.5:1,0.25:1,0.12:1 and 0.06:1 and injected as a single
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Figure 3.3
Lysis of Autologous and Allogeneic Targets by CTLs in a Standard
51Chromium Release Assay
□ CTL:Autologous Peptide Pulsed PBMC 20:1
□ CTL:Autologous Peptide Pulsed PBMC 5:1
■ CTL:Autologous LCL 10:1
■ CTL:Allogeneic LCL 20:1
■ CTL:Allogeneic LCL 5:1
□ CTL:Autologous Unlabelled PBMC 10:1
■ CTL:Autologous Peptide Pulsed PBMC 10:1
S CTL:Autologous LCL 20:1
□ C1L:Autologous LCL 5:1
□ CTL:Allogeneic LCL 10:1
□ CTL:Autologous Unlabelled PBMC 20:1
■ CTL:Autologous Unlabelled PBMC 5:1
midline subcutaneous injection in SCID mice. Each ratio was tested in duplicate
in two separate animals. Two LCL (2xl06 LCL cells each) and one CTL (2xl06
CTL cells) only controls for each of the six CTLs were included. Tumours
developed in both LCL only controls within six weeks. None of the animals
injected with CTL only developed tumours. Mice which received LCL cells
mixed with CTLs specific for GP350, BMLF1, EBNA3, EBNA4 and
EENLLDFVRF epitope from EBNA6 developed tumours at CTL:LCL ratios
below 1:1 within 6-10 week. However, in the group which received CTLs specific
for the EBNA6 KEHVIQNAF epitope, only one mouse developed a tumour at the
lowest CTL:LCL ratio injected (0.06:1). Results are shown in table 3.11.
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TABLE 3.11
Tumour Outgrowth In SCID Mice Injected with EBV Peptid-Specific CTL
Lines from Donor 5
Subcutaneous Tumours in SCID Mice
CTLrLCL RATIOS INJECTED
1:1 0.5:1 0.25:1 0.12:1 0.06:1
SCID MICE
1 2 1 2 12 12 1 2
EBV Peptide-
Specific CTLs
BMLF1 - - + + + + + + + +
GP350 + + + + + + + + + +
EBNA3 NT NT NT NT + + + + + +
EBNA6 - - +
EBNA6 - - + + + + + + +
EBNA4 - - + + + + + + + +
+ = Gross subcutaneous tumour - = No Tumour Isrr = Trot tesited.
All CTL only control animals remained tumour free
Both mice in LCL only control groups developed tumours.
3.2.5 Analysis of CTL Response to Peptides Representing Immunodominant
Epitopes from EBNA3 and EBNA6 in Donor2 PBMC
In the next set of experimenfcpeptide-specific CTLs were expanded from donor 2
PBMCs and CTLp frequency for each was measured (the techniques used were
same as in section 3.2.3). The HLA type of Donor 2 was HLA A2, A19, B12,
B44. PBMC were pulsed with exogenous peptides representing one
immunodominant HLA A2 restricted EBNA3 epitope; SVRDRLARL and two
HLA B44 restricted EBNA6 epitopes KEHVIQNAF and EENLLDFVRF. CTLp
frequency for each epitope was measured. CTLp were detectable for all three
epitopes in the PBMC of donor 2. Precursor frequency for CTL directed against
the EBNA3 SVRDRLARL epitope was 123 CTLp per 106 PBMC, and for the
EBNA6 EENLLDFVRF and KEHVIQNAF epitopes was 114 and 48 CTLp per
106 PBMC respectively. Results are shown in table 3.12 and the Poisson
distribution is shown in figure 3.4.
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Table 3.12
EBV Epitope-Specific CTL Precursor Frequency in Peripheral Blood of
Donor 2




EBNA3 SVRDRLARL A2 123
EBNA6 KEHVIQNAF B44 48
EBNA6 EENLLDFVRF B44 114
3.2.5.1 In vivo Testing ofPeptide-Specific CTLs From Donor 2 In Prevention
ofAutologous LCL Tumours in SCID Mice
Each peptide-specific CTL was mixed with 2xl06 autologous LCL cells at
CTL:LCL ratios of 1:1, 0.5:1, 0.25:1, 0.12:1 and 0.06:1 and injected as a single
midline subcutaneous injection in SCID mice. Each ratio was tested in duplicate
in two separate animals. Two LCL and one CTL only controls for all the three
CTLs were included. Tumours developed in LCL only controls within six weeks.
CTLs on the"v/"own did not cause tumours. Mice which received LCL cells mixed
with peptide-specific CTLs developed tumours at CTL:LCL ratios below 0.25:1
and below within 6-10 week. One animal out of the two from each group which
received the two EBNA6 epitope-specific CTLs also developed tumours at
CTL:LCL ratio of0.5:1. Results are shown in table 3.13.
3.2.6. Characterization of In vivo Effect of CTL Response to an LMP1
Epitope-Specific CTL on Autologous LCL tumours in SCID Mice.
In the next experiment effect of CTLs targeting a subdominant epitope from
LMP1 on outgrowth of autologous LCL tumours was investigated. CTL specific
for an HLA A2 restricted LMP1 epitope YLLEMLWRL representing residues
125-133 from within LMP1 sequence were generated in vitro from PBMC of
Donors 6 and 7. The HLA type of donor 6 was HLA A2, B8, B44 and donor 7
was HLA A2, All, B8, B35. YLLEMLWRL-specific CTL were mixed with
2xl06 LCL cells at CTL:LCL ratios of 1:1,0.5:1, 0.25:1, 0.12:1 and 0.06:1.
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Figure 3.4
Poisson Distribution Slope of Relationship Between Number of Responding
and Percentage of Non-Responding Wells in LDA for Peptide-Specific CTLp
in Donor 2 PBMC.
a, Frequency ofSVRDRLARL Specific CTLp
0 10 20 30 40 50
b, Frequency ofEENLLDFVRF Specific CTLp
0 10 20 30 40 50
-100 J
Number of Responder Cells per Well
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c, Frequency ofKEHVIQNAF Specific CTLp
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TABLE 3.13
Tumour Outgrowth in SCID Mice Injected with EBV Peptide-Specific CTL
Lines from Donor 2
Subcutaneous Tumours in SCID Mice
CTL:LCL RATIOS INJECTED
1:1 0.5:1 0.25:1 0.12:1 0.06:1
SCID MICE
LD 2 1 2 1 2 1 1 2 1 2
EBV Peptide-
Specific CTLs
EBNA3 - - - + + + + + +
EBNA6 - - - + + + + + + +
EBNA6 - - - + + + + + + 4-
+ = Gross subcutaneous tumour - = No Tumour ]NTT = ]Slot tested.
All CTL only control animals remained tumour free
Both mice in LCL only control groups developed tumours.
Each ratio was injected in duplicate in two separate animals. CTL and LCL only
controls were included. Tumours developed within six weeks in LCL only
controls from both donors. No tumours were seen in the CTL only control group.
CTLs from donor 6 prevented tumours in CTL:LCL ratios of 0.25:1 and above.
Animals injected with the lower CTL:LCL ratio developed tumours at 7 and 8
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weeks respectively. In contrast, donor 7 LMP1-specific CTLs failed to control
vivo proliferation of autologous LCL cells at all CTL:LCL ratios tested. Tumours
occurred in all animals within 8 weeks. Results are shown in Table 3.14.
Table 3.14
In vivo autologous LCL induced subcutaneous tumour outgrowth in
SCID mice Injected with LMP11 Epitope specific CTLs
CTL:LCL RATIOS INJECTED
1:1 0.5:1 0.25:1 0.12:1 0.06:1
Donor SCID Mice
1/2 1/2 1/2 1/2 1/2
6 -/- -/- -/- + / + + / +
7 + / + + / + + / + + / + + / +
+ = Positive for tumour, - = No gross tumour
3.3 Adoptive Immunotherapy of Subcutaneous EBV Positive Tumours in
the SCID Mouse Model
The next step in the study was to test the polyclonal CTLs for their ability to cause
regression of already established autologous LCL induced subcutaneous tumours
in the SCID model.
3.3.1 Therapy of Established LCL induced Subcutaneous Tumours with a
Single Fixed Dose Autologous CTL Infusion
Four donors; 1, 2, 4, 5 were selected from the original panel of ten for an initial
pilot study. Single midline subcutaneous LCL tumours were induced in three
SCID mice for each donor. In each group one mouse served as a no therapy LCL
only control and the other two received autologous CTLs for tumour therapy. I/V
and I/T routes ofCTL delivery were compared in separate mice for each donor. In
preliminary experiments a single fixed dose injection of 3 x 106 CTLs was
delivered in each case after appearance of gross tumours. The dose of CTL
selected was the average of the highest two doses ofCTLs (2xl06 and 4xl06) used
in the previous experiment with polyclonal CTLs, which resulted in 100%
inhibition of tumour outgrowth.
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3.3.1.1 Measurement and Monitoring of Tumour Mass
Gross tumour mass was measured in cubic millimeters (mm3) by talcing two
measurements, 90 degrees to each other using Vernier calipers. Tumour mass was
calculated with the formula given below (Conway et al, 2000).
Tumour Mass (tm) = ab2/2 = (tm) mm3
Where a = length, b = width
Tumour mass was measured on Day 1 (prior to CTL injection delivery) and then
every other day thereafter. The duration of the experiment was 100 days.
Reduction in the rate of increase of tumour mass was observed in all treated cases
as compared to the rate of increase of tumour mass in the untreated animals
(figures 3.5-3.8). This decrease in rate of tumour growth was apparent within 2-3
days of CTL delivery. Apart from two all animals in both I/V and I/T treated
groups showed a decrease in the tumour mass after the CTL injection and in 20% A
cases a total disappearance of gross tumour was observed.
3.3.1.2 Response to Intra-venous Adoptive CTL Therapy
Reduction in tumour size with I/V injections was more rapid as compared to the
reduction seen with I/T CTL delivery. Overall three out of four (75%) mice
treated with 1/V CTL showed complete disappearance of gross tumour and were
tumour free at the end of the experiment (day 100). The fourth showed aninitial
decrease in tumour mass but then a rapid increase in tumour size on day 14 (two
weeks after injection). The animal was sacrificed once tumour mass increased
beyond 10% total body weight.
3.3.1.3 Response to Intra-tumour Adoptive CTL Therapy
Amongst the animals which received I/T CTL injections, all showed reduction in
the rate of increase of tumour mass as compared to the non treated control group.
Donor 1 and 2 CTLs failed to successfully control tumour growth and animals
were sacrificed due to rapid increase in tumour growth rate. Both donor 4 and 5
CTLs caused a complete but transient disappearance of gross tumour but were
eventually sacrificed due to rapid increase in tumour mass. Results of the
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experiment are displayed in figure 3.5 to 3.8. Survival analysis by Kaplan-Meier
method showed that the probability of survival for the non-treated control group
and I/T treated group became zero on day 10 and 40 respectively (figure 3.9).
However, it remained steady at 0.75 for the I/V treated group, suggesting that I/V
delivery ofCTL is a better route of delivery for the cells to target the tumour cells
via its blood supply.
Figure 3.5
I/T & I/V Treatment of Subcutaneous LCL induced tumours in SCID mice
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Figure 3.6
I/T & I/V Treatment of Subcutaneous LCL induced tumours in SCID mice
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Figure 3.7
I/V and I/T Treatment of Subcutaneous LCL induced tumours in SCID mice
with autologous polyclonal CTL from donor 4.
Days Post CTL Injection
[-♦-LCL only control -o-l/T CTL therapy -a-l/V CTL therapy
Figure 3.8
I/T & I/V Treatment of Subcutaneous LCL induced tumours in SCID mice
with autologous polyclonal CTL in donor 5.
Day Day Day DAY DAY DAY DAY DAY DAY DAY DAY DAY DAY
0 2 3 7 9 14 20 25 30 35 40 SO 100
Days post CTL injection
-♦-LCL only control -o-l/T CTL therapy -a-I/V CTL therapy
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Figure 3.9
Comparison of survival curves for non-treated I/V treated and I/T treated
animals
For each X value (time) the fraction still alive is shown. Survival fractions were
calculated using the Kaplan-Meier method.
Days Post Injection
-I/VCTL, -I/TCTL, - Untreated
3.3.2 Therapy of established LCL induced Subcutaneous Tumours with
Multiple Autologous CTL Infusions
Results of the previous experiment showed that reduction in tumour mass could
be achieved with a single infusion of autologous CTLs and could cause total
regression of gross tumour in some cases. Since I/V therapy appeared to be more
efficient in causing tumour regression as compared to I/T CTL therapy, the next
set of experiments was designed to test the efficacy of multiple (weekly) fixed
dose autologous I/V CTL infusions for treatment of already established
subcutaneous LCL tumours in the SCID model.
Single midline LCL tumours from donor 1, 2 and 5 were generated in three SCID
mice each. In each group one mouse served as a non-treated LCL control and the
other two were treated with weekly fixed dose (3 x 106 cells) I/V injections of
autologous CTLs. Treatment was started after the appearance of gross tumours
(Day 0) and I/V CTL injections were delivered weekly on day 1, 7 and 14. A
reduction in the rate of increase of tumour mass was observed in all treated cases
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as compared to the LCL only control groups. When animals from all three treated
groups were considered collectively 67% of treated animals displayed a total
disappearance of gross tumour between day 7 and 9. With CTL from donor 1 both
treated animals displayed no change in size or rate of growth of tumour after the
first injection for the first three days. SCID 1 showed a decrease in tumour mass
on day 6 post-injection but the tumour did not respond to subsequent injections
and the animal was sacrificed. SCID 2 did not show a change in tumour
mass after the first CTL injection, however, complete regression of gross tumour
was observed by day 14, one day after the delivery of third CTL infusion. The
animal remained tumour free till end of experiment. Results are shown in figure
3.10.
With CTL from donor 2 decrease in the rate of tumour growth was observed in
both treated animals after the first CTL infusion but the outcome was different in
the two animals. In SCID 1 tumour mass stabilised after the first CTL infusion.
Subsequent weekly CTL injections were delivered and the tumour mass remained
stable until day 14 (third CTL infusion) but started to increase thereafter and
animal was sacrificed on day 35. Tumour mass stabilized in SCID 2 after first
CTL infusion and complete regression of tumour was observed by day 9. The
animal remained tumour free till the end of the experiment. Results are shown in
figure 3.11.
With CTL from donor 5 after the first CTL infusion both treated animals showed
decrease in rate of increase in tumour mass as compared to the LCL only control.
Complete reduction in gross tumour mass was seen in both animals by day 14,
and they remained tumour free till the end of experiment. The results are shown in
figure 3.12. Survival analysis using the Kaplan-Meier method showed that
probability of survival remained between 0.75-1.0 for the treated group while it
became 0.0 for the non-treated animals by day 15 after tumour appearance.
Survival curve is shown in figure 3.13.
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Figure 3.10
Response of LCL induced subcutaneous tumours in SCID mice to multiple
fixed dose autologous CTL infusions from donor 1.
(Blue arrow indicates time ofCTL injection)
Day Day Day DAY DAY DAY DAY DAY DAY DAY DAY DAY DAY
0 2 3 7 9 14 20 25 30 35 40 50 100
Days post CTL injection
-»-LCL only control -o-CTL therapy 1 -&-CTL therapy 2
Figure 3.11
Response of LCL induced subcutaneous tumours in SCID mice to multiple
fixed dose autologous CTL infusions in donor 2.
(Blue arrow indicates time ofCTL injection)
Day Day Day DAY DAY DAY DAY DAY DAY DAY DAY DAY DAY
0 2 3 7 9 14 20 25 30 35 40 50 100
Days post CTL injection
-»-LCL only control -o-CTL therapy 1 -^-CTL therapy 2
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Figure 3.12
Response of LCL induced subcutaneous tumours in SCID mice to multiple
fixed dose autologous CTL infusions in donor 5.
(Blue arrow indicates time ofCTL injection)
Day Day Day DAY DAY DAY DAY DAY DAY DAY DAY DAY DAY
0 2 3 7 9 14 20 25 30 35 40 50 100
Days post CTL injection
LCL only control -o-CTL therapy 1 -a-CTL therapy 2
Figure 3.13
Survival analysis of treated and non-treated SCID groups after Multiple
CTL Infusions
For each X value (time) the fraction still alive is shown. Survival fractions were
calculated using the Kaplan-Meier method.
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Results of these experiments showed that repeated fixed dose CTL injections were
successful in causing regression of autologous LCL induced subcutaneous
tumours in SCID mice. Collectively four out of six tumour bearing animals (67%)
which were treated with autologous CTLs showed disappearance of gross tumour
and were tumour free at the end of the experiment. Tumours that did not respond
to CTL treatment were larger (tumour mass 4050 and 5000 mm3) at the time of
start ofCTL therapy than those which responded (tumour mass 312 and 450mm3).
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4. RESULTS 2
4.1 Standardization ofNon-isotopic In Situ Hybridization Technique for
Cytokine mRNA Detection in EBV Related Diseases
The aim of this study was to investigate the cytokine profile ofEBV positive cells
in normal lymphoid tissue and EBV related malignancies by non-isotopic in situ
hybridization and to identify the cell type(s) responsible for cytokine production.
The cytokines probed for included Interleukin (IL)-2, 4, 6, 10 and interferon
gamma (INFy). Cytokine mRNA was detected using commercially available 3'
and 5' Digoxigenin (DIG) labeled oligonucleotide probe cocktails, /i-actin was
included as a positive control for mRNA detection and PHA stimulated human
PBMC were used as positive controls for cytokine mRNA detection. Negative
controls included no probe sections and RNase treated sections and specificity of
the technique was tested by inclusion of mouse tissue. The technique was used to
probe paraffin embedded tissue from human PBMC-induced I/P tumours in SCID
mice, EBV related malignancies: PTLD, NPC and HD and a tonsil from an I/M
patient.
The NISH protocol used in this study was a modification of a previous protocol
used to detect IFNy mRNA transcripts in formalin fixed wax embedded allergen
stimulated skin biopsies (Howie et al, 1996). This protocol was modified and re-
standardized for the current study. The modified technique (protocol 3, table 2.5)
was first applied to formalin fixed paraffin embedded allergen-stimulated skin
sections to detect INFy mRNA expression. The sections stained positive for INF}'
mRNA transcripts and results are shown in figure 4.1 which shows both a positive
and a no-probe section.
With protocol 3 PHA-stimulated blasts consistently gave a positive signal for all
cytokines tested and were used as positive controls for cytokine mRNA detection
in the study. Results are shown in figure 4.2 a and b. Negative controls (no probe
and RNase treated sections) are shown in figure 4.2a. RNase treated sections
received one type of probe per NISH run (IL-2). For specificity control paraffin
embedded SCID mouse liver and spleen tissue was included with each NISH run.
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Inclusion of mouse tissue also checked the cross reactivity of cytokine probes
with mouse cytokines (figure 4.2a).
Figure 4.1
In situ detection of INFy mRNA in allergen stimulated skin tissue by NISH
technique
a, Positive INFy Signal b, No Probe Negative Control
White arrow points at positive signal, indicated by a purple precipitate (BCIP/NBT). Original
Original magnification x400
Figure 4.2





Rnase treated (IL-2) Mouse Spleen
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4.2b Cytokine mRNA Expression in PHA stimulated PBMC
Originalmagnification ofall sections x200. Arrow indicates some ofthe positive cells
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Paraffin embedded sections were dewaxed and rehydrated as described in the
materials & methods (section 2.9.2). Signal to noise ratio (specific to non-specific
staining) was enhanced by incubating slides in 2 x SSC at 60°C for ten minutes
before hybridisation. Omitting this step or a change in temperature or time
resulted in increased non-specific staining.
For unmasking the mRNA signal, sections were treated with an optimum
concentration of PK (lOug/ml for 10 minutes at 37°C). Overdigestion of sections
was visible as tissue detachment from slides, vacuolated areas within sections and
intensely staining nucleoli, which are resistant to PK digestions.
Cytospin preparations and wax embedded sections were incubated with 20ng of
each probe for 18-24 hours at 37°C in a humid chamber. Stringency washes were
carried out as described in the materials and methods section. Sections were also
incubated in 2-20% sheep, rabbit and donkey serum for ten minutes to block non¬
specific binding of primary, secondary and tertiary antibodies.
Signal detection and amplification
Three protocols were followed to detect and enhance the detection of cytokine
mRNA signal (Table 2.5, section 2). Protocol 1, in which an anti-digoxigenin
antibody coupled with alkaline phosphatase (AP) was used for probe detection did
not give any signal in all cases. With protocol 2 mRNA signal was detected in
some sections but was not strong enough for adequate interpretation. To enhance
the signal, in protocol 3 another amplification step was introduced by including a
FITC labelled and an anti-FITC antibody. Addition of this step enhanced cytokine
mRNA signal without resulting in non-specific staining. BCIP/NBT was the AP
substrate of choice for in situ hybridization because it gave a good localization of
signal and had a high sensitivity.
Sections were observed under a light microscope to examine the intensity and
distribution ofmRNA signal. The signal was reported by counting the number of
positive cells per field and 15-20 fields per section were counted. Results were
reported in a semiquantitative way as described in table 4.1
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Table 4.1
Semiquantitative Measurement of Cell Numbers Positive for Cytokine
mRNA Signal
negative,
+/- <1% positive cells
+ 1-5% positive cells
-H- 5-20% positive cells
+-H- 20-50% positive cells
I i i i >50% positive cells
15-20 fields were counted per section under x 200 magnification.
4.1.1 Detection Of Cytokine mRNA in EBV Positive Tumours from SCID
Mice
Human PBMC from EBV positive donors result in human B cell tumours when
injected I/P into SCID mice. These tumours mimic EBV positive PTLD in
humans and serve as a pre-clinical murine model for PTLD. Cytokine mRNA
expression of ten such tumours was investigated using NISH. The cell type
responsible for cytokine production and the relationship to EBV status was tested
by staining serial sections for CD3 (T cell marker), CD20 (B cell marker) and
EBER expression. The number of cytokine positive cells was reported as
percentage of (3-actin positive cells expressing cytokine mRNA.
Although cytokine mRNA was detected in most cases, the number of cells
positive for different cytokines varied between different tumours. Notably
tumours which gave a poor signal for (3-actin mRNA (tumours No. 6, 9 and 10)
failed to show appreciable signal for cytokine mRNA. Cytokine positive areas
predominantly equated with those of CD20 and EBER positive cells. This was
suggestive of predominant autocrine cytokine production by tumour cells
themselves. All negative controls remained negative for mRNA signal. Results are
presented in table 4.2. Figure 4.3 shows SCID tumour no 1 which stained positive
for all the cytokines in the panel and serial sections stained for CD20 and EBERs.
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Table 4.2
Cytokine mRNA Production by EBV Positive Human PBMC Induced
Tumours in SCID Mice
Tumour Cytokines
P-actin IL-2 IL-4 IL-6 IL-10 INFy
1 ++++ ++++ +++ +++ + ++++
2 till I I M - ++++ ++++ ++++
3 + ++ + - +/- +/-
4 +++ NT ++ +++ +++ +++
5 ++ +++ ++ - + +
6 + - - - + -
7 ++++ +++ - +++ ++++ +++
8 +++ + + +++ - -
9 + - NT - - -
10 + - - - - -
Number ofcytokine positive cells is the percentage off-actin positive cells
expressing cytokine mRNA. Positive control (PHA Blasts) were positivefor mRNA
ofall cytokines tested. No probe, RNase digested human tissue and mouse tissue
were negative
Figure 4.3
CD20 Staining, EBER and Cytokine mRNA Detection in a Human PBMC-
Induced EBV-Positive Tumour in SCID Mouse (Tumour No. 1)










4.3b Results of NISH for EBERS and Cytokine gene transcripts on SCID
tumour 1 (Original Magnification x 400. Arrows point at some of the
positive cells)
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4.1.2 Detection Of Cytokine inRNA In EBV Positive PTLD Tumours
The cytokine mRNA profile of 13 PTLD tumours was studied using the N1SH
technique. Paraffin embedded blocks were kindly supplied by Dr. J A Thomas,
Department of Infection and Immunity, London School of Hygiene & Tropical
Medicine, London and Dr P Amlot, Department of Immunology, Royal Free
Hospital School of Medicine, London. Blocks were cut into bum sections,
mounted on silane coated slides and probed for the IL-2, 4, 6, 10 and INFy
mRNA. Serial sections from all tumours were probed for EBER RNA and stained
for CD3 and CD20. In situ detection of (3-actin mRNA served as a positive control
for mRNA detection and tumours with lower number of p-actin positive cells
(tumour 10) showed lower number of cytokine positive cells than tumours which
showed higher number of cells positive for P-actin mRNA. Apart from tumour
number 10, all tumours showed cells positive for transcripts for all cytokines in
the panel. Negative controls including RNase treated sections, no-probe sections
and mouse tissue did not stain for cytokine mRNA. > 80% cells in all tumours
were positive for EBER mRNA and CD20. Less than 1% cells stained for CD3.
Positive areas for cytokine transcripts equated with those of CD20 and EBER
positive cells, indicative of autocrine cytokine production by tumour cells. Results
are shown in table 4.3 and figure 4.4.
Table 4.3 In situ Cytokine mRNA Detection in PTLD Tumours
PTLD CYTOKINES
Pt. No. p-Actin IL-2 IL-4 IL-6 IL-10 INFy Neg.
1 +++ + ++ +++ +++ ++ -
2 ++ + + ++ + ++ -
3 ++ ++ ++ ++ ++ ++ -
4 ++ ++ + ++ + ++ -
5 ++ + ++ + ++ ++ -
6 ++ + ++ +++ +++ + -
7 ++ NT + ++ ++ + -
8 ++ + ++ +/- + + -
9 ++ + +/- ++ + ++ -
10 +/- - - - + +/- -
11 ++ + ++ ++ ++ ++ -
12 ++ ++ ++ ++ ++ + -




Cytokine and EBER mRNA Detection and CD20 Staining of a PTLD
Tumour









4.1.3 Detection OfCytokine mRNA In EBV Positive NPC Tumours
Six paraffin embedded NPC tumour biopsies were kindly provided by Dr J A
Thomas, London School of Hygiene & Tropical Medicine. Tumour sections were
probed for IL-2 4, 6, 10 and INFy mRNA. Tumours were positive for transcripts
of all the cytokines on the panel, with a higher number of cells positive for IL-6
and IL-10 (5-20% cells). Negative controls which included no probe sections,
RNase treated sections and mouse tissue remained negative for cytokine mRNA.
Serial sections from each tumour were stained for EBERs, cytokeratin (epithelial
tumour cell marker) and CD3 (infiltrating T cell marker) expression. Cytokine
signal was observed both in tumour and infiltrating CD3 positive cells with a
higher number of infiltrating T cells positive for cytokine transcripts than
epithelial tumour cells. The results of cytokine mRNA detection in tumour cells
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and CD3 cells are separately detailed in table 4.4 a and b. EBER signal was only
observed in the malignant epithelial cells. Figure 4.5 shows one NPC tumour (No.
5) stained for cytokine and EBER mRNA, and cytokeratin and CD3 cell surface
markers.
Tabic 4.4
a, Cytokine mRNA Detection in Infiltrating CD3 Positive Cells in EBV
positive NPC tumours
NPC CYTOKINES
Pt. No. 3-Actin IL-2 IL-4 IL-6 IL-10 INFy Neg.
1 ++ + + ++ ++ - -
2 + +/- - - +/- - -
3 ++ + - ++ ++ - -
4 ++ + + ++ ++ + -
5 ++ + ++ ++ ++ + -
6 + - +/- + + + -
b, Cytokine mRNA Detection in EBER Positive Malignant Cells in EBV
positive NPC tumours
NPC CYTOKINES
Pt. No. (3-Actin IL-2 IL-4 IL-6 IL-10 INFy Neg.
1 ++ + - ++ ++ - -
2 + +/- - - +/- - -
3 ++ +/- - + + - -
4 ++ + - + + - -
5 ++ - + ++ ++ - -
6 + - - + + - -
Figure 4.5
Cytokine and EBER mRNA Detection and Cytokeratin and CD3 Staining of
EBV Positive NPC Tumours
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4.1.4 Detection OfCytokine mRNA In EBV Positive HD
Five EBV positive HD tumours, kindly provided Dr A Krajewski from
Department ofPathology, University of Edinburgh, were stained for expression of
IL-2, 4, 6, 10, INFy, EBERs and R/S cell specific markers: CD15 and 30.
Detection of P-actin transcripts served as a positive control for mRNA detection.
Positive cytokine controls included PHA stimulated blasts. Negative controls
included no probe tumour sections, RNase-treated sections and mouse tissue.
Sections were necrotic and only l%-20% cells stained positive for p-actin
transcript and cytokine signal was only observed in cells within the P-actin
positive areas. Cytokine transcripts were detected in 1-5% cells in all tumours and
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cytokine and EBERs signal was mainly limited to CD30 and CD15 positive cells,
of which over 50% were positive. Only tumour number 3 tested positive for all
cytokines. Due to poor quality of sections and low (3-actin signal the results were
not interpretable. Results are shown in table 4.5 and figure 4.6.
Table 4.5
Cytokine mRNA Expression in EBV Positive HD
HD CYTOKINES
Pt. No. P-actin IL-2 IL-4 IL-6 IL-10 lNFy Neg
1 +/- - - - - - -
2 ++ + + - + + -
3 ++ + + + + + -
4 + + - + + - -
5 + - + + - + -
Figure 4.6
Cytokine, EBER, CD15 and CD30 Staining of EBV Positive HD (tumour no.
3)
Original magnification x400. Arrows indicatepositive cells








4.1.5 Detection OfCytokine mRNA in Tonsil From an Acute I/M Patient
Paraffin embedded tonsil tissue from an acute IM case was kindly provided by Dr
A. Krajewski, Department of Pathology. Sections were probed for IL-2, 4, 6, 10 ,
INFy and EBER transcripts. Positive controls included P-actin and PHA
stimulated blasts. Negative controls included no probe and RNase treated sections.
Tissue tested positive for all cytokines. 20% cells stained positive for IL-6 and 10.
1-5% cells gave a positive signal for IL-2 and less than 1% cells stained positive
for INF-y and IL-4. Serial sections were stained positive for EBERs and the cells
positive for EBERs signal equated with those of cytokine production. Results are
shown in Table 4.6 and figure 4.7.
Table 4.6
Cytokine mRNA detection in tonsil sections from an acute case of Infectious
Mononucleosis
EBERs P-Actin IL-2 IL-4 IL-6 IL-10 INFy Neg.
Pt + ++ + +/- ++ ++ +/- -
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Figure 4.7
Cytokine and EBER mRNA Detection in Tonsillar Tissue from an I/M
Patient


































5.1 Adoptive Cellular Immunotherapy ofEBV Related Lymphoproliferative
Disease in the SCID Mouse Model
EBV associated PTLD is an important clinical problem in transplant recipients
receiving immunosuppressive therapy for prevention of allograft rejection. In
individuals with normal immune responses, EBV infected B cells are kept in
check by EBV-specific CTLs (Rickinson & Moss, 1997). However,
immunosuppression in transplant recipients reduces the EBV-specific CTL
activity and can result in uncontrolled expansion of EBV infected B cells leading
to PTLD (Penn, 1987; Sokal et al, 1997). PTLD is conventionally treated with
reduction or withdrawal of immunosuppressive drugs and/or delivery of cytotoxic
drugs such as vincristine and corticosteroids (reviewed in Kawa, 2000). These
treatment modalities can cause tumour reduction in some PTLD cases but can
result in graft rejection and/or toxic side effects.
Cell mediated immunity plays a critical part in controlling EBV infection in the
normal host and in recent years the potential use of EBV-specific CTLs in
treatment ofEBV related PTLD has been investigated by several research groups.
Previously adoptive transfer ofPBMC and in vitro expanded EBV-specific CTLs
from EBV seropositive bone marrow transplant donors have been successfully
used to control EBV associated PTLD tumours in transplant recipients
(Papadopoulos et al, 1994; Heslop et al, 1994; Rooney et al, 1995; Heslop et al,
1996). Heslop et al have also shown that EBV-specific CTLs not only restore the
cellular immune response to EBV in the short term but also induce CTL
precursors which respond to in vivo and in vitro challenge with virus for up to 18
months post infusion (Heslop et al, 1996). The results of these previous studies
suggest a definite role of cellular immunotherapy in controlling PTLD and
support wider use of EBV-specific CTLs in both BM and solid organ transplant
recipients.
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Until recently, immunotherapy of PTLD was restricted to BMT recipients. This
was because PTLD in BMT patients is of donor cell origin and since the donors
are available and not immunosupressed, EBV-specific CTLs can be successfully
expanded in vitro from donor PBMC for treatment of PTLD in the recipient. In
solid organ transplant recipients the tumours are mostly of recipient B cell origin
(Thomas et al, 1991) and in vitro activation of CTLs from these patients is
difficult because of the effects of immunosuppression on the cellular immune
response. However, recently Khanna et al, have reported in vitro activation of
autologous CTLs from solid organ transplant patients undergoing primary EBV
infection and have successfully used these cells to treat PTLD in one case
(Khanna et al, 1999). This data is encouraging because it suggests that EBV-
specific CTLs can be generated from recipient CTLs and thereby increases the
scope of adoptive immunotherapy to PTLD in solid organ transplantation.
To further the knowledge on pathogenesis of PTLD, and to test new treatments,
the pre-clinical SCID mouse model has been used regularly in recent years
(Johannessen & Crawford, 1999; Boyle et al, 1993; Rencher et al, 1994). I/P
injection of LCLs or PBMC from some EBV seropositive donors into SCID mice
results in immunoblastic B cell lymphomas within a period of few weeks (Mosier
et al, 1988, 1990, 1991; Ramqvist et al, 1991). The tumours are EBV positive,
have a type III EBV gene expression pattern (Rowe et al, 1990) and have similar
characteristics to PTLD in transplant recipients (Rowe et al, 1991, Gratama et al,
1991). These properties make the SCID mouse an effective model to investigate
the efficacy of various treatment modalities and tumour vaccines before using
them in humans. In our study we used the SCID model to investigate the effect of
different autologous immune effector cells (unmanipulated PBMC, in vitro
expanded EBV-specific polyclonal and epitope-specific CTLs) on outgrowth and
treatment ofLCL induced S/C tumours in the SCID model.
Although in humans Papadopoulos et al have reported successful control ofPTLD
by adoptive transfer of donor leukocytes to graft recipients (Papadopoulos et al,
1994), Lacerda et al reported no significant in vivo anti-tumour activity of
unfractionated autologous PBMC in the SCID model (Lacerda et al, 1996). To
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investigate if autologous unmanipulated PBMC would affect the outgrowth of
EBV positive tumours, we monitored the effect of varying doses of autologous
unfractionated PBMC on outgrowth of S/C LCL induced tumours in SCID mice.
Our hypothesis was that PBMC from EBV seropositive donors contain EBV-
specific CTLs which could potentially activate in vivo and target EBV positive
PTLD. However, we recorded no notable reduction in tumour occurrence or time
to tumour development (Table 3.3). These findings are consistent with the results
reported by Lacerda et al (1996). Notably, three out of twelve animals which
received PBMC:LCL ratios higher than 0.5:1 did not develop tumours (table 3.3).
It is possible that tumours in these cases were prevented because a larger number
of unfractionated PBMC would contain more EBV-specific memory CTLs than
lower PBMC doses which could potentially activate and expand in the SCID
mouse and control the EBV driven B cell proliferation. Due to limited time
available, higher doses ofPBMC were not injected, but further investigation with
varying doses of unfractionated PBMC are required to clarify the role of PBMC in
suppression of tumour outgrowth. Previously it has been shown that high doses
(107 cells) of PBMC from EBV seropositive donors cause I/P tumours in SCID
mice on their own (Lacerda et al, 1996). Therefore it is possible that a higher
number of PBMC infused subcutaneously to prevent LCL tumours might
themselves result in tumours. In our study we failed to observe PBMC induced
S/C tumours in the control mice that received PBMC only. Further experiments
would clarify this point.
In the next set of experiment? we investigated whether in vitro expanded
autologous EBV-specific polyclonal CTLs would alter outgrowth of LCL tumours
in the SCID model. We titrated the number of CTLs by varying the CTL:LCL
ratios injected. The goals were: (1) to observe whether EBV-specific CTLs could
control EBV induced proliferation of autologous LCL in vivo (2) to determine if a
minimum critical CTL to tumour cell ratio was required for effective T cell
control ofEBV induced B cell proliferation.
Ten T cell lines were generated in this study and all contained CD4 and CD8
positive cells, cell types known to play an important role in immune responses to
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viruses and cancers (Greenberg, 1991; Zajac et al, 1998). They were HLA-
restricted and EBV-specific as confirmed by the lysis of HLA-matched LCL and
the failure of lysis of HLA mismatched LCLs and K562 cells in conventional
chromium release assays (Brunner et al, 1968). Polyclonality of CTL lines was
preserved by limiting the in vitro culture time to 4-6 weeks, because it has been
reported that prolonged in vitro stimulation of T cells results in preferential
selection of a subpopulation directed against one immunodominant epitope and
may not reflect the true anti-EBV T cell repertoire of the donor (Dietrich et al,
1997; Faure et al, 1998).
All ten CTL lines prevented outgrowth of autologous LCL tumours in all SCID
mice at CTL:LCL ratios as low as 0.5:1 (table 3.5). CTLs also prevented tumours
at CTL:LCL ratio of 0.25:1 in 70% cases. Our results are similar to the findings of
other groups (Boyle et al, 1993; Buchsbaum et al, 1996) and show that CTLs are
important effectors in controlling EBV driven B cell proliferation. Although at
lower ratios CTLs failed to control tumour outgrowth, the average time to tumour
development was prolonged in all animals which received a mixture of CTL and
LCL cells as compared to the LCL only control group. Our results suggest that
EBV-specific CTLs can effectively control in vivo expansion of EBV infected B
cells at very low cell numbers and can prolong survival in cases where tumour
outgrowth is not controlled completely.
Since prolonged in vitro culture of EBV-specific CTLs results in preferential
selection and expansion of CTLs directed against one or two immunodominant
epitopes (Dietrich et al, 1997; Faure et al, 1998), in the next set of experiments we
investigated if in vitro expanded EBV epitope-specific CTL lines would affect
outgrowth of autologous LCL tumours in vivo in the SCID mouse. Most frequent
known HLA restricted CTL responses in EBV infected hosts are to
immunodominant epitopes from EBNA 3, 4 and 6 and are associated with a wide
range ofHLA types (Murray et al, 1992; Khanna et al, 1992; Gavioli et al, 1992).
Therefore, we studied the effect of CTL specific for immunodominant epitopes
from these 3 latent EBV genes (Table 3.9 and 3.12) in donor 5 and 2. CTL lines
specific for lytic cycle antigens BMLF1 and gp350 were also investigated in one
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of the two donors (donor 5) because it has been reported that these antigens are
often expressed in PTLD tumours and have been detected in biopsy specimens
(Rea et al, 1994; Oudejans et al, 1995; Montone et al, 1996; Niedobitek et al,
1997). In our study all peptide-specific CTLs lysed comparable percentages of
autologous peptide pulsed PBMC and LCLs in vitro (figure 3.4). However, each
CTL line showed a higher percentage of lysis for autologous peptide coated
targets as compared to autologous LCL cells. Similar results have been reported
by Hill et al who also observed reduced in vitro killing of autologous LCL cells as
compared to autologous peptide coated target cells by peptide-specific CTLs (Hill
et al, 1995). The exact cause of this reduced LCL killing has not been addressed
previously and requires further investigation.
To investigate if in vitro and in vivo ability of peptide-specific CTLs to grow and
control growth of EBV infected cells was dependant upon the number of CTLp
present in the peripheral blood attempts were made to measure CTLp frequencies
by LDA for each epitope in PBMC ofboth donors (2 and 5). The overall detection
To
of CTLp was low in our study and this was thought to be due^the fact that fresh
PBMC were not available from the donor and CTLp frequency was measured
from frozen PBMC. The test could not be repeated because of the limited number
ofPBMC available from the donor.
Although we could only detect precursors to the two EBNA6 epitopes in donor 5
PBMC, all six peptide-specific CTL lines gave specific lysis of autologous LCLs
in vitro. We further investigated whether all the peptide-specific CTL lines would
affect the outgrowth of autologous LCL tumours in vivo in the SCID model. All
peptide-specific CTLs prevented tumour occurrence at a CTL:LCL ratio of 1:1.
However, only the CTLs directed against the KEHVIQNAF epitope of EBNA6
prevented autologous LCL induced tumour outgrowth at lower ratios. This CTL
line prevented LCL tumours at CTL:LCL ratio as low as 0.06:1. Out of the two
EBNA6 epitopes the number of CTL precursors for this epitope was higher than
that for the EENLLDFVRF EBNA6 epitope (table 3.10). Results suggest that in
vivo EBNA6 epitope KEHVIQNAF might be the immunodominant epitope for
donor 5. However, it must be noted that all six CTL lines showed comparable
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percentage of lysis of autologous LCL in vitro and CTL specific for BMLF1,
EBNA4 and EENLLDFVRF EBNA6 epitopes prevented tumour outgrowth at
CTL:LCL ratio of 1:1 (table 3.11). This raises the possibility that perhaps higher
numbers of these peptide-specific CTLs could be successful in controlling growth
ofEBV infected malignant cells in vivo. Due to limited time and number of cells
available from the donor, the experiment could not be repeated with higher cell
numbers. Further investigations would be required to confirm our results. An
interesting study would be to combine more than one epitope-specific CTL line
and observe their combined effect on tumour outgrowth.
In another similar experiment we expanded three peptide-specific CTL lines from
PBMC of donor 2. EBV peptides used were two EBNA6 epitopes; KEHVIQNAF
and EENLLDVFRM and an EBNA3 immunodominant epitope SVRDRLARL
(Rickinson & Moss, 1997). CTL precursors for all three epitopes were detected in
the peripheral blood of this donor. 100% tumours were prevented at CTL:LCL
ratio of 1:1 by all three peptide-specific CTL lines and 66% at CTL:LCL ratio of
0.5:1 (table 3.13). Results show that peptide-specific CTLs on their own were not
as effective as polyclonal CTLs in controlling autologous LCL tumour outgrowth
because polyclonal CTL from the same donor prevented tumour outgrowth down
to CTL:LCL ratio of 0.25:1 in 100% animals (table 3.5). However, it cannot be
assumed that polyclonal CTL from this donor were more effective in controlling
tumour outgrowth than peptide-specific CTLs because tumour response to CTLs
directed against a limited number of EBV epitopes was measured and the
immunodominant epitope for the donor was not identified. Immunodominant CTL
epitopes could be identified by T cell cloning or prolonged in vitro culture of LCL
stimulated polyclonal CTLs, which would allow time for selection of the CTL
specific for the immunodominant epitope(s) (Dietrich et al, 1997; Faure et al,
1998), which could then be detected by observing the killing of target cells pulsed
with different peptides in a cytotoxicity assay.
Although all peptide-specific CTL lines lysed autologous LCLs in vitro, overall
the majority of epitope-specific CTLs failed to have an appreciable effect on
tumour outgrowth in vivo at the doses injected. The results suggest that perhaps in
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vitro and in vivo parameters for effective control ofEBV immortalized B cells by
T cells targeting specific epitopes are different. Compared to polyclonal CTLs a
higher number of peptide-specific CTLs may be required for more effective
control ofEBV driven B cell proliferation in vivo.
The results of this pilot study are encouraging because tumour outgrowth was
prevented by at least one peptide-specific CTL line from donor 5 at very low cell
numbers. This suggests that if an immunodominant epitope is identified for an
individual donor it could serve as an effective CTL target for immunotherapy of
PTLD. However, identification of an immunodominant epitope for each
individual patient would be time consuming and labour intensive. A logical
approach would be to use peptide pools representing a set of already defined EBV
immune epitopes to expand CTL lines in vitro and then observe their effect on
proliferation of EBV infected cells in vivo. This was a preliminary study and to
draw a conclusion that like polyclonal CTLs, peptide-specific CTLs might have a
place in immunotherapy of EBV positive tumours, a study on a larger number of
individuals and a wider variety ofEBV CTL epitopes is required. If subsequent in
vivo investigations can confirm our results, epitope-specific CTLs could be used
in treatment ofEBV related malignancies in humans.
Success of adoptive immunotherapy in treatment of PTLD has suggested the
possibility of extension of this treatment to other EBV related malignancies. EBV
is associated with a subset of HD (Klien et al, 1979; Gutensohn & Cole, 1980;
Weiss et al, 1987; 1989) and NPC (Klein et al, 1979; de The, 1982), which are
more common and of bigger public health concern than PTLD. In HD, EBV is
carried in the R/S cells (Weiss et al, 1987) and it has been reported that EBV-
specific CTLs can lyse EBV infected R/S cells in vitro (Sing et al, 1997).
Recently, Roskrow et al have successfully generated EBV-specific CTL from a
proportion of EBV-positive HD patients and shown that these cells can persist in
vivo for more than 13 weeks (Roskrow et al, 1998). Rooney et al treated three of
the cases from Roskrow's study with gene-marked autologous CTLs and observed
transient improvement in all cases (Rooney et al, 1998). However, the potential of
CTL therapy ofHD and NPC is complicated by the fact that unlike PTLD, where
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cells express all the EBV latent antigens, HD and NPC tumours only express
EBNA1, LMP1 and LMP2a and b (Brooks et al, 1992; Busson et al, 1992;
Deacon et al, 1993; Rickinson & Kieff, 1996). This reduces the number of CTL
epitopes presented on the tumour cell surface and enhances evasion of the
immune response.
CTL targets have been recognized within EBNA1 and CD4 positive CTLs against
a peptide epitope from EBNA1 have been expanded from healthy donors (Khanna
et al, 1995). However, these CTLs failed to lyse infected cells in vitro. Levitskaya
et al have shown that EBNA1 epitopes are not processed and presented on cell
surface via the class I pathway because of inhibition of peptide processing and
presentation by a glycine-alanine repeat region within EBNA1 sequence
(Levitskaya et al, 1995). Thus CD8 T cells directed against EBNA1 are not
generated in a normal immune response and can not be used for immunotherapy.
Subdominant epitopes within sequences of LMP1 and LMP2a and b have been
identified which are presented in association with a limited number ofHLA types
(Rickinson & Moss, 1997). This suggests that immunotherapy of HD and NPC
would be feasible with CTL directed against epitopes from LMP1 and LMP2a and
b. Recently Khanna et al have identified CTL epitopes YLLEMLWRL and
YLQQNWWTL, within LMP1 which are recognized by both polyclonal and
peptide-specific CTLs (Khanna et al, 1998). They have reported that although the
LMP1-specific CTL responses constitute a minor component of the anti-EBV
CTL response, the CTL were able to lyse HLA A2 expressing EBV-infected B
cells. These findings are encouraging because of the possibility of using CTLs
directed against subdominant EBV epitopes to control in vivo proliferation of
EBV positive HD and NPC.
In our study we tested the effect of in vitro expanded CTLs specific for the LMP1
epitope YLLEMLWRL from donor 6 and 7 on autologous LCL tumours in SCID
mice. Peptide-specific CTLs from donor 6 prevented tumours at CTL:LCL ratios
of 0.25:1 and higher. However, donor 7 CTL failed to alter tumour outgrowth at
all CTL:LCL ratios injected (table 3.14). Although we tested LMPl-specific
CTLs from only two donors in a small number of animals, suppression of tumour
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outgrowth in one of two cases is encouraging since it shows that a CTL response
to a subdominant epitope can be successful in controlling EBV induced B cell
proliferation in vivo. Apart from tumours with a restricted EBV gene expression
pattern CTLs directed against subdominant epitopes may also have a place in the
treatment of PTLD. Although, most PTLD cases express all the EBV latent
antigens, cases have been identified which have a restricted EBV gene expression
pattern similar to HD and NPC (Thomas et al, 1990; Gratama et al, 1991; Rea et
al, 1994; Delecluse et al, 1995). CTLs targeting these subdominant epitopes might
be effective in the immunotherapy of these tumours.
Since in vitro expanded CTLs prevented outgrowth of autologous LCL tumours in
SCID mice in the next set of experiments we studied the effect of a single dose of
in vitro expanded autologous polyclonal CTLs on growth of already established
subcutaneous LCL tumours in SCID mice and compared intravenous and
intratumour routes of CTL delivery. Our results showed that a single fixed dose
CTL injection caused reduction in tumour mass in all I/V treated and two I/T
treated animals. These findings are similar to those reported by Lacerda et al who
showed that in vitro activated EBV-specific CD8+ T cells were effective in
controlling autologous PBMC or LCL tumours in SCID mice (Lacerda et al,
1996). Intravenous delivery of CTLs was a superior route and resulted in
improved survival as compared to the intra-tumour treated and non-treated control
groups. Kaplan-Meier survival analysis showed that the probability of survival for
intra-tumour treated group became zero at day 40 while it remained at 0.75 for the
TV treated group till the end of the experiment(figure 3.10).
Since a single I/V injection ofCTL led to tumour mass reduction in SCID mice, in
the next experiment we investigated if multiple fixed dose I/V CTL injections
delivered weekly would increase the probability of survival and control growth of
tumours of different masses. Our results demonstrated that CTL therapy was
successful in causing total tumour regression if initiated at a tumour mass below
500mm3 (figures 3.11 - 3.13). However, no beneficial effect was observed once
tumour mass had increased beyond 2000 mm3. These findings indicate that
multiple CTL injections can cause a rapid reduction in tumour mass, however, as
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in in vitro experiments, effective lysis of target cells in vivo is also dependant
upon a critical CTL to tumour cell ratio. Tumours with a large mass at the start of
therapy might require a higher dose and/or more frequent injection of CTLs to
effectively control their growth.
These were preliminary studies using small numbers of donors and animals, but
the results demonstrate that autologous EBV-specific CTLs are effective in
improving survival and causing regression of EBV positive tumours in SCED
mice. Results suggest that this effect is dependent upon the route of delivery and
the initial tumour burden. EV injection route which is more comparable to human
situations (Servida et al, 1993; Rooney et al, 1995) gave better results in terms of
overall survival. We were also successful in demonstrating the importance of
optimum CTL:tumour cell ratio for effective control of tumour growth. Our
findings also show that multiple CTL injections may be more effective than single
injections in controlling EBV-driven B cell proliferation. A larger study testing
the efficacy of different numbers of CTL on already established tumours is
required to further clarify our results. We did not include allogeneic targets in our
in vivo study, however, failure of the CTLs to lyse HLA mismatched targets in
vitro constituted evidence of HLA restriction of our CTL lines. In subsequent
studies it would be interesting to investigate if CTLs would lyse allogeneic cells
in vivo as well as in vitro.
It has been reported that CTLs infused into SC1D mice successfully home on to
autologous tumour cells in vivo (Greenberg et el, 1988; Alexander & Rosenberg,
1991; Wallace et al, 1993). However, detection of CD3 positive cells in tumour
tissue is not sufficient evidence of their cytotoxicity in vivo. It has been suggested
that in vivo CTLs cause tumour regression by both direct cytotoxicity and by
production of IFN-y (Barth et al, 1991). We did not investigate IFN-y production
by the infiltrating T cells in our LCL tumours treated with autologous CTLs,
however, in future studies this issue could be addressed by immunohistochemical
double staining of tumour sections for CD3 and IFN-y expression.
In conclusion, the overall results of our study on immunotherapy of EBV related
PTLD are consistent with earlier investigations both in humans and SCID mice
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(Rooney et al, 1995; Lacerda et al, 1996). We have taken the investigations
further by titrating the CTL numbers and showing that effective control of EBV
driven B cell proliferation is dependant upon a minimum CTL:LCL ratio (.25:1 in
our experiments), below which CTLs fail to effect tumour outgrowth. Our results
also suggest that peptide-specific CTLs targetting EBV immunogenic epitopes
could have a place in immunotherapy of EBV related tumours, especially of
tumours which have a restricted EBV gene expression pattern and cannot be
treated by polyclonal CTLs. Future studies on a larger panel of donors and a
larger group of animals would be required to confirm our results and assess the
true potential of peptide based CTL therapy ofEBV related diseases.
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5.2 In situ Hybridization
Many in vitro studies have identified cytokines as soluble autocrine or paracrine
growth factors for EBV immortalized cells (Randhawa et al, 1994; Oppenheim &
Fugiwara, 1996; Su et al, 1997; Rochford et al, 1997; Sairenji et al, 1998). It has
been suggested that cytokines maintain the sustained growth ofEBV positive cells
both in vitro and in vivo (Tosato, 1987; Straus et al, 1993; Randhawa et al, 1997).
Most previous studies have investigated cytokine profiles ofEBV related diseases
with RT-PCR (Nalesnik et al, 1999), a technique which is sensitive but does not
localize the cytokine to the cell type producing it. In our study we used non-
isotopic tn situ hybridization (NISH) to study the cytokine expression pattern of
ten human PBMC-induced I/P tumours in SCID mice (in vivo model for PTLD), a
tonsil from an acute IM patient, thirteen PTLD, six NPC and five HD tumours.
We focused on detection of IL-2, 4, 6, 10 and IFN-y, cytokines reported to
regulate growth and proliferation ofEBV infected cells (Tosato et al, 1990; Estrov
et al, 1993; Miyazaki et al, 1993; Durandy, et al, 1994; Tosato et al, 1998; Takashi
& Puri, 1997). NISH technique was performed on paraffin wax embedded tissue
to histologically localise the cytokine mRNA signal to the cell type responsible
for its production. Subsequent staining of serial sections for cell surface markers
was undertaken to identify the predominant cell type encoding cytokine
transcripts within the tissues tested.
5.2.1 Standardization of NISH Technique
We used DIG labelled probes in our study because DIG is a plant alkaloid, is not
present in mammalian tissue, and has previously been used successfully for
nucleic acid detection by NISH (Herrington et al., 1989). Although previous
studies have reported that radioisotopic labels are more sensitive than non¬
radioactive reporter molecules (Li et al, 1993; Stefaneanu et al, 1993), we selected
a non-isotopic label since signal localisation is reported to be more accurate. This
is because, unlike radioisotopically labelled sections non-isotopically probed
tissue does not require to be layered in emulsion, and the signal is localised in the
tissue itself rather than in the emulsion layer (Wiethege et al, 1991). Non-isotopic
labels are also more convenient to use than radioactive probes in large ISH studies
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because they are safer and there is no requirement for a designated work area
(Hermanson et al, 1994). Non-radioactive reporter molecules do not have a half
life and therefore do not degrade like radioisotopic labels and do not require a
prolonged development time (Hermanson et al, 1994).
In our study the NISH technique was standardised on cytospin preparations of
formalin-fixed human PHA-stimulated PBMC and paraffin-wax embedded
sections of normal human tissue. Formalin was preferred to ethanol as a fixative
for cytospin preparations because ethanol is less effective in immobilizing RNA
and can cause loss of target during tissue processing (Lawrence & Singer, 1985).
Although cryopreservation of tissue has been reported to be better for probe
penetration (Le Guellec et al, 1992), formalin fixed and paraffin-wax embedded
tissue was used because it was the only material available from our test samples.
We used PHA blasts as positive controls for cytokine detection because a
consistently strong mRNA signal could be detected for all the cytokines on our
panel in these cells with each NISH run. Normal human lymphoid tissue was not
routinely used as a control because mRNA transcripts could not be consistently
detected in this tissue. The sensitivity ofmRNA detection by NISH was tested by
inclusion of a probe for detection of P-actin mRNA. Sections that gave a low
signal for P-actin also gave a poor signal for all the cytokines. This was attributed
to either poor preservation of tissue resulting in mRNA degradation (Bromely et
al., 1994) or due to tumour necrosis, as observed by H&E staining of the sections.
H&E staining of sections from some of the tumours showed large necrotic areas
and in serial sections the cells positive for p-actin and cytokine transcripts were
interspersed among areas of necrotic tissue. These tumours also showed a reduced
number of cells positive for EBERs mRNA and cell surface markers. The results
from these tumours could not interpreted.
Negative controls included no-probe sections to exclude non-specific binding by
the multiple layers of antibodies. RNase-treated sections were included as target
removal controls, which remained negative because of digestion of mRNA prior
to application of the probe. The specificity of the technique was tested by
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inclusion of non-human tissue (mouse tissue), which lacked the target sequences.
No signal was detected in any of the negative controls tested during the study.
Probe access to mRNA target was facilitated by dewaxing and dehydration of
sections followed by Pk digestion. Digestion with Pk was essential because
fixation of tissue with formalin causes cross-linking of nuclear proteins and
nucleic acids (Feldman, 1973). Pk treatment broke down these cross-links and
made the target more accessible (Hopman et al, 1989). The conditions of Pk
digestion were optimised for both paraffin-wax embedded and formalin-fixed
PHA-stimulated blasts. Optimization of Pk concentration and time and
temperature of digestion were critical for penetration of the probe into the tissue
and preservation of tissue morphology. We observed that both over or under
digestion of the tissue resulted in weak or no mRNA signal. Over digestion often
resulted in loss of tissue morphology and detachment of sections from slides
during the procedure.
Our initial attempts to detect and amplify cytokine mRNA signal in both cytospin
preparations and paraffin embedded tissue failed. Sensitivity of the technique was
increased by introduction of FITC as an additional reporter molecule in the
protocol. Addition of extra antibody layers could have potentially resulted in non¬
specific signal but this was avoided by including additional incubation of sections
in normal sheep, rabbit and donkey sera (host animals for primary, secondary and
tertiary antibodies) after stringency washes. The streptavidin-biotin system was
chosen for signal amplification because streptavidin has a high affinity for biotin
and each streptavidin molecule contains four biotin-binding sites, which gives a
high amplification of the signal (Hoefakker et al, 1995). The biotin in the Dako
ABC kit is coupled with alkaline phosphatase (AP) molecules and binding of the
AP-biotin complex to four streptavidin sites increases the number of molecules of
enzyme available to degrade the substrate. BCIP/NBT was the AP substrate of
choice for our study because it reacts for a longer time with AP than most other
AP substrates (Cremers et al, 1987; Ehrlein et al, 1994). It has good localisation
properties, sensitivity and stability (De Jong et al, 1985; Scopsi & Larson, 1986)
and produces a stable purple-blue colour when hydrolysed and reduced by AP.
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Solvents do not degrade it and sections can be mounted permanently without loss
of signal.
5.2.2 Cytokine Profile of EBV Related Diseases
In our study we analysed the In situ expression of TL-2, 4, 6, 10 and IFN-y in EBV
related diseases, identified the cell type responsible for cytokine production and
its association with EBV infection. We investigated EBV positive PTLD tumours,
tumours from SCID mice induced by I/P injection of PBMC from EBV
seropositive donors, NPC tumours and HD tumours. The cytokine profile of a
tonsil from an acute IM patient was also studied to compare the cytokine
expression pattern of primary EBV infection with that of EBV related
malignancies. This was included because recently Setsuda et al have reported
elevated level of cytokine gene expression by lymphoid tissue from acute IM
patients as compared to PTLD tumours (Setsuda et al, 1999).
Expression of IL-2, 4, 6, 10 and IFN-y mRNA was detected in human PBMC
induced I/P tumours from SCID mice and cytokine positive areas predominantly
equated with areas positive for CD20 and EBERs signal confirming autocrine
cytokine production by EBV infected tumour cells. PTLD tumour B cells also
expressed a similar cytokine mRNA expression pattern. The tumours were
positive for signal of all the cytokines in our panel, however, as compared to IL-2,
4 and IFN-y, a higher percentage of cells were found to be positive for IL-6 and
IL-10, which are both B cell growth factors (Yokoi et al, 1990; Emelie et al,
1992). Our results are different from those of Nalesnik et al who failed to detect
any IL-2 and IFN-y by RT-PCR in 11 PTLD cases (Nalesnik et al, 1999). In our
study we detected transcripts of IL-2 and IFN-y in all the tumours, but the number
of cells positive for these cytokines was lower as compared to IL-6 and IL-10. IL-
10 is known to suppress IL-2 and IFNy expression, which may account for the
reduced expression of these cytokines in our tumour panel. Our results showed
that cytokine mRNA expression was predominantly localized to EBV positive
tumour cells suggesting that EBV positive PTLD tumour cells produce cytokines
in an autocrine fashion. This might enable them to directly stimulate their own
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growth and suppress the anti-EBV cellular immune response by inducing
expression of the immunosuppressive cytokine IL-10. It has been reported that
PTLD tumours are infiltrated with CD4 positive cells in their early stages (Perera
et al, 1998) and these T cells might contribute to the pathogenesis of the tumour
by providing cytokines for initial cell growth. However, immunohistochemical
analysis of four of the PTLD tumours in our study showed less than 1%
infiltrating CD3 positive T cells, interspersed among CD20 and EBER positive
cells. It is likely that these infiltrating T cells may also be expressing cytokines
but because of their sparse distribution it was not possible to localize cytokine
production to these cells on serial sections. Double and triple labeling techniques
for cytokine and EBERs mRNA detection and cell surface markers were
attempted by using protocols described in a previous study (Rex et al, 1997), but
did not give satisfactory results in the time available. If these techniques could be
developed and refined, more conclusive results could be obtained about the
contribution of infiltrating T cells to pathogenesis ofPTLD.
More than 50% cases of HD in Europe are now known to be EBV positive, with
the giant R/S and Hodgkin cells carrying the virus (Weiss et al, 1989, Alexander
et al, 2000). It has been suggested that EBV might be a co-factor in HD
pathogenesis and one possible mechanism of its contribution to tumour pathology
and immune evasion might be through induction of cytokine expression. In our
study the cytokine and EBERs mRNA signal was predominantly confined to giant
CD30 positive R/S cells of which, over 50% were positive for cytokine and
EBERs mRNA in all cases. In a recent immunohistochemical study Dukers et al
have reported expression of IL-2, 4, 10 and IFNy by both malignant and
infiltrating reactive cells in HD (Dukers et al, 2000). However, we failed to detect
cytokine expression or EBERs signal in the infiltrating cells. Our results suggest
that in HD cytokine gene expression is limited to EBV positive R/S cells and the
virus might regulate tumour proliferation via induction of autocrine cytokine
production. We did not investigate cytokine expression pattern of EBV negative
HD but Dukers et al found no difference in level of expression of IL-2, 4 and
IFNy between EBV positive and negative HD. However, EBV negative tumours
expressed lower levels of IL-10 protein as compared to EBV positive cases
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(Dukers et al, 2000). IL-10 is an autocrine B cell growth factor and can also
modulate the host anti-tumour immime response by suppression of production of
other immuneregulatory cytokines such as IL-12 and IFNy (Chouaib et al, 1997).
In our study three out of five tumours expressed IL-10 mRNA. However due to
poor tissue quality we failed to observe a relationship between expression levels
of IL-10 and other cytokines on our panel. Further investigation is required on a
larger number of both EBV negative and positive HD tumours to confirm our
findings.
Previous studies using RT-PCR and intracellular cytokine staining by
immunoflowcytometry have reported expression of IL-1, IL-2, IL-4, IL-5, IL-6,
IL-10, INF-y, TNF-a and TGF-p in both NPC tumour cells and the infiltrating T
cells (Busson et al, 1987; Huang et al, 1999). Other studies on
immunohistochemical detection of individual cytokines in NPC tumours have
shown expression of IL-10 and IFNy (Tang et al, 1999, Fujieda et al, 1999) and
IFN-y signal was predominantly observed in the infiltrating T lymphocytes (Tang
et al, 1999). We investigated the cytokine expression pattern ofEBV related NPC
and the cell type(s) responsible for their production. Our results showed that both
the epithelial tumour cells and the infiltrating CD3 positive T cells expressed
cytokine transcripts with the predominant expression in the infiltrating cells. We
also found that the signal for IL-6 and IL-10 was present in a higher number of
both tumour and infiltrating cells as compared to other cytokines. Our findings
suggest that in NPC tumour growth is regulated by both autocrine and paracrine
cytokine production by the malignant and the infiltrating cells. Since in NPC the
infiltrating T cells fail to control the EBV driven malignant cell proliferation our
results suggest that paracrine cytokine production by infiltrating cells might
contribute positively to the expansion of the NPC tumour. To further investigate
our results a study on a larger number ofNPC tumours is required and compared
with cytokine mRNA expression by EBV negative NPC cases and normal
nasopharyngeal tissue.
To observe if the cytokine expression pattern of normal lymphoid cells during
acute EBV infection would resemble that of the EBV related malignancies,
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tonsillar sections from a case of acute IM were probed for IL-2, 4, 6, 10 and IFNy
mRNA. The IM tonsil tested positive for all the cytokines in our panel with the
highest percentage of cells positive for IL-6. Areas of cytokine expressing cells
equated with areas positive for EBERs signal in serial sections. Previously, it has
been reported that serum levels of IL-6 and IL-10 are raised in patients with acute
IM as compared to healthy individuals (Wright-Browne et al, 1998; Tage et al,
1995). In contrast to our study the findings of an immunohistochemical study by
Setsuda et al, who reported higher levels of IFNy production in IM than PTLD
tumours (Setsuda et al, 1999). We only detected IFNy in <1% cells in the IM
tonsil. In our study the cytokine expression pattern of the IM tonsil was similar to
that ofEBV related malignancies. These results suggest that like in EBV positive
tumours cytokine transcription by EBV infected B cells in IM may modulate the
pathogenesis of the disease.
Overall our results show that EBV infected cells express cytokines in an autocrine
fashion. This suggests that EBV infected cells might modulate their growth and
regulate the host immune system via the expression of both B cell growth
promoting and immunosuppressive cytokine. Our findings and previously
reported data suggest that EBV induced B cell immortalisation and proliferation
and immune escape are controlled by the virus via the cytokine network. Further
studies are required to identify the mechanism by which EBV induces and
controls cytokine expression in infected cells. Better understanding of the
interaction between EBV and the cytokine network could lead to new
immunotherapies for treatment and prevention ofEBV related malignancies.
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Summary. Epstein-Barr virus (EBV)-positive B-cell lym¬
phoproliferative disease (BLPD)-like lesions develop in severe
combined immunodeficient (SCID) mice inoculated with
peripheral blood mononuclear cells (PBMCs) from EBV-
seropositive donors. We used this model to investigate the
pathogenesis of EBV-associated BLPD. Tumour incidence fell
from 81% to 11% when only B cells were inoculated,
suggesting a key role for T cells in tumour formation. This
was further underlined by the reduction in tumour
incidence from 76% to 7% when PBMCs were depleted of
CD4 positive (+ve) helper T cells. Tumour outgrowth was
also reduced when PBMC were depleted of CDS +ve.
CD45RA +ve or CD45RO Ave T cells. The majority of
PBMC-derived tumours analysed by reverse transcriptase-
polymerase chain reaction (RT-PCR) expressed mRNA for
interleukin (IL) 2. 4. 6. 10 and interferon (IFN) y. This is the
cytokine pattern seen in activated T cells and includes B-cell
growth factors. In situ hybridization studies confirmed that
the tumour cells themselves express the growth factors,
which is consistent with autocrine-stimulated tumour
growth.
Our results suggest the following sequence of events: (1) T
cells are essential for the initial outgrowth of tumorigenic
EBV +ve B cells in vivo: (2) the neoplasm sustains its growth
in an autocrine, cytokine-stimulated manner: and (3)
established tumours become independent of T-cell help.
Keywords: EBV. lymphoma. T cells, cytokines. SCID mice.
INTRODUCTION
The term B-cell lymphoproliferative disease (BLPD) denotes
a spectrum of B-cell proliferations arising in 1-10% of
organ transplant recipients (Thomas et al, 1995). BLPD
ranges from a diffuse (viral lymphadenitis-like) polymorphic
B-ceil proliferation with polyclonal immunoglobulin (Ig)
expression to a malignant monoclonal lymphoma. Epstein-
Barr virus (EBV). a human herpes virus, is aetiologicallv
associated with BLPD (Crawford et al. 1980). Tumour cells
generally express the nine EBV latent genes, together with
B-cell activation markers and cellular adhesion molecules
(CAMs) (Young et al. 1989: Thomas et al. 1990). This
phenotype is similar to that of continually proliferating B
lymphoblastoid cell lines (BLCLs) established in vitro by
infection of B cells with EBV.
Correspondence: Prof D. H. Crawford. Department of Medical
Microbiology. University of Edinburgh Medical School. Teviot
Place. Edinburgh EH8 9AG. UK. E-mail: d.crawford@ed.ac.uk
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The precise mechanism of BLPD development in trans¬
plant recipients is yet to be elucidated, although major risk
factors include high-dose immunosuppression and primary
EBV infection in previously seronegative transplant recipi¬
ents (Ho et al. 1985: Thomas et al. 1990). The tumour
commonly arises in the brain, gut or transplanted organ,
where the microenvironment is thought to provide the right
milieu for EBV-driven B-cell proliferation. There is com¬
monly a large non-neoplastic component in BLPD mainly
consisting of mature CD4 +ve (helper) CD45RO Ave
(memory) T cells (Thomas et al. 1990: Perera et al. 1998).
which may provide a source of soluble growth factors and
facilitate tumour growth.
The severe combined immunodeficient (SCID) mouse,
which lacks functional B and T cells, is a recent small-
animal model for EBV-associated BLPD by virtue of its ready
acceptance of human (hu) xenografts (Bosma et al. 1983:
Mosier et al. 1988). Peripheral blood mononuclear cells
(PBMCs) from EBV-seropositive healthy blood donors give
rise to EBV Ave BLPD in a proportion of animals (hu-PBMC-
SCID) (Picchio et al. 1992). These SCID tumours are
immunoblastic lymphomas (Mosier et al. 1990: Purtilo
600 © 2000 Blackwell Science Ltd
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et ah 1991) closely resembling BLPD in graft recipients
(Rowe et al, 1991). The tumours are of human B-cell origin
and show a surface phenotype identical to that seen in
BLCLs and BLPD with expression of all the latent viral
proteins, B-cell activation antigens and CAMs (Mosier et al,
1990; Rowe et ah 1991). BLCLs give rise to similar tumours
in the SCID mouse model (Rowe et ah 1991).
The present study was designed to investigate the
requirements for tumour outgrowth in PBMC-inoculated
SCID mice as a model for BLPD in transplant recipients.
Tumour incidence was dramatically reduced when CD2 +ve
or CD4 +ve cell populations were depleted from PBMCs
prior to inoculation. Tumour incidence was reduced to a
lesser extent by removal of CD8 +ve, CD30 +ve, CD45RA
+ve or CD45RO +ve T cells. Using reverse transcriptase-
polymerase chain reaction (RT-PCR), the presence of
amplifiable human interleukin (IL) 2, 4. 6. 10, and
interferon (IFN) -y, mRNA was regularly detected in the
tumour material. In situ hybridization studies demonstrated
that the transcripts are produced by the tumour cells.
The results suggest that initial tumour outgrowth
requires T-cell help but that established tumours are
maintained in an autocrine, cytokine-stimulated fashion.
MATERIALS AND METHODS
SCID mice. All animal work was carried out in full
compliance with the Animals (Scientific Procedures) Act
1986. C.B17 SCID mice, aged betweeen 3 and 34 weeks,
were supplied from a breeding colony kept under specific
pathogen-free conditions at the London School of Hygiene &
Tropical Medicine.
Blood donors. Aliquots containing 50-100 ml of hepar-
inized blood were drawn from healthy volunteers. Blood
bags containing PBMCs were obtained from the National
Blood Transfusion Centre in Colindale, London, UK.
EBV serology. Analysis of anti-VCA IgG antibody titre was
carried out by routine indirect immunofluorescence (Henle
& Henle. 1966).
Separation of PBMC from heparinized whole blood. Whole
blood, or buffy coat, was layered over Ficoll-Hypaque
(Pharmacia. Sweden) and spun at 540 g for 20 min.
Plasma was harvested and stored at —20°C for serological
analysis. The interface containing the PBMCs was collected
and washed twice. Cells were either used directly, or frozen
viably and stored in liquid nitrogen.
Fractionation of PBMC by E-rosette separation. PBMCs were
fractionated by E-rosette separation by the standard method
(Kaplan & Clark. 1974). E-rosette-negative (CD2-ve) cells
enriched for B cells, monocytes and natural killer (NK) cells,
were harvested, washed, and either used directly or stored at
4°C for later use. E-rosette-positive T cells and NK cells, were
briefly resuspended in 1 ml of sterile injectable water in
order to lyse sheep red blood cells. The lysis was halted by
the immediate addition of a large volume of wash medium.
Cells were washed and either used directly or subjected to
further in vitro manipulation. The enrichment of the E-
negative and E-positive populations was determined in
separate experiments to be > 97%. Control experiments
entailed the injection of SCID mice with unfractionated
PBMCs. Whenever possible, the control animals were
inoculated at the same time as the test mice.
Cell fractionation using antibody-coated magnetic beads.
Monoclonal antibodies (mAbs) to human CD4 (QS4120),
CD8 (UCHT4) and CD45RO (UCHL1) were kindly provided
by Professor P. C. L. Beverley (The Edward Jenner Institute
for Vaccine Research. Compton, Berkshire. UK). mAbs to
human CD45RA (SN130) were provided by Professor G.
Janossy (Royal Free Hospital Medical School, London, UK).
mAb to human CD30 was supplied by Cymbus Biotechnol¬
ogy (Hampshire, UK). The T-cell enriched population was
resuspended in 1 ml of culture medium (1 x RPMI—1640,
10% v/v fetal calf serum, lOOIU/ml penicillin. 100 p-g/ml
streptomycin, 2 mmol/1 L-glutamine) containing a working
dilution of azide-free murine IgG mAbs (approx. 10 p-g) to
either human CD4 (Reinherz et ah 1979a. b). CD8 (Reinherz
et ah 1980), CD30 (Schwab et ah 1982; Schwarting et ah
1989), CD45RA (Akbar et ah 1988: Serra et ah 1988). or
CD45RO (Akbar et ah 1988: Merkenschlager et al, 1988)
surface antigens, and was then incubated at 4°C for 30 min.
After two washes the cells were incubated with (10 |xl/10h
cells) prewashed sheep anti-mouse IgG-coated magnetic beads
for 10 min at 4°C. The uncoated cells were collected by a 3
min application of a magnetic particle separator (Vartdal et ah
1987). Successful depletion of a cell subpopulation was
determined in separate experiments to be > 85%, except for
the CD30-depleted population which was > 70% depleted.
Lectin-stimulation of PBMC. 10 pg/ml phytohaemagglut-
inin (PHA) was added to PBMCs at 2 x 10h cells/ml
(Goldstein and Hayes. 1978). Cells were cultured for 24 h
at 37°C in 5% CCD and washed before in vivo use.
Inoculation and monitoring of SCID mice. Cells were injected
intraperitoneally (ip) in 500 pi of culture medium. Between
42 x 106 and 54 x 10ft unfractionated PBMCs were
inoculated into each control animal. This number of cells
was also either PHA-treated in vitro for 24 h and inoculated
into each test mouse, or separated into E-negative and E-
positive cells followed by depletion of a specific T-cell
subpopulation and inoculation of the recombined E-negative
and subpopulation-depleted E-positive cells into each test
mouse. Each test group consisted of three animals. On
showing signs of illness, or after a preset time limit of 100 d.
mice were culled and lung, liver, spleen, and any tumour
tissue were removed. Pieces from each tissue were fixed in
neutral buffered formalin and snap-frozen.
Classification of blood donors. We and colleagues have
previously found PBMCs from individual blood donors to
give rise to tumours in a similar proportion of inoculated
SCID mice upon repeat testing (Picchio et ah 1992;
Johannessen et ah 1998). Thus our panel of 24 blood
donors contained 8 high (> 70% tumour incidence), 12
intermediate (30-70% tumour incidence), 2 low (1-30%
tumour incidence), and 2 no incidence donors.
Immunohistochemistry. All tissues were routinely stained
with haematoxylin and eosin (H&E). Frozen or paraffin
wax-embedded tissue sections were immunostained with a
panel of primary antibodies: polyclonal anti-EBNAl-6. anti-
CD3 mAb (Dako, Buckinghamshire, UK); anti-CD4 mAb
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Table IA. Primer sequences used for RT-PCR amplification of (3-actin and human cytokine gene transcripts (IL-2,
IL-4, IL-5, IL-6, IL-10, IFN--y).
Human gene/primers Primer sequences (5'—>3') Product size (bp)]:
P-actin*
5': 5' GTG GGG CGC CCC AGG CAC CA 3' 540
3': 5' CTC CTT AAT GTC ACG CAC GAT TTC 3'
IL-2*
5': 5' ACT CAC CAG GAT GCT CAC AT 3' 266
3': 5'AGG TAATCC ATC TGTTCAGA 3'
IL-4f
5': 5' CGG CAA CTT TGA CCA CGG ACA CAA GTG CGA TA 3' 344
3': 5' ACG TAC TCT GGT TGG CTT CCT TCA CAG GAC AG 3'
IL-5*
5': 5' ATG AGG ATG CTT CTG CAT TTG 3' 405
3': 5' TCA ACT TTC TAT TAT CCA CTC GGT GTT CAT TAC 3'
IL-6*
5': 5' ATG TAG CCG CCC CAC ACA GA 3' 190
3': 5' CAT CCA TCT TTT TCA GCC AT 3'
IL-lOf
5': 5' AAG CTG AGA ACC AAG ACC CAG ACA TCA AGG CG 3' 328
3': 5' AGC TAT CCC AGA GCC CCA GAT CCG ATT TTG G 3'
IFN-y*
5': 5' AGT TAT ATC TTG GCT TTT CA 3' 356
3': 5' ACC GAA TAA TTA GTC AGC TT 3'
•Yamamura et al (1991. 1992).
fClontech Laboratories, USA.
:j:bp, base pairs.
(Dako): anti-CD8 mAb (Dako); anti-CD20 mAb (Dako): anti-
CD45RB mAb (Dako); anti-mouse MHClDd mAb (Serotec.
Oxford. UK). Bound antibody was visualized with either a
peroxidase [peroxidase antiperoxidase (PAP) test] or alkaline
phosphatase label [alkaline phosphatase antialkaline phos¬
phatase (APAAP) test] in accordance with standard
methods (van Noorden, 1986). EBNA staining was detected
by a routine indirect anti-complement technique (Reedman
& Klein. 1973). Cells were quantified by counting the
numbers of labelled and unlabelled cells in five high-power
fields ( x 1000). The results were expressed as a percentage
of marker-positive cells in the total cell population counted.
Reverse-transcriptase-polymerase chain reaction (RT-PCR).
RT-PCR was carried out essentially as described by Hart et al
(1988). Total RNA was extracted from control cell pellets or
tumour tissues using RNAzol1MB in accordance with the
manufacturer's protocol (Cinna/Tel Test, TX, USA). The
synthesis of complementary DNA (cDNA) was carried out
using an 'RT-PCR Kit' from Stratagene Cloning Systems
(CA, USA) in accordance with the manufacturer's protocol
using reverse transcription from random primers by reverse
transcriptase. PCR was carried out using sequence-specific
primers synthesized by Oswel DNA Services (Hampshire,
UK) (see Table IA). The IL-10 primers were not found to
cross-amplify EBV-vIL-10. Positive and negative control
samples, as well as sterile distilled water (SDW) as a DNA
template-free negative control, were included in each run.
Human (3-actin served as a control to ensure the presence of
amplifiable cDNA in the samples. The PCR products were
run on a 2-5% w/v NuSieve 3:1 agarose (FMC BioProducts,
ME. USA) gel and blotted onto Hybond N + nylon
membranes (Amersham International. Buckinghamshire.
UK) in accordance with the method of Southern (1975) (for
probes, see Table IB). The RT-PCR was sensitive enough to
detect 102—103 copies of each of the IL-2. IL-5, IL-6. and
IFN-y mRNAs, or approx. 25 attomoles of each of the IL-4
and IL-10 mRNAs (Clontech. USA).
In situ hybridization (ISH) for EBV-encoded small RNAs
(EBERs). ISH for EBERs was carried out on paraffin wax-
embedded tissue sections by routine methods (Howe &
Steitz, 1986).
In situ hybridization (ISH) for cytokine mRNA. ISH was
carried out essentially as described by Fleming et al (1992)
and Karr et al (1995), using digoxigenin-labelled oligonu¬
cleotide probes supplied by R & D Systems. UK. Positive
signals were amplified with sheep anti-digoxigenin antibody
(Boehringer Mannheim, UK), followed by a biotin-labelled
anti-sheep antibody (Vector. UK). Bound antibody was
detected using streptavidin-biotin/alkaline phosphatase
(ABC) complex kit (Dako). and the complex was visualized
with a 5-bromo-4-chloro-3-indolylphosphate/nitroblue tet-
razolium (BCIP/NBT) substrate (Sigma. UK). Positive
controls included PHA-stimulated PBMCs, and negative
controls included unprobed sections and RNAase-treated
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Table IB. Probe sequences used in RT-PCR to detect |3-actin and human cytokine gene
transcripts (IL-2, IL-4, IL-5, IL-6, IL-10, IFN-y).
Human gene Probe sequence (5'—>3')
P-Actin 5' GGA TAG CAA CGT ACA TGG CT 3'
IL-2 5' CCC TGG GTC TTA AGT GAA AG 3'
IL-4 5' GTC TGT TAC GGT CAA CTC GG 3'
IL-5* 5' GCC AAT GAG ACT CTG AGG ATT CCT G 3'
IL-6* 5' TCT TGT TAC ATG TCT CCT TTC TCA C. 3'
IL-10* 5' CAG GTG AAG AAT GCC TTT AAT AAG CTC CAA GAG AAA GGC ATC
TAC AAA GCC ATG AGT GAG TTT GAC ATC 3'
IFN-y 5' GCT ACA TCT GAA TGA CCT GC 3'
* Yamamura et al (1991,1992).
sections. These controls were included in every staining run
and results were used only if control staining was
satisfactory.
Statistical analysis. The statistical tests used in this study
were the chi-squared (x2) test with Yates' correction, the
Fisher's exact test and the Wilcoxon rank sum test.
RESULTS
Immunohistology of PBMC-derived tumours
The analysis of a total of 27 PBMC-derived peritoneal
tumours consistently showed the lesions to comprise of large
EBV +ve immunoblasts when stained with H & E. EBNA
and/or EBERs. H&E further showed areas of necrosis.
Detailed analysis of 12 of the tumours demonstrated a
human CD45RB +ve. human CD20 +ve. mouse MHClDd-
negative phenotype, indicating that they were human B-cell
lesions. Tumours contained <6-6% human CD3 +ve T
cells, the majority of which were CD8 +ve T cells with a
small CD4 +ve population.
Characterization of cell type required for tumour outgrowth in
SCID mice
Initially, the separation procedure was tested to determine
the enrichment of separated populations and whether cell
manipulation and/or cell loss during in vitro manipulations
significantly affected the tumour incidence. 25 x 10'
PBMCs from each of two high incidence donors were
separated into E-positive and E-negative cells and recom-
bined. prior to inoculation in equal numbers into each of
five animals. Six out of 10 (60%) mice inoculated with
recombined E-positive and E-negative cells developed
tumours, whereas 19 out of 22 (86%) of the controls
developed tumours. Although there was some loss of
tumour outgrowth, this was not a significant difference
(Fisher's exact test: P > 0-1). A comparison of the time to
tumour did not show a significant difference (Wilcoxon rank
sum test: P > 0-1). The results are shown in Table II. In
light of these results, it was concluded that in vitro
manipulations did not significantly affect tumour incidence
in SCID mice.
In order to characterize the cell type(s) required for
tumour development in SCID mice. 15 x 10' PBMCs
from each of three high incidence donors were separated
by E-rosetting and the E-negative and E-positive cells
inoculated separately ip into two groups of three test mice
each. One out of nine (11%) mice inoculated with either E-
negative or E-positive cells developed tumour. In compar¬
ison with the earlier results, 21 out of 26 (81%) PBMC-
inoculated control mice developed tumours. The results are
shown in Table II. This statistically significant reduction in
tumour incidence observed in mice injected with B and T
cells alone (Fisher's exact test, P < 0-001) suggests that
despite their B-cell origin, both B and T cells are required
for tumour outgrowth. The possibility that T-cell-derived
soluble factors are required for tumour outgrowth was
therefore investigated.
Analysis of the role of T-cell activation in tumour induction
PBMCs (13 x 107—16 x 107) from each of 10 EBV-
seropositive donors were PHA-treated for 24 h in vitro
prior to ip inoculation of equal cell numbers into three test
mice for each PBMC donor. Cells from two high, five
intermediate, one low, and two no incidence donors were
used. Tumours occurred in 18 out of 30 (60%) mice
inoculated with PHA-stimulated PBMCs. whereas 2 7 out of
49 (55%) control mice developed tumours. Statistical
analyses showed that prior in vitro PHA treatment of
PBMCs did not significantly affect the tumour incidence
(chi-squared test with Yates' correction: P > 0-8). However,
the time from inoculation to tumour development was
significantly shortened with PHA treatment in high and
intermediate incidence donors (Wilcoxon rank sum test:
P < 0-05). The results are shown in Table III.
Furthermore, when between 15 x 10' and 16 x 10'
PBMCs from each of three high and one intermediate
incidence donors were depleted of CD30 +ve-activated T
cells prior to inoculation into groups of three test mice, 3
out of 12 (25%) test mice developed tumours, whereas 29
out of 36 (81%) control mice developed lesions (Table II)
(Fisher's exact test, P < 0-001). The median time to
tumour was significantly increased in the test mice
compared with the control animals (Wilcoxon rank sum
test: P < 0-05).
These data suggested the importance of activated T cells
in tumour formation, and therefore experiments were
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Table II. Data from cell separation and cell depletion experiments.
Number of
Number of cells tumours/
injected per number of mice Median time
Cells mouse injected to tumour
Procedure injected (x 106) (%) (days)
Injection of PBMC 49-54 19/22 (86) 61
recombined E- and E+ cells 37-42 6/10 (60) 58
E- and E+ cells
Injection of PBMC 44-54 21/26 (81) 55
either E- or E+ E- cells 9-11 1/9* (11) 70
cells alone E+ cells 19-26 1/9* (11) 86
Injection of E- cells PBMC 42-54 22/29 (76) 56
recombined with E- and CD4- 10-22 1/15f (7) 98
E+ cells depleted depleted E+ cells
of a particular PBMC 44-54 22/29 (76) 58
T-cell subset E- and CD8- 18-31 7/18$ (39) 60
depleted E+ cells
PBMC 44-54 29/36 (81) 58
E- and CD30- 11-38 3/12§ (25) 71H
depleted E+ cells
PBMC 49-54 19/24 (79) 55
E- and CD45RA- 8-35 6/15** (40) 64
depleted E+ cells
PBMC 49-54 17/21 (81) 55
E- and CD45RO- 11-26 3/12tt (25) 61
depleted E+ cells
Significance compared with the relevant unfractionated PBMC controls (shown in the table):
*P < 0-001. tP < 0-001. JP < 0-05. §P < 0-001. HP < 0-05. **P < 0-05. ffP < 0-005.
undertaken to determine the T-cell subpopulation(s)
required.
Characterization of T-cell subpopulations required for tumour
outyrowth.
E-rosette-positive cells separated from 13 x 10' to
16 x 10' PBMCs from each of seven high and six
intermediate incidence donors were depleted of either CD4
+ve, CD8 +ve. CD45RA +ve or CD45RO +ve T cells prior
to inoculation into groups of three test mice. Tumours arose
in 1 out of 15 (7%) mice receiving CD4-depleted PBMCs,
whereas 22 out of 29 (76%) control animals developed
lesions (chi-squared with Yates' correction. P < 0-001).
Tumours developed in 7 out of 18 (39%) mice injected with
CD8-depleted PBMCs. whereas tumours arose in 22 out of
29 (76%) controls (chi-squared with Yates' correction:
Table III. Data from activation experiments using phytohaemagglutinin (PHA).
Number of tumours/ Median time
Donor subgroup/ number of mice to tumour
cells inoculated (%) (days)
High incidence donors Untreated PBMC 18/23 (78) 58
PHA-treated PBMC 6/6 (100) 51*
Intermediate Untreated PBMC 8/15 (53) 62
incidence donors PHA-treated PBMC 9/15 (60) 50*
Low Untreated PBMC 1/11 (9) 46
incidence donors PHA-treated PBMC 3/9 (33) 100
'Statistically significant (P < 0-05) compared with the relevant untreated PBMC (shown in the
table).
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P < 0-05). Tumours arose in 6 out of 15 (40%) mice
receiving CD45RA-depIeted PBMCs, whereas 19 out of 24
(79%) control mice developed tumours (chi-squared with
Yates' correction, P < 005). Tumours developed in 3 out
of 12 (25%) mice receiving CD45RO-depleted PBMCs,
whereas 17 out of 21 (81%) control mice developed
lesions (Fisher's exact test, P < 0-005). Analysis of the
median time to tumour did not show any statistically
significant difference between test and control groups
(Wilcoxon rank sum test, all P-values >0-1). The results
are summarized in Table II.
These results, together with the data from the analysis of
the role of T-cell activation in tumour incidence, suggested
that T-cell-derived soluble growth factors were required for
tumour outgrowth. As all tumours tested contained very
few T cells, we postulated that T cells are essential for the
initial outgrowth of tumorigenic EBV +ve B cells, but later
become independent of T-cell help and sustain their own
growth in an autocrine, cytokine-stimulated manner. This
was investigated by analysing human cytokine gene
expression of the tumours using RT-PCR.
Analysis of human cytokine gene expression in EBV + ve
tumours arising in SCID mice.
Tumours were analysed for the presence of amplifiable
human IL-2, IL-4, IL-5, IL-6, IL-10. and IFN-y, mRNA by
RT-PCR. RNA was extracted from 12 peritoneal tumours
which had arisen from unfractionated PBMCs from 12
seropositive donors (five high, six intermediate, and one
low incidence donors). On two occasions cDNA was
prepared from the tumour RNA, and each of the two
batches of cDNA were then amplified in a RT-PCR reaction.
cDNA from PHA-treated human PBMCs was used as a
positive control template, whereas cDNA from PHA-treated
murine BALB/c splenocytes was included as a species-
specific negative control template. The pattern of cytokine
gene expression in the PBMC-derived SCID mouse tumours
was compared with that observed in four BLCLs. Amplifi-
able cDNA was detected in all of the samples tested, as
determined by the (3-actin RT-PCR. The IL-5 transcript was
not detected in any of the test samples. Four out of four
(100%) BLCLs expressed human IL-4. IL-6. IL-10 and IFN-y.
but none expressed IL-2. Twelve out of twelve (100%)
tumours expressed human IL-10 and IFN-y, and 11 out of
12 (92%) tumours expressed IL-6. Nine (75%) and eight
(67%) out of 12 tumours expressed IL-2 and IL-4,
respectively. A representative result showing amplification
of human IL-2 and IL-10 is shown in Fig 1. The results are
summarized in Table IV. Thus, the main difference
observed between BLCLs and the PBMC-derived tumours
was the expression of IL-2 in the majority of tumours but
in none of the BLCLs. These data indicate that the PBMC-
derived SCID mouse tumours have a similar cytokine
profile to activated T cells which includes the expression of
a variety of B-cell growth factors.
In order to identify the cellular origin of the cytokine
transcripts, in situ hybridization studies were carried out on
serial sections using oligonucleotide and EBER probes. Seven
of the ten tumours examined expressed high levels of (3-
actin and these were further analysed for the expression of
human IL-2, IL-4, IL-6, IL-10 and IFN-y. 100% of the
tumours were positive for EBERs, IL-2 and INF7, whereas
86% were IL-6 and IL-10 positive. 71% of the tumours were
IL-4 positive. Representative results showing ISH for IL-2,
IL-10 and EBER are shown in Fig 2. The results are
summarized in Table V. These results correspond with the
RT-PCR data and show that the EBER +ve tumour cells
express the cytokines examined.
DISCUSSION
EBV-associated BLPD in transplant recipients carries a
mortality rate of up to 70% (Armitage et al, 1991).
Reduction or withdrawal of immunosuppression, together
with the anti-viral agent acyclovir, is currently the
treatment of choice, but an optimal therapeutic strategy
has yet to be formalized. A better understanding of the
pathogenesis of BLPD would help in this formulation of new
therapeutic regimes. However, only limited amounts of
BLPD biopsy material are available, and this has proved to
be very difficult to grow in vitro. Recently, BLPD material has
been successfully grown directly in SCID mice, but further
expansion of this material was not achieved (Perera et al,
1996; our unpublished observations). As a result of this, the
Ml M2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
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Fig 1. Representative results of the amplification of human cytokine gene transcripts in the tumour material: interleukin 2 (IL-2) and
interleukin 10 (IL-10). cDNA from 5 |xg of RNA was amplified in a 35 (IL-10)- or 40 (IL-2)-cycle RT-PCR reaction using sequence specific
primers in a 100-p.l reaction mix. Twenty microlitres of RT-PCR product was run onto a 2-5% w/v NuSieve agarose gel, Southern transferred
onto a nylon membrane, and hybridized using a gene-specific 32P-labelled oligonucleotide probe. Hinfl-digested <j>X174 DNA and 1 kbp DNA
ladder were used as 32P-radiolabelled and non-radiolabelled DNA size markers respectively. Lane 1, PHA-treated human PBMC; Lane 2, PHA-
treated Balb/c murine splenocytes; Lane 3, sterile distilled water; Lanes 4-7, BLCLs A, B, C and D, respectively; Lanes 8-19, human PBMC-
derived SCID mouse tumours 1-12 respectively. The size of the IL-2 (266 bp) and IL-10 (328 bp) RT-PCR products is indicated.
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Table IV. Data from RT-PCR analysis of human cytokine gene expression in 4 B lymphoblastoid cell lines (BLCLs) and 12 SCID mouse-grown
tumours.
P-Actin IL-2 IL-4 IL-5 IL-6 IL-10 IFN-7
Controls Hu-PBMCs* + + + + + + +
Mo-splenocytest + - - - - - -
SDW - - - - - - -
BLCLs A + - + - + + +
B + - + - + + +
C + - + - + + +
D + - + - + + +
Tumours 1§ + + + - + + +
2§ + + - - + + +
31 + + + - + + +
4$ + + + - + + +
5t + + + - + + +
6§ + + + - + + +
7§ + + + - + + +
8t + - - - + + +
n + + - - + + +
lot + - - - - + +
11§ + - + - + + +
12§ + + + - + + +
* Human PBMCs treated with PHA in vitro for 24 h.
"["Murine BALB/c splenocytes treated with PHA in vitro for 24 h.
Tumours derived from PBMCs from thigh, intermediate or llow incidence donors.
























Fig 2. Representative results of in situ hybridization for EBV-encoded RNAs (EBERs) and human cytokine gene transcripts: interleukin-2 (IL-2)
and interleukin-10 (IL-10). Serial sections of tumour 2 with B-cell-specific anti-CD20 mAb (Fig 2a). EBER probe (Fig 2b). (3-actin probe
(positive control) (Fig 2c), IL-2 probe (Fig 2d), IL-10 probe (Fig 2e), no probe control (Fig 2f). (original magnification x400).
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Table V. Data from in situ hybridization analysis of human cytokine gene expression in 10 SCID mouse-grown tumours.
Controls
Tumours
fl-Actin IL-2 IL-4 IL-6 IL-10 IFN--
Hu-PBMCs* + + + + + +
No probe - - - - - -
RNAase treatment - - - - - -
Mo tissue NT - - - - -
It 4 + 4 + 3 + 3 + 1 + 4 +
2% 4 + 4 + - 4 + 4 + 4 +
5t 2 + 3 + 2 + - 1 + 1 +
6t 5 + 3 + - 3 + 4 + 3 +
n 2 + 2 + 2 + 2 + 2 + NT
8t 3 + 1 + 1 + 3 + - 2 +
9t 1 + - - - 1 + -
lot 3 + 2 + 2 + 1 + 3 + 3 +
lit 1 + - NT - - -
12| 1 + - - - - -
'Human PBMCs treated with PHA in vitro for 24 h.
Tumours derived from PBMCs from thigh or ^intermediate incidence donors.
Percentage of positive cells: 5+, >80%; 4+, 51-80%; 3+, 21-50%; 2+, 6-20%; 1 + , 1-5%; -, 0%; NT, not tested.
present study was designed to investigate the pathogenesis
of EBV-associated BLPD using the PBMC-inoculated SCID
mouse model (Mosier et al, 1988).
Our experimental design was to separate PBMCs into CD2
+ve T-cell and non-T-cell populations and then deplete the
T cells of specific subpopulations. The depleted fractions
were then recombined with the non-T cells prior to
inoculation into mice. Tumour incidence in these mice
was compared with tumour formation in animals receiving
unseparated PBMCs. The use of tumour outgrowth in mice
inoculated with unfractionated PBMCs as a control, rather
than in animals inoculated with recombined B and T cells,
could possibly have exaggerated differences in tumour
formation between control and test mice. However, we did
not find a significant difference in tumour incidence when
carrying out initial studies comparing tumour outgrowth in
mice inoculated with either unfractionated or fractionated
and recombined PBMCs (Table II).
The inoculation of T-cell-depleted PBMCs significantly
reduced the tumour incidence, indicating that T cells were
required for tumour formation despite the B-cell origin of
BLPD. This result is in line with earlier observations
(Veronese et al, 1992). Removal of CD4 +ve T cells from
PBMCs prior to inoculation gave a highly significant
reduction in tumour incidence, and removal of CDS +ve,
CD45RO +ve and CD45RA +ve T cells also resulted in a
significant, but less dramatic, reduction. As either CD45RA
or CD45RO antigens are expressed on both CD4 +ve and
CD8 +ve T-cell subsets (Thomas, 1989). the reduction of
tumour incidence following their depletion probably reflects
a reduction in numbers of both the CD4 +ve and CD8 +ve
T-cell subsets in the inoculum. Our results contrast with
those of Veronese et al {1992) who found only a minor, non¬
significant. reduction in tumour incidence in mice inocu¬
lated with CD4-depleted PBMCs, and a minor increase in
tumour incidence when mice were inoculated with CD8-
depleted PBMCs. In their study, Veronese et al (1992)
inoculated 60 x 106 to 100 x 106 unfractionated or
fractionated PBMCs into each SCID mouse, whereas we
inoculated 42 x 106 to 54 x 106 unfractionated PBMCs
into each control animal and depleted that same number
of cells of a specific T-cell subset before injection into a test
mouse. Furthermore, Veronesi et al (1994) obtained
tumour outgrowth when B cells were inoculated into
SCID mice depleted of murine NK cell activity with an anti-
asialo GM1 antiserum. We did not find the administration
of this antiserum to have a significant effect on tumour
outgrowth in PBMC-inoculated SCID mice (data not
shown) and we did not therefore routinely use it in our
animals. Thus, it is difficult to compare the results
obtained between the two laboratories due to variability
in engraftment and lymphoma development, and lack of a
consensus protocol.
In order to investigate the nature of the T-cell assistance
required for tumour development, we stimulated T-cell
cytokine production with PHA in vitro prior to inoculation
into SCID mice, and demonstrated a significant decrease in
the median time to tumour development. Taken in
conjunction with the finding of a reduction in tumour
incidence following removal of CD30 +ve activated T cells,
this suggests that activated T cells are involved in promoting
tumour growth. These results cannot be attributed to
elimination of CD30 +ve B lymphocytes (and thus EBV-
infected cells) from the test inoculum as only E-rosette-
positive populations were depleted of CD30 cells. Thus, in
the depletion experiments, all animals (whether control or
test mice) received similar numbers of B cells.
We postulated that the role of T cells in tumour outgrowth
is to supply the tumorigenic EBV +ve B cells with essential
growth factors. Direct cell-to-cell contact may also be of
importance, although antibody stimulation of the CD40 co-
stimulatory molecule on B cells has been shown to inhibit
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Fig 3. Model of tumour outgrowth in the SCID mouse.
(rather than promote) lymphomagenesis in the PBMC-
injected SCID mouse (Murphy et ah 1995; Funakoshi et al,
1997). We used RT-PCR to analyse the human growth factors
involved in tumour formation. 100% of tumours tested
expressed mRNA for human IL-10 and IFN-7, and the
majority also expressed IL-2. IL-4 and IL-6 mRNA. All of these
cytokines are potential stimulators of B-cell growth. As very
few T cells were demonstrated in the tumours, it seemed likely
that the cytokine mRNAs were transcribed by the tumour
cells. To confirm this suspicion, in situ hybridization studies
were carried out to determine the cellular origin of the
cytokine transcripts. Analysis of serial sections of the tumours
probed with EBER and cytokine probes confirmed the RT-PCR
results and showed that the tumour cells themselves
expressed the cytokines tested (Fig 2).
Our results confirm and extend the observations by
Baiocchi et al (1995), who demonstrated the expression of
human IL-10 and its receptor in PBMC-derived SCID
tumours. Based on their results, and the observation that
human IL-6 or IL-10 maintain in vitro viability of fresh SCID
tumour material, the group suggested that human IL-6 and
IL-10 may be involved in an autocrine stimulatory loop
favouring tumour outgrowth in the SCID mouse (Khatri
et ah 1997).
Our results suggest that in the PBMC-inoculated SCID
mouse the sequence of events leading to tumour formation
is as follows: (1) T cells mediate initiation of outgrowth of
EBV +ve tumorigenic B cells; (2) maintenance of tumour
growth in an autocrine, cytokine-stimulated manner
occurs: (3) tumour formation becomes independent of T-
cell assistance (Fig 3). This model is supported by our recent
finding that T-cell-rich primary BLPD biopsy material gives
rise to biopsy-derived tumours in the SCID mouse model
(unpublished observations). These biopsy-derived SCID
tumours show paucity of T cells but express (as do the
primary lesions) human IL-2. IL-6, IL-10 and IFN-7 similar
to that observed in this study in the PBMC-derived SCID
tumours. Therefore, similar mechanisms may lead to BLPD
in the SCID mouse and in the graft recipient, thus making
the murine model a valuable tool in which to investigate the
disease and test novel therapeutic regimens against BLPD in
the organ transplant patient.
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